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Abstract 
An acute asthmatic episode can occur following exercise and is termed exercise induced 
asthma (EIA). The purpose of this thesis was to investigate the prevalence, diagnosis, 
and treatment of EIA in elite British athletes. 
The addition of objective pulmonary function assessment to the criteria an 
athlete must submit to use inhaled 02-agonists at Olympic Games may result in a change 
in the prevalence of asthma within elite athletes. The purpose of study 1 was to compare 
the prevalence of asthma at the 2000 and 2004 Olympic Games in the Great British 
Olympic team (Team GB). The asthma prevalence of Team GB reported in 2000 
(21.2%) was similar to the asthma prevalence reported in 2004 (20.7%). 13 out of 62 
(21.0%) athletes, from 2004 Team GB with a previous diagnosis of asthma failed to 
present evidence of EIA. The overall asthma prevalence of Team GB remained 
unchanged between 2000 and 2004. 
Mid-expiratory airflow measurements may improve the diagnosis of EIA in elite 
athletes. Study 2 investigated the response of Forced Expiratory Flow at 50% vital 
capacity (FEFso) following eucapnic voluntary hyperpnoea (EVH) and exercise 
challenge, in elite athletes, as an adjunct to Forced Expiratory Volume in one second 
(FEVI). 66 male and 50 female athletes were tested for EIA. Sixty athletes 
demonstrated a fall in FEVI >10% leading to the diagnosis of EIA. Using the FEF50 
criteria (1FEF50 >-26%) led to 21 (35%) asthmatic athletes receiving false negative 
diagnosis. The addition of FEF50 failed to enhance the diagnosis of EIA in elite athletes. 
It is unclear, between exercise and EVH challenges as to which one provides the 
greatest sensitivity and most suitable method of EIA diagnosis in elite athletes. Study 3 
investigated the response of elite winter athletes to EVH and two exercise challenges 
(laboratory-based [LB] and sport-specific [SS]). 14 athletes from the British Short-track 
Speed Skating and Biathlon teams volunteered for the study. Ten athletes presented 
with a positive response to EVH (71%); of these, only 3 (21%) had a positive response 
to the SS challenge. No athletes had a positive test to the LB challenge. Our results 
suggest that the EVH challenge is more sensitive, compared with either LB or SS 
exercise challenge, to diagnose EIA in elite winter athletes. 
A limited number of studies exist examining the optimal pharmacotherapy for 
elite athletes with EIA. The purpose of study 4 was to examine the effects of fluticasone 
propionate and salmeterol in the control of EIA in athletes. Eight athletes were 
prescribed 200mcg fluticasone propionate (FLU), 50mcg Salmeterol (SAL), 250mcg 
fluticasone propionate and salmeterol in combination (FXS) or placebo (PLA), in a 
randomised double blind design. No significant (p=0.07) differences were observed in 
the FEV1 change (zFEV1) following EVH challenge between the 4 treatments. Baseline 
eNO for both FXS (20.3+_8.2ppb) and FLU (19.7+_9.2 ppb) were significantly (p=0.02) 
lower than SAL (39.3+_26.7ppb) or PLA (46.3+_26.8ppb). Four athletes were prescribed 
FLU, 2 athletes were prescribed FXS and 2 athletes were prescribed SAL. The results of 
this study demonstrate the heterogeneity of response in elite athletes with EIA to the 
three medication regimes employed. Therefore, suggesting differences in the 
pathogenesis of EIA in this population. 
This thesis is the first to investigate EIA within elite British athletes. The 
prevalence of asthma within elite athletes is greater than that of the British general 
population. Optimal EIA diagnostic methods should include EVH challenges using 
FEV1 as the criterion measurement. Treatment for athletes with EIA should be taken on 
an individual basis due to the heterogeneity of response to medications that attenuate 
EIA in elite athletes. 
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Chapter 1 
Introduction 
Asthma is an obstructive condition that results in a reduced expiratory airflow, within 
susceptible individuals, that is reversible with appropriate therapy or spontaneously. 
The pathophysiology of asthma is not entirely understood, however, airflow limitation 
is thought to be the result of airway smooth muscle contraction and inflammation. A 
number of inflammatory mediators including cytokines, prostaglandins, leukotrienes, 
histamine and eicosanoids from mast cells and macrophages are thought to be key 
contributors to acute asthma episodes. Prolonged exposure to these inflammatory 
mediators (e. g. from multiple acute EIA episodes) can lead to an increased mast cell 
survival rate and a reduction in apoptosis within the airways, which may lead to the 
development of chronic inflammation and airway remodelling. It is therefore important 
that individuals who suffer from acute episodes of asthma receive correct diagnosis and 
suitable therapy to control asthma and prevent the potential airway remodelling and 
increases in asthma severity. 
An acute asthmatic episode can occur following exercise and is termed exercise induced 
asthma (EIA). EIA is defined as a transient narrowing of the airways following exercise 
and is present in approximately 80-90% of people with asthma (Anderson, 1997). 
Exercise is a trigger for approximately 90% of all asthmatics and may be the only 
trigger for those with mild asthma. As with asthma, the pathophysiology of EIA is not 
fully understood. It is thought however, to be caused by water loss from the small 
airways, which is due to an increase in the volume of `unconditioned' air entering the 
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smaller airways during exercise (Anderson and Daviskas, 2000; Anderson and 
Kippelen, 2005). This explanation of EIA pathophysiology is known as the osmotic 
hypothesis and is based around the understanding that an increase in osmolarity 
produces a favourable environment for mediators to be released, which causes the 
smooth muscle surrounding the airways to contract, limiting expiratory air flow. 
Furthermore, other cells such as mast cells, eosinophils, macrophages and sensory nerve 
cells can pptentially be subjected to cell volume loss (figure 2.6). Inflammatory 
mediator release is stimulated by the regulatory volume increase, after cell shrinkage 
(Anderson and Daviskas, 2000). Strauss et al. (1978) and Anderson et al. (1982) 
reported the severity of EIA is directly proportional to the water content of inspired air 
and the water loss at the mouth. In addition, they noted that when water loss was 
prevented, so to was EIA, even in severe asthmatics. As EIA can occur without 
significant cooling, the osmotic effects are thought to be more important than thermal 
effects (Anderson and Daviskas, 1993; Evans et al., 2005). It is therefore generally 
accepted that the osmotic hypothesis accommodates the established findings regarding 
the pathophysiology of EIA and asthma. 
The prevalence of asthma within the general population of the UK is 8% (Asthma UK, 
2001). In contrast, the prevalence of asthma/EIA within elite athletic populations has 
been reported to be between 11-50% (Voy, 1986; Wilber et al., 2000), depending on the 
type of sport studied. It therefore appears that asthma prevalence is higher in athletic 
populations compared with the general population. Reports within literature on the 
prevalence of asthma/EIA within national Olympic squads are limited. The United 
States of America (USA) first reported the prevalence of asthma within their 1984 
Olympic squad to be 11 % (Voy, 1986). Further reports from the USA Olympic teams 
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have demonstrated that the prevalence of asthma has risen to 14% at the 1996 Atlanta 
Olympic Games (Weiler et al., 1998) and 17% at the 1998 Nagano Winter Olympic 
Games (Weiler and Ryan, 2000). Whilst there seems to be a progressive rise in EIA 
within the USA Olympic teams, there are limited reports of asthma prevalence from 
other nations' Olympic teams. What remains unclear is whether the observed increase in 
the prevalence of asthma in the United States teams is an indication of a global trend at 
elite athletic level. Furthermore, limited data exist examining sport specific prevalence 
(Rundell, 2004). However, winter sports typically have a higher prevalence of 
asthma/EIA compared with summer sports (Rundell et al., 2000). 
In 2001 the International Olympic Committee - Medical Commission (IOC-MC) 
changed the criteria for the use of inhaled 02-agonists in the treatment of asthma and 
EIA (Appendix 1). Prior to 2001 asthmatic athletes competing at the Olympic Games 
required a doctor's note with signature explaining symptoms and history of asthma to 
enable them to use asthma medication (inhaled 02-agonists). Since 2001 all athletes who 
wish to use inhaled 02-agonists (IBAs) as therapeutic treatment of asthma in Olympic 
competition must submit objective evidence of asthma to justify their use (Anderson et 
al., 2003). An athlete is now required to submit an abbreviated therapeutic use 
exemption form (Appendix 2), which includes the maximum flow-volume loops from 
either a bronchoprovocation or bronchodilator challenge in addition to a past history of 
asthma, required medication and doctor's signature. This decision by the IOC-MC 
provided the initial stimulus to investigate exercise induced asthma (EIA) within British 
elite athletes. 
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Common symptoms associated with EIA include wheezing, coughing, excess mucus 
production and dyspnoea. It is common however, for many athletes not to report any 
symptoms of EIA, but present with EIA following bronchoprovocation challenges 
(Rundell et al., 2001). The IOC-MC accepts bronchodilator and bronchoprovocation 
challenges as objective evidence of EIA. Most athletes require a bronchoprovocation 
challenge as their forced expiratory volume in one second (FEVI) is above 90% of their 
predicted value at rest. Despite an exercise challenge being the most specific challenge 
for EIA (Anderson et al., 2003; 2005), approximately half the submissions to use 
inhaled ß2-agonists at the Salt Lake City 2002 winter Olympic Games were direct 
airway challenges such as methocholine and histamine (Anderson et al., 2003). Direct 
airway challenges have been shown to have a lower sensitivity and specificity compared 
with indirect airway challenges such as exercise and eucapnic voluntary hyperpnoea 
(EVH) (Holzer et al., 2002). Due to the large number of challenges accepted as 
evidence for EIA by the IOC-MC and the variety of challenges submitted to the IOC- 
MC at the Salt Lake City 2002 winter Olympic Games the most appropriate challenge 
in the assessment of EIA in elite athletes remains unclear. 
At present there is no 'gold standard' measurement of airflow for the diagnosis of EIA 
in athletes, or non-athletes (Godfrey, 1999). In all EIA tests recognised by the IOC- 
MC, FEV1 is the parameter of choice by which changes in maximal expiratory function 
are assessed. Despite the absence of a `gold standard' measure for the diagnosis of EIA 
in athletes, the IOC-MC has ruled that an exercise or EVH challenge is positive for EIA 
when the FEV1 falls >_10% from the baseline measurement. It is possible that the 
addition of other measurements of expiratory lung function may provide greater 
sensitivity and specificity in the diagnosis of EIA. For example, Forced Expiratory 
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Flow between 25-75% of vital capacity (FEF25_75) has been used in conjunction with 
FEV1 to aid the diagnosis of EIA in children (Custovic et al., 1994; Fonseca-Guedes et 
al., 2003) and athletes (Rundell et al., 2000). Implicitly, FEVI measures expiratory flow 
at high and mid-lung volumes, whereas FEF25_75 and Forced Expiratory Flow at 50% of 
vital capacity (FEF50) are markers of expiratory flow through middle lung volumes. It 
has been suggested that FEF25_75 and FEF50 are more sensitive to airway obstruction in 
the small airways than FEVI (McFadden and Linden, 1972; Lebecaque et al., 1993). 
Custovic et al. (1994) demonstrated the combined application of FEV1 (-10%) and 
FEF25_75 (-26%) criteria enabled detection of all subjects with EIA, with no false positive 
diagnosis of non-asthmatics. Thus, the Custovic et al. (1994) study provides promising 
evidence supporting the addition of mid-expiratory flow-rates to FEV1 in the diagnosis 
of EIA in children that may be valuable in the assessment of the elite athlete. 
There are a number of medications that have been reported to attenuate EIA including: 
inhaled corticosteroids (Adams et al., 2001a; 2001b), short and long acting inhaled ß2- 
Agonists (Scottish Intercollegiate Guidelines Network (SIGN), 2002), theophylines 
(Nassif, 1981; SIGN, 2002), leukotrienes receptor agonists (SIGN, 2002), chromes 
(Kelly et al., 2001) and 02-Agonists tablets (SIGN, 2002). At present inhaled 
corticosteroids and inhaled 02-Agonists are recommended as the first line treatment for 
individuals with asthma by the British Thoracic Society (BTS) (2004). 
Since 1976 it has been accepted that inhaled ß2-agonists are effective relievers of EIA 
(Anderson et al., 1976). Within the elite athletic population the number of submissions 
for inhaled ß2-Agonists has increased at each Olympic Games since 1984 (IOC-MC, 
2002). However, Anderson and Brannan (2004) have recently reported that the long- 
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term use of inhaled ß2-agonists may lead to a worsening of asthma severity. Anderson 
and Brannan (2004) argue the increase in the severity is due to the down regulation of 
02-receptors in the lung (Barnes, 1995) and the stimulation of chloride secretion and 
movement across the epithelial cells to the airway surface, which leads to the 
dehydration of the airway submucosa (Boucher, 1994). Furthermore, the use of once 
daily long-acting ß2-agonists results in a reduction in the duration of airway protection 
from bronchoconstriction (Hancox et al., 2002; Simons et al., 1997). Therefore, the 
individual use of p2-Agonist therapy to attenuate EIA should be used with caution as 
this treatment does little to attenuate the underlying inflammatory and remodelling 
processes that may occur. Despite this many athletes still use inhaled ß2-agonists as 
their only source of therapy to attenuate EIA. 
Inhaled corticosteroids have previously been reported to be associated with a reduction 
in inflammatory cells in the airway (Schleimer, 1983) as well as improve symptoms, 
lung function and exacerbation frequencies (Dompeling et al., 1993). Therefore, the use 
of inhaled corticosteroids should attenuate the potential airway remodelling processes 
that may occur within EIA individuals. Despite this, recent studies have reported that 
the addition of long-acting inhaled 02-Agonists to corticosteroid therapy leads to better 
control of symptoms and lower frequency of asthma exacerbations (Shrewsbury et al., 
2000; Koopmans et al., 2005; Masoli et al., 2005). However, Aziz et al. (2000) reported 
that patients preferred the combination therapy but that it provided no greater effect on 
the inflammatory markers, exhaled nitric oxide and serum eosinophilic cationic protein, 
than corticosteroid therapy alone. 
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As there is currently no cure for asthma/EIA it is important once an athlete presents 
EIA, following a recognised IOC-MC test, they receive optimal pharmaceutical 
treatment, which will lead to improvements in well being and performance. However, 
there are few controlled studies that have been conducted on the effects of anti-asthma 
drugs and elite athletes (Helenius et al., 2005). 
1.1 Aims 
The aims of this PhD are to investigate: 
1) The prevalence of EIA within the British Olympic Team at the 2000 Sydney 
Olympic Games and 2004 Athens Olympic Games with special reference to the 
introduction of the IOC-MC asthma guidelines 
2) The impact of mid-expiratory measures of airflow on the sensitivity and specificity of 
EIA diagnosis 
3) The diagnosis of EIA in elite athletes through EVH and exercise challenges 
4) The optimal pharmaceutical therapy for elite athletes with EIA. 
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Chapter 2 
Literature Review 
Asthma obstructs expiratory airflow in susceptible individuals. The airflow obstruction 
is a result of smooth muscle contraction, inflammation and remodelling in the upper and 
lower airways that can be reversed and controlled with suitable treatment. Asthma can 
manifest itself in a variety of ways and symptoms include wheezing, coughing and 
breathlessness. These symptoms can vary between individuals, especially when 
individuals are exposed to triggers such as cold air, exercise, viral upper airway 
respiratory infection, cigarette smoke, pollution, and respiratory allergens. This 
literature review will discuss the prevalence and basic pathophysiology of asthma 
leading to a discussion of exercise induced asthma (EIA) and the implications that it 
may have for elite athletes. 
2.1 Prevalence of Asthma 
Asthma has only become a public health issue since the 1960s. Since this time, surveys 
suggest that the prevalence of asthma is increasing. For example, between 1978 and 
1988 asthma prevalence within school children living in Wales increased 5% (Burr et 
al., 1989) and in Scotland the chance of children developing lifetime asthma increased 
from 10% in 1989 to 20% in 1994 (Omran and Russel, 1996). These data demonstrate 
that asthma prevalence is increasing in children within the UK and are commensurate 
with data on the global prevalence of asthma in children (Magnus and Jaakkola, 1997; 
Nysted et al., 1998; Downs et al., 2001). Increases in adult asthma seem to be occurring 
at similar rates to increases in childhood asthma (Hansen et al., 2000; Peat et al., 1992). 
Brogger et al. (2003) reported that the risk of asthma in adults living in Norway, aged 
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less than 40 years, had tripled between 1972 and 1999. Asthma prevalence over this 
period increased from 3.6% to 7.6% in males and from 3.2% to 10.7% in females. 
Asthma prevalence has been shown to be significantly different between sexes. In 
childhood, boys have a higher prevalence of asthma than girls (Kao et al., 2001; Joseph 
et al., 1998; Schaubei et al., 1996; Skobeloff et al., 1991; To et al., 1996; Wilkins and 
Mao, 1993; Hyndman et al., 1994; Bloomberg et al., 2003) however, women above the 
age of 22 years have a higher asthma prevalence than men of similar ages (Cydulka et 
al., 2001; Krishman et al., 2001; Prescott et al., 1997; Singh et al., 1999; Awadh et al., 
1996; Tuuponen, 1993; Legoretta et al., 1998; Trawick., et al 2001). Most recently, 
Schatz and Carmargo (2003) studied 60,694 asthmatics living in Southern California. 
They reported between the ages of 2-13 a greater number of males (63%) had been 
diagnosed with asthma compared with females (37%) of the same age. Furthermore, the 
severity of asthma was greater in males. This trend was reversed (males 35% and 
females 65%) for those aged between 23-64 years, with asthma severity also being 
greater in females compared with males of the same age. The potential mechanisms for 
these trends are not clearly understood, however, it has been suggested that sex 
hormones (Hermano et al., 1998; Kirsch et al., 1999), changes in airway size (Britton et 
al., 1994), anxiety-depression (Von Brehan et al., 2002) or obesity (Carmargo et al., 
1999; Guerra et al., 2002) may contribute to the observed changes in asthma prevalence 
and severity in males and females across the lifespan. 
Current research suggests that asthma prevalence is rising across all age groups. The 
mechanisms underlying this increase are not clearly understood, however, a number of 
potential mediators have been suggested. Increased exposure to environmental factors, 
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such as pollution, may increase the risk of an individual 
developing asthma. Flodin and 
Jonsson (2004) reported that three or more years working in polluted environments was 
associated with an increased risk of developing asthma and exposure to pollution caused 
by road traffic has also been linked to a greater risk of asthma development in children 
(Zmirou et al., 2004). It has been documented that children who live in areas with high 
ozone concentrations and who exercise frequently have a higher risk of developing 
asthma than children who are similarly active but live in areas with low ozone 
concentrations (McConnell et al., 2002). McConnell et al. (2002) recorded the incidence 
of asthma over the period 1993-1998 in 3,535 children who lived in either a low ozone 
area (37.7-67.9 ppb) or a high ozone area (69.3-87.2 ppb). The activity levels of the 
children were quantified by the number of sports they participated in (1,2,3+). The 
overall risk of developing asthma was not greater for children living in high ozone areas 
compared to the children living in low ozone areas; however, those who played 3+ 
sports in a high ozone area were at a greater risk of developing asthma than those who 
played 3+ sports in a low polluted area. This study suggests that high physical activity 
levels in high ozone areas leads to a greater risk of the development of asthma. 
Increases in exposure to pollution may be one reason why asthma prevalence has 
increased in developed countries; however, other factors that may have contributed to 
this are increased prosperity, increased awareness of asthma and easier access to doctors 
(Pearce, 1998). Whilst the mechanisms underlying the increased asthma prevalence are 
not fully understood it is clear that insights into the pathophysiology, optimal diagnosis 
and treatment of asthma will help reduce the impact of asthma in susceptible 
individuals. 
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2.2 Pathophysiology of Asthma 
In the airways of a non-asthmatic, the smooth muscle surrounding the bronchioles and 
bronchi are relaxed and the bronchial epithelium is not inflamed, which allows non- 
asthmatics to inhale and exhale air with relative ease when at rest or exercising. 
During 
an asthma `attack' the airways display inflammation, smooth muscle contraction, and 
mucosal gland hyper-secretion (Fireman, 2003). At microscopic levels the 
following 
events occur within the larger and smaller airways, leading to decreased baseline airway 
calibre and exaggerated airway narrowing in susceptible individuals: 
- Hyperplasia of the smooth muscles of the 
bronchus and bronchioles 
- Thickening of the submucosal basement membranes 
- Mucosal oedema throughout the lung tissue 
- Sloughing of the mucosal epithelium 
- Loss of ciliated epithelium cells 
- Mucous gland hypertrophy in the submucosa 
The decreased baseline airway calibre and exaggerated airway narrowing result in 
restricted expiratory airflow that is typified by a reduced Forced Expiratory Volume in 
one second (FEV1) (figure 2.1). In a 15-year follow-up study, Lange et al. (1998) 
conducted measurements of FEVI in asthmatics and non-asthmatics (figure 2.2). The 
study was conducted between 1976 and 1994 and included 17,506 subjects of whom 
1,095 had asthma. Among women and men, and among smokers and non-smokers, the 
decline in FEV1 over time was greater in subjects with asthma. The average drop in 
FEV 1 for a non-asthmatic was 22 ml per year, and 38m1 per year for an asthmatic. It is 
normal to expect a reduction in lung function over time (years) in non-asthmatics, but 
the reduction in lung function seems to be accelerated in individuals with asthma. 
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Figure 2.1: Maximal Voluntary Flow Volume Loop: Asthmatic vs Non-Asthmatic. 
The maximal flow volume loops illustrate the difference in the level of obstruction 
within the airway between a non-asthmatic and an asthmatic of similar height, weight, 
age and ethnicity. The reduced PEF rate and subsequent scalloping during expiration 
results in the asthmatic presenting with a lower FEV 1 compared with the non-asthmatic. 
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Figure 2.2: Changes of lung function with age (from Lange, P., Parner, J., Vestiho, J., 
Schnohr, P. & Jensen, G. (1998). A 15 year follow up study of ventilatory function in 
adults with asthma. New England Journal of Medicine, vol. 339, pp. 1194-1200). 
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Inflammation lammation 
Airway inflammation is a major cause of airway calibre reduction and is thought to be 
produced by two different mechanisms 
(Bousquet et al., 2000). The first of these 
mechanisms is allergic inflammation, which 
is characterised by elevated levels of 
immoglobulin E (IgE) that is associated with TH2-lymphocyte response. The second 
mechanism involves pro-inflammatory cytokines, enzymes and growth 
factors 
generated by the damaged bronchial epithelium and submucosal cells of the activated 
airway that leads to structural changes of the bronchial tissues (airway remodelling). 
The allergic inflammatory response is thought to be a characteristic of acute 
inflammation and may be caused by several known or unknown factors such as 
allergens (Platts-Mills and Wheatley, 1996), viruses (Busse and Gern, 1997), or 
pollutants (Wardlaw, 1993). Inflammation may also be caused by exercise hyperpnoea 
or hyperventilation. Bousquet et al. (2000) outlined the series of events that are thought 
to occur during acute inflammation: 
- Activation of allergen specific IgE 
- Rapid activation of airway mast cells (Murray et al., 1985; Liu et al., 1991) and 
macrophages (Tonnel et al., 1983; Calhoun et al., 1992) 
- Mast Cells and Macrophages release proinflammatory mediators such as 
histamine (Jarjour et al., 1997), eicosanoids (Wenzel et al., 1989), leukotrienes, 
prostaglandin (Cho et al., 2002) and reactive oxygen species, which induce 
contraction of the airway smooth muscle, mucus secretion and vasodilatation 
- The pro-inflammatory mediators induce vascular leakage (Grieff et al., 1993; 
Van-Vyve et al., 1995), which contains plasma protein that induce a thickened 
engorged and edematous airway wall 
- The combined result is a narrowing of the airway lumen. 
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The acute inflammation is known as the early phase-reaction and can be followed by a 
late phase inflammation. The late phase inflammation typically occurs 6-9 hours 
following the initial acute inflammation and involves the recruitment of eosinophils (De 
Monchy et al., 1985), CD4+ T cells (Robinson et al., 1993), basophils (Guo et al., 1994), 
neutrophils (Koh et al., 1993; Montefort et al., 1994) and macrophages (Calhoun et al., 
1993). The late phase is characterised by the selective retention of T cells (Gratziou et 
al., 1996), the expression of adhesion molecules (Lassalle et al., 1993; Georas et al., 
1992) and release of pro-inflammatory mediators (Liu et al., 1991; Smith et al., 1992). 
This late phase inflammation reaction has been used as a model system to study the 
mechanisms of chronic inflammation (Holgate, 1993; Bochner et al., 1994). 
The susceptibility of an individual to either an acute or chronic inflammation depends 
on the number of inflammatory cells lining the airways. As previously discussed airway 
inflammatory cells exist within the healthy airway, but their number is controlled by 
apoptosis. Apoptosis terminates the inflammatory process by reducing the number of 
inflammatory cells within the airway. The two principal cytokines that promote mast 
cell proliferation and differentiation are Interleukin-3 (IL-3) and stem cell factor (SCF) 
(Cho et al., 2002). IL-3 appears to be important for proliferation, whereas SCF 
maintains mast cell viability and promotes maturation (Bianchine et al., 1992; 
Blechman et al., 1993). Fibroblasts produce SCF when they are activated by allergic 
inflammation. When the levels of SCF are increased the survival rate of mast cells 
would also increase due to a reduction of apoptosis (Cho et al., 2002) and increased 
adhesion expression of adhesion molecules to epithelial cells (Vignola et al., 1993; 
Canonica and Ciprandi, 1994). Other pro-inflammatory cells such as eosinophils are 
thought to increase due to a reduction in apoptosis (Wooley et al., 1996; Sousa et al., 
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1993). Therefore, if apoptosis is reduced there is potential for acute inflammation to 
develop into chronic inflammation. One benefit of using treatments such as 
glucocorticoids is that they increase the rate of apoptosis and therefore reduce the 
inflammatory response. For example, glucocorticoids such as fluticasone proprionate 
reduce the survival of pro-inflammatory cells such as eosinophils and mast cells 
(Anderson, 1996; Her et at., 1991; Wallen et at., 1991; Meagher et al., 1996; Adachi et 
al., 1996; Mentz et al., 1995). 
Bronchial Epithelium 
The bronchial epithelium is in a key position where gene-environment and 
environment-environment interactions can occur. The bronchial epithelium acts as a 
barrier between the internal environment of the body and the external environment, and 
it is continuously exposed to gaseous and particulate components of the external 
environment. Thus, the epithelium is involved in many of the reactions that lead to 
airway inflammation and smooth muscle contraction. 
When exposed to inhaled pollutants, infectious agents and other particulate matter, the 
epithelium acts as a protective barrier. When the epithelium is exposed to these irritants 
it releases pro-inflammatory mediators that help to protect the internal milieu of the 
lungs. Salvi et al. (2000) demonstrated that diesel exhaust particles cause epithelial 
activation with increased expression of interleukin-8 (IL-8), which was consistent with 
the observed increase in neutrophils in bronchial biopsies and lavage fluid following 
exposure. Similar reactions from the epithelium have been demonstrated when exposed 
to dust mite proteolytic allergens (King et al., 1998) and following rhinovirus infection 
(Papadopoulos et al., 2000). A healthy bronchial epithelium is able to repair itself 
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rapidly, which enables the down regulation of the inflammatory response caused by 
acute exposure to potential asthma triggers. When an asthmatic bronchial epithelium is 
exposed to potential asthma triggers it has an increased susceptibility to inflammation 
due to an increase in the production of remodelling growth factors and mucus 
production as well as an inability to repair rapidly (Holgate, 2002). This inadequate 
repair response and epithelial damage may lead to heightened airways responsiveness 
(Jeffery et al., 1989; Ohashi et al., 1992 ), a failure to metabolise agonists (Inoue et al., 
1992), the destruction of the diffusion barrier altering permeability of airway mucosa 
(Sparrow and Mitchell, 1991), the depletion of epithelial-derived relaxant factors (Rabe 
et al., 1995) and loss of enzymes responsible for degrading pro-inflammatory 
neuropetides (Lilly et al., 1993) (figures 2.3,2.4 and 2.5). The implications of this being 
an increase in asthma symptoms, exacerbation frequency and severity. 
inflammatory cell products 
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Figure 2.3: Sloughing of the asthmatic bronchial epithelium caused by inhaled 
environmental agents (From: Fireman, P. (2003). `Understanding Asthma 
Pathophysiology'. Allergy and Asthma Proceedings, vol. 24, pp. 79-83) 
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Figure 2.4: Bronchial Epithelium of a normal and asthmatic subject 
Panel A of Figure 2.4 is a normal bronchial epithelium from a subject who died 
accidentally. Show epithelium is intact, few numbers of inflammatory cells and 
bronchial smooth muscle. Panel B of Figure 2.4 is a bronchial epithelium of a subject 
who suffered from fatal asthma. Shows epithelial sloughing, thickened reticular 
basement membrane, intense infiltration of the mucosal by inflammatory cells and 
enlargement of the bronchial smooth muscle. (From: Bousquet, J. Jeffery, P. Busse, W. 
Johnson, M. & Vignola, A. (2000). `From Bronchoconstriction to Airways Inflammation 
and remodelling'. American Journal of Respiratory and Critical Care Medicine, vol. 
161, pp. 1720-1745) 
Airway Remodelling 
Acute inflammation generally leads to repair and restoration of normal structure and 
function to the airway. Chronic inflammation may result in an altered structure 
(Rennard, 1996) such that airway remodelling occurs. This involves epithelial shedding, 
sub-basement thickening, smooth muscle hyperplasia and an increase in the number of 
nerves and blood vessels. These changes result in increased resistance to airflow 
particularly when there is bronchial contraction and bronchial hyperresponsiveness 
(Boulet et at., 1995; Kamn and Drazen, 1992). Airway muscle mass may increase in 
volume by 3-4 fold in an asthmatic (Hogg, 1993). This increase has been found in major 
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bronchi (Dunnil et al., 1969) and in peripheral airways (Saetta et al., 1991; Carroll et al., 
1993) with muscle mass being thickest in the major bronchi. 
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Figure 2.5: Epithelial injury, airway inflammation and remodelling (From Davies, D. 
(2001). 'The bronchial epithelium: translating gene and environment interactions in 
asthma'. Current Opinion in Allergy and Clinical Immunology, vol. 1, pp. 67-71) 
The thickening of the reticular basement membrane is a typical characteristic that 
occurs early on in the asthmatic bronchus (Dunnill et al., 1969). This thickening is 
usually homogenous and hyaline in appearance. In asthma the basal lamina is of normal 
thickness whereas the reticular layer is thickened, which is associated with deposition of 
immunoglobins, collagen I and III, and fibronectin (Altraja et at., 1996). The degree of 
thickening has been related to the severity of asthma (Chetta et at, 1997); however it is 
generally thought to have no significant correlation with the severity of asthma (Jeffery 
et al., 1989; Saetta et al., 1996). Another feature of airway remodelling is an increase in 
the number of blood vessels surrounding the airways. These new vessels originate by 
budding or sprouting of pre-existing vessels by angiogenesis (Battegay, 1995). The new 
blood vessels have been found to be hyperpermeable and increase oedema. During 
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airway remodelling, concomitant to an increase the number of blood vessels is an 
increase in vessel area (Saetta et al., 1991; Carroll et al., 1993). Thus, asthmatics have a 
greater number and size of vessels than non-asthmatics in their airways (Li and Wilson, 
1997). The increase in muscle mass, reticular basement membrane and number and size 
of vessels in the asthmatic airways, results in a thickened airway wall that contributes to 
airway remodelling and a reduction in expiratory airflow in asthma (due to incursion 
into the airway lumen). 
In summary, the prevalence of asthma has been increasing within the general population 
since the 1960's. Triggers for asthma include exercise, dust, pollution and pollen. 
Exposure to these triggers can lead to susceptible individuals presenting with 
inflammation, smooth muscle contraction and mucosal gland hyper-secretion within the 
small airways, which limit expiratory airflow leading to reduced measures of expiratory 
function such as FEV1. The inflammatory mediators that are released from mast cells 
and macrophages during an acute asthmatic episode include cytokines, prostaglandins, 
leukotrienes, histamine and eicosanoids. Prolonged exposure to these inflammatory 
mediators can lead to an increased mast cell survival rate and a reduction in apoptosis 
within the airways, which may lead to the development of chronic inflammation. 
Chronic inflammation can result in airway remodelling that leads to a reduction in 
expiratory airflow and potentially to the development of chronic asthma. It is therefore 
important that individuals who suffer from acute episodes of asthma receive correct 
diagnosis and suitable therapy to prevent the potential airway remodelling and increases 
in severity. 
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2.3 Exercise Induced Asthma (EIA) 
The first record of exercise induced asthma (EIA) was reported approximately 1,800 
years ago by Aretaeus (120-200AD) who noted that physical exertion provoked airway 
obstruction (Adams, 1856). EIA is currently defined as a transient narrowing of the 
airways following exercise and is present in approximately 80-90% of people with 
asthma (Anderson, 1997). EIA is associated with smooth muscle contraction, airway 
inflammation and mucus production developing maximally approximately five to ten 
minutes after cessation of exercise (Rundell et al., 2000). EIA is characterised by a 
broad spectrum of symptoms similar to those observed in asthma. In individuals with a 
mild to moderate asthma severity, exercise may be the sole trigger in the genesis of 
bronchoconstriction. Therefore, exercise has the potential to be a valuable tool when the 
diagnosis of asthma is in doubt. In the literature, EIA has also been termed exercise 
induced bronchoconstriction (EIB), however within this literature review the term ETA 
will be employed as the two terms describe the same processes. 
2.4 Prevalence of EIA 
The prevalence of EIA in athletes is higher than the 8% asthma prevalence rate of 
general population of the UK (Asthma UK, 2001; Helenius et al., 1998; Wilber et al., 
2000). The prevalence of asthma/EIA in athletic populations has steadily increased (see 
table 2.1) since Voy (1986) first reported the prevalence of asthma in the 1984 United 
States Olympic team as 11%. Since 1984 the prevalence within the United States 
Olympic team has been reported at 14% in 1996 (Weiler et al., 1998) and 17% at the 
1998 Winter Olympics (Weiler and Ryan, 2000). Athletes who compete in winter sports 
have a higher prevalence of EIA than those who compete in summer sports (Rundell et 
al., 2000), which suggests the environment that an individual trains and competes in 
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may be an important precursor in the development of EIA. For example, the 1996 U. S. 
Summer Olympic Team had a prevalence of 14%, whereas winter sports such as ice- 
skating had a reported prevalence of 30 - 35% (Craig et al., 1996; Mannix et al., 1996). 
Wilber et al. (2000) have also reported high prevalence rates in winter athletes such as 
cross-country 
Author Prevalence Population Method of diagnosis 
Voy, 1986 11% U. S. Olympic Symptom and family Athletes history 
Mannix et al., 1996 35% 
Figure Exercise Challenge FEV, 
Skaters >15% 
Helenius et al., 1996 25% Elite runners 
Exercise Challenge FEV, 
>4.7 (2 SD) 
Schoene et al., 1997 15% 
Elite track and 
field PEF >10% 
Kukafka et al., 1998 20% 
American Exercise Challenge PEF 
Football >10% 
Helenius et al., 1998 26% Elite runners 
Exercise challenge FEV, 
>6.5% =2 SD 
Weiler et al., 1998 14% 
U. S. Olympic Survey Sq uad 
Mannix et al., 1999 55% Figure Exercise and EVH Skaters challenge FEV, >10% 
U. S. Olympic 
Weiler and Ryan, 2000 17% Winter Athlete questionnaire 
Athletes 
Wilber et al., 2000 23% U. S. Olympic Exercise Challenge FEV, Athletes >10% 
Nystead et al., 2000 
Elite athletes 10%, Athletes and Survey General Population 7% non-athletes 
Rundell et al., 2001 
Exercise challenge 26%, Elite Athletes Exercise challenge FEV, Questionnaire 29% >10% and Questionnaire 
Thole et at., 2001 14% Collage Athletes PEF >15% 
Ogston and Butcher, 2002 28% Cross country Exercise Challenge skiers FEV1>10% 
Halsstrand et al., 2002 9% High School Exercise challenge FEV1 
athletes >10% 
EVH either FEV1 >10%, 
Mannix et at., 2003 19% Gym users FEF50 > 20%, PEF 
>25% 
Kippelen et al., 2004 4% Endurance Questionnaire 
athletes 
Runde) et al., 2004 
Exercise challenge 29%, Elite Winter Exercise and EVH 
EVH 45% athletes challenge FEV1 >10% 
Alaranta et at., 2004 
Athletes 13.9% 
Control 8.4% 
Finnish 
Olympic Questionnaire 
Athletes 
Table 2.1: Prevalence of EIA in athletic populations 
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skiers, where 50% [(females (57%) vs males (43%)] were diagnosed with EIA. The 
Wilber et al. (2000) study also demonstrated that the overall prevalence of EIA was 
higher in females (23%) than males (18%) and this overall trend was consistent through 
all of the seven winter sports examined. What remains unclear is whether the observed 
increase in the prevalence of EIA in the United States teams is an indication of a global 
trend within elite athletes. Further, limited data exists examining sport specific 
prevalence across both winter and summer sports. 
2.5 Pathophysiology of EIA 
During normal resting conditions, the nasal airway is involved in conditioning the 
inhaled air resulting in an alveoli air temperature of 37°C that is fully saturated with 
water (Hahn et al., 1984). During exercise, minute ventilation (VE) is greatly increased 
and breathing through the mouth predominates over nasal breathing. This increase in 
breathing through the mouth causes inhaled air to bypass the nasal warming and 
humidifying process. The lower airways, therefore, become exposed to `unconditioned' 
air that will not only require warming and humidifying but, may also contain particles 
such as pollution, dust or pollen. As individuals exercise to higher intensities, their VE 
continues to increases leading to larger doses of `unconditioned air' reaching the lower 
airways. The exact mechanisms that lead to expiratory flow limitation (through 
inflammation and smooth muscle contraction) following exercise are unclear. However, 
it has been proposed that EIA may occur through several mechanisms, but two main 
hypothesis predominate; 1) osmotic, 2) thermal hypothesis. 
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Thermal Hypothesis 
The thermal hypothesis suggests EIA is initiated through airway cooling during exercise 
that is followed by a rapid warming of the airways following cessation of exercise (Deal 
et al., 1979). The rapid rewarming of airways is thought to produce vasodilatation of the 
pulmonary capillaries causing bronchial congestion (McFadden et al., 1986; McFadden, 
1987). This hypothesis therefore, suggests that airway narrowing is a direct 
consequence of these events. Anderson and Daviskas (2000) have highlighted that the 
thermal hypothesis does not accommodate smooth muscle contraction or inflammatory 
markers. Furthermore, the thermal hypothesis fails to account for the fact that EIA can 
occur in dry air, which can be either hot or cold (Deal et al., 1979; Evans et al., 2005). 
Hahn et al. (1984) and Deal et al. (1979) have both reported that FEVI following 
exercise did not alter when the water loss form the airway remained the same but, the 
temperature was altered. Water loss in these studies was calculated by assuming full 
saturation of the expired air at the temperature measured, which was later questioned by 
Eschenbacher and Sheppard (1985). Using a more reliable measure of water loss 
Eschenbacher and Sheppard (1985) demonstrated that heat loss was not the sole trigger 
for EIA and respiratory water loss was also important. Eschenbacher and Sheppard 
(1985) measured water loss by separating the inspired and expired air and measured 
both humidity and temperature during hyperventilation with cold air. Other studies also 
failed to provide strong support for the thermal hypothesis (Ingenito et al., 1988; 
Argyros et al., 1993; Evans et al., 2005), and suggest that water loss is essential for the 
development of EIA. 
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Osmotic hypothesis 
Due to the failure of the thermal hypothesis to account for established findings 
regarding the pathogenesis of EIA, the osmotic hypothesis of EIA was developed as a 
possible explanation. The osmotic hypothesis suggests that the dehydration and the 
osmotic effects of water loss (caused by the increased volume of `unconditioned' air 
entering the airway during exercise) initiates events leading to EIA (Anderson, 1984). 
The osmotic changes occur in the airway surface liquid (Anderson, 1984) and epithelial 
cells (Anderson et al., 1989), due to the respiratory water loss, which also leads to 
submucosal involvement signalling bronchial blood flow (Anderson and Daviskas, 
1992). The hypothesis is based around the understanding that an increase in osmolarity 
produces a favourable environment for mediators to be released, which causes the 
smooth muscle to contract, limiting expiratory air flow. Other cells such as mast cells, 
eosinophils, macrophages and sensory nerve cells can potentially be subjected to cell 
volume loss (figure 2.6). This can lead to further inflammatory mediator release, which 
is stimulated by the regulatory volume increase, after cell shrinkage (Anderson and 
Daviskas, 2000). Experimental support for the osmotic theory has been provided by 
Strauss et al. (1978) and Anderson et at. (1982). They reported the severity of EIA is 
directly proportional to the water content of inspired air and the water loss at the mouth. 
In addition, they noted that when water loss was prevented, so too was EIA, even in 
severe asthmatics. As EIA can occur without significant cooling, the osmotic effects 
are thought to be more important than the thermal effects (Anderson and Daviskas, 
1993; Evans et al., 2005). Airway cooling and rapid rewarming do occur, however, they 
are not prerequisites for EIA. The osmotic hypothesis appears to accommodate the 
established pathophysiology of EIA and asthma. 
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Additional Triggers 
As previously discussed exercise results in an increase in `unconditioned' air inspired 
through the mouth due to an increased VE during exercise, which results in 
bronchoconstriction in susceptible individuals. However, the EIA response (especially 
in atopic individuals) may be more complex. For example, an individual who does not 
have an EIA response under normal exercise conditions may respond if exercise is 
accompanied by another asthma trigger such as pollution or pollen. Therefore the 
pathophysiology leading to bronchoconstriction in susceptible atopic individuals may 
involve changes in airway osmolarity due to large volumes of `unconditioned' air, 
including greater concentrations of triggers such as pollen, entering the airways. 
Helenius et al. (1998) demonstrated that EIA severity is related to allergen response; the 
more `allergic' asthmatics are, the more severe their EIA. Helenius et al. (1998) 
compared falls in FEV1 after an exercise challenge between those who suffered from 
EIA in the winter and those who suffered in the pollen season. The results demonstrated 
that more athletes demonstrated a fall in FEV, post exercise in the cold, but those who 
demonstrated falls in FEV1 during the pollen season had larger post exercise changes. 
This study demonstrates that the `pure' EIA response to cold dry air may be milder than 
the response to a combined trigger of exercise and pollen in affected individuals, where 
expiratory obstruction is more severe. 
Swimming training has been shown to have a beneficial effect on the aerobic capacity 
of asthmatics (Matsumoto et al., 1999). Swimming can benefit those with EIA as it is 
generally thought that breathing the warm humid air environment reduces incidence of 
EIA (Bar-Or and Inbar, 1992). However, the issue of possible irritant exposure 
resulting from water chlorination have not been widely addressed. Anecdotal evidence 
25 
suggests that asthmatic individuals present with greater severity when exposed to the 
environment of a chlorinated pool (Mustchin and Pickering, 1979; Penny, 1983). It has 
also been reported that competitive swimming has a higher prevalence of asthma than 
other sports (Zwick et al., 1990; Helenius et al., 1998). The reasons for these 
observations are unknown and further studies should investigate whether irritants from 
water chlorination, or asthmatics choosing swimming as a sport due its protective 
effects against EIA, are responsible for the high EIA prevalence in swimming. 
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Figure 2.6: Flow-diagram of the pathogenesis of EIA 
Flow chart describing the events leading to EIA in the classic asthmatic (left) and the 
events leading to the development of EIA in the athlete (right) (From Anderson, S. and 
Kippelen, P. 2005. `Exercise Induced Bronchoconstriction-Pathogenesis'. Current 
Asthma and Allergy Reports, vol. 5, pp. 116-122) 
Refractory Period 
It has been reported that exercise conducted within 4 hours of an initial airway 
bronchoconstriction will result in bronchoconstriction that is less severe than the initial 
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bronchoconstriction (Argyros et al., 1995; Zach and Polgar, 1987; Malo, 1986; Rundell 
et al., 2003). This phenomenon is known as the refractory period and is thought to be 
due to a release of bronchodilating prostaglandins following the initial 
bronchoconstriction (Manning et al., 1993; Margolskee et al., 1988; O'Bryne and Jones, 
1986; Wilson et al., 1994). Reports suggest that the refractory period does exist, 
however there is debate as to whether it is present within all EIA individuals (Argyros et 
al., 1995; Zach and Polgar, 1987; Malo, 1986; Rundell et al., 2003). Argyros et al. 
(1995) reported that all individuals with EIA demonstrated some level of refractory 
period. Argyros et al. (1995) demonstrated that the fall in FEVI was smaller following a 
second eucapnic voluntary hyperpnoea (EVH) challenge that was conducted 
approximately I hour after an initial EVH challenge, however, all 11 participants had 
falls in FEV1 of >10% in the second EVH challenge. Furthermore, 3 participants had a 
FEV1 fall within 5% of their initial EVH challenge. In contrast Rundell et al. (2003) 
reported that only I out of 9 winter athletes with EIA demonstrated a significant 
refractoriness following a subsequent sport specific exercise challenge. Studies 
investigating the refractory period suggest that it does not provide full attenuation to 
EIA and that it is not present in all athletes. Therefore the potential protective effects 
that are associated with the refractory period should not be relied upon by EIA athletes 
and should certainly not be used as an alternative for therapeutic pharmaceutical 
intervention. 
Inspiratory Stridor 
Inspiratory Stridor (IS) is a condition that is characterised by high-pitched inspiratory 
noise that is often mistaken for the wheeze of asthma (Brugman and Simons, 1998; 
Corren and Newman, 1992; Niven et al., 1992; Heiser et al., 1990; Baughman and 
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Loudon, 1989; Kivity et al., 1986; Lakin et al., 1984; Christopher et al., 1983). The 
presence of IS is associated with vocal cord dysfunction (Brugman and 
Simons, 1998; 
Corren and Newman, 1992; Niven et al., 1992; Heiser et al., 1990; Baughman and 
Loudon, 1989; Lakin et al., 1984) that can be diagnosed by laryngoscopy. The problem 
with laryngoscopy however, 1) it is very invasive, 2) the patient must 
be symptomatic, 
which is problematic if the IS is caused by high intensity exercise, thus, symptom 
based 
diagnosis is a more common and practical method. 
The prevalence of IS is relatively unknown, but it has been estimated at 2-3% of the 
general population with the majority of cases reported in adolescent females (Sullivan, 
et al., 2001; Kenn and Schmitz, 1997). The prevalence within elite athletic populations 
has been reported to be 5%; with 53% of IS suffers also presenting with EIA (Rundell 
and Spiering, 2003). Rundell and Spiering (2003) also reported that it is common for IS 
to be mis-diagnosed as EIA, reporting 7 out of 19 athletes who were diagnosed with IS 
had a previous diagnosis of EIA and were prescribed 02-agonists. It is therefore 
important to recognise the differences between EIA and IS before a diagnosis of either 
condition is made (see table 2.2). 
EIA Inspiratory Stridor 
Occurs 5-10 minutes after exercise Occurs during exercise and resolves within 
5 minutes of stopping exercise 
Wheeze on expiration Wheeze in inspiration 
Fall in FEV1 post exercise No fall in FEV, post exercise 
Sound is primarily from the chest Sound originates in the neck 
EIA responds to inhaled 02-agonists No response to inhaled ß2-agonists 
treatment treatment 
Table 2.2: Characteristics of EIA and Inspiratory Stridor 
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2.6 Diagnosis of EIA 
At present, there is no gold standard methodology to diagnose EIA in elite athletes 
(Rundell and Jenkinson, 2002). Methods that have been used in the past include: 
questionnaire (symptoms based or history of medical diagnosis), exercise challenge, 
eucapnic voluntary hyperpnoea (EVH), saline, mannitol, methacholine and histamine. 
Symptom based diagnosis 
The questionnaire, or symptoms based method for the diagnosis of asthma, has been 
widely employed (see table 2.1), and involves the athlete reporting symptoms of asthma 
either during or following training or competition. The main symptoms reported are 
wheezing, cough, tight chest and breathing difficulties; although other symptoms 
include a mismatch between performance and fitness, problems getting rid of chest 
infections and difficulties in sleeping (Storms, 1998). These symptoms are usually, but 
not exclusively seen in asthmatics, and it has been argued that the accompaniment of a 
physiological test is crucial for the reliable diagnosis of EIA (Boulet et al., 1999). 
Rundell et al. (2001) examined the accuracy of symptom-based diagnosis of EIA in elite 
winter athletes. They distributed a questionnaire asking athletes to report symptoms of 
EIA or asthma following exercise. Each athlete also underwent an exercise challenge. 
The questionnaire proved to be no more reliable than a `coin toss' to predict EIA. Of the 
41 athletes that presented with EIA following exercise, only 18 (44%) reported more 
than one EIA symptom. Post-race cough was the most commonly reported symptom for 
both EIA positive athletes and non-EIA positive athletes. It was concluded that the 
diagnosis of EIA without a pulmonary function test would yield false positive and false 
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negative results. This finding supports earlier research (Rundell et al., 2000), and 
highlights the requirement for a physiological test to confirm diagnosis of EIA. 
Direct Airway Challenges 
Many studies investigating EIA have used a direct airway challenge as the diagnostic 
test (Anderton et al., 1979; Avital et al., 1995; Lin et al., 1991; Fourie and Joubert, 
1988). The two most common direct airway challenges are histamine and methacholine. 
Histamine challenges activate smooth muscle and secretory receptors, whereas 
methacholine is a non-specific cholinergic agonist. Both challenges produce falls in 
FEV1 that are proportional to the dose administered. Histamine and methacholine 
challenges have been previously suggested as more sensitive markers of EIA than 
exercise (Anderton et al., 1979; Avital et al., 1995; Lin et al., 1991; Fourie and Joubert, 
1988). However, the sensitivity and/or specificity of these methods have been 
challenged. For example, Holzer et al. (2002) screened 50 athletes for EIA using 
methacholine and EVH challenges and found only 9 (18%) athletes presented with a 
positive challenge to methacholine, whereas 25 (50%) athletes (including the 9 
methcholine positive athletes) presented with a positive EVH challenge. The authors 
concluded that an EVH challenge was more sensitive and specific than a methacholine 
challenge for the diagnosis of EIA in athletes. This study concurs with data from 
previous studies that suggest indirect airway challenges, such as exercise and EVH, are 
more sensitive and specific in the diagnosis of EIA than direct airway challenges (Haby 
et al., 1994,1995; Clough et al., 1991). Thus, the available evidence suggests that direct 
airway challenges are not sufficiently sensitive or specific for the diagnosis of EIA in 
athletes and indirect airway challenges are more appropriate. 
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2.7 Indirect Airway Challenges 
Exercise Challenge 
Exercise challenges are considered to be the most specific indirect airway challenge 
used to test athletes for EIA (Anderson et al., 2003; 2005), but their sensitivity has been 
questioned (Rundell et al., 2004; Mannix et al., 1996). In the past, exercise challenges 
have been structured so that the athlete completes a bout of exercise that lasts between 
6-8 minutes in which they exercise at an intensity of 85% maximum heart rate ((220- 
age/100) x 85) for at least the final 4 minutes of exercise (Godfery et al., 1975; Konig, 
1989; Mahler, 1993; McKenzie et al., 1994). A significant post-test fall in FEV is most 
likely to be seen 5 to 10 minutes following cessation of exercise (Rundell et al., 2000). 
Exercise challenges have a high external validity, as the test can be structured to 
incorporate a sports specific environment, whereas other EIA testing methods are less 
sport specific. The exercise challenge is also very simple to carry out in the field, as 
portable spirometry equipment is available for most situations. However, the inability to 
regulate the duration and VE response during a field-based assessment offers less inter- 
test reliability and internal validity. Notwithstanding this limitation, Wilber et al. (2000) 
demonstrated that speed skaters could present with EIA (FEVI fall >10%) following a 
sport specific challenge, which lasted for 1 minute and 20 seconds. Their data led them 
to conclude that sport specific exercise at near maximal intensity may be more crucial in 
the identification of EIA, than the duration of the challenge. Exercise challenges should 
be carried out in the field where possible and the exercise should replicate the athlete's 
actual event and, where possible, conditions under which, they experience symptoms 
(Anderson et al., 2005). Criteria for a positive exercise challenge have varied from 7% 
to 15% falls in FEV1 from baseline (Wilber et al., 2000; Rundell et al., 2000; Anderson 
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et al., 1971). However, a fall of 10% in FEV1 following exercise is the current criterion 
accepted by the International Olympic Committee - Medical Commission (IOC-MC, 
2002). 
Early EIA studies incorporating exercise challenges (Anderson et al., 1971) did so in 
laboratory conditions. However, laboratory conditions do not provide either a sport 
specific or a cold dry environment that is likely to trigger EIA. Rundell et al. (2000) 
demonstrated that exercise challenges in the field were more effective than exercise 
challenges in the laboratory in ambient conditions. They tested 23 elite winter athletes 
(14 men, 9 women) following exercise challenges in the laboratory and field. Both 
challenges attempted to mimic the cardio respiratory requirements of competition. 78% 
of athletes who demonstrated positive tests in the field failed to demonstrate a positive 
test in laboratory. This study provides evidence that even an exercise challenge 
conducted at race pace in the laboratory may not provide appropriate conditions to 
reliably assess elite athletes for EIA. 
Eucapnic Voluntary Hyperpnoea (EVH) Challenges 
An EVH test is conducted in the laboratory and has a greater level of standardisation 
and may be more sensitive than an exercise challenge used to diagnose EIA (Rundell et 
al., 2004). There are two types of EVH challenge: stepped and single staged. The 
inspirate for both types of EVH challenges is from a compressed gas source that 
contains 21% oxygen, 5% carbon dioxide, with the balance nitrogen. This concentration 
of gas is safe, stimulates ventilation, and is thought to maintain normal end-tidal CO2 
levels throughout the challenge. The inspirate is best administered from a gas cylinder 
via a Douglas Bag (figure 3.3). 
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A stepped protocol is used mainly in those with severe or unstable asthma. It usually 
involves three stages of hyperventilation. Stage 1 involves 3 minutes of hyperventilation 
at 30% maximal voluntary ventilation (MVV) followed by spirometry at 1,3,5 and 7 
minutes. Stage 2 involves three minutes hyperventilation at 60% MVV followed by 
spirometry and stage 3 involves threes minutes of hyperventilation at 90% MVV 
followed by spirometry. If FEV1 falls >_20% from baseline after any stage, the test is 
terminated (Holzer and Brukner, 2004). 
The single-stepped EVH test involves a single stage of hyperventilation for 6 minutes at 
a target ventilation of 85% of MVV, which approximately equals 30 x baseline FEVI. 
This is only a target rate and most elite athletes should easily achieve 25 x FEV,, 
whereas asthmatics need only breath at 21 x FEV1 to provoke an airway response 
(Anderson et al., 2001). Spiering et al. (2004) have suggested 85% of actual maximal 
minute ventilation is more relevant and reliable than simply multiplying FEV1 by 30. 
This however, may not be practical in patients who have not completed a test which 
measures their maximal minute ventilation. 
Eucapnic voluntary hypervpnoea testing has been shown to be more sensitive than 
exercise in identifying EIA (Rundel et al., 2004; Mannix et al., 1999). A higher number 
of cases of bronchoconstriction have been diagnosed using EVH challenges than using 
exercise challenges in the same subjects (Mannix et al., 1999; Rundell et al., 2004). 
EHV has also been shown to provoke bronchoconstriction in asthmatic non-athletes 
(Deal et al., 1979). It could therefore be argued that EVH is a more sensitive test for 
EIA than an exercise challenge and may be a more desirable test for the athlete. Despite 
this over half the applications for therapeutic use of inhaled ß2-agonists at the 2002 Salt 
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Lake City Winter Olympic Games used direct airway challenges (Anderson et al., 
2003). Despite the greater sensitivity offered by an EVH challenge in the diagnosis of 
EIA, the EVH test may be fundamentally and practically flawed because 1) it can 
currently only be carried out in a laboratory 2) it eliminates potential triggers for EIA 
such as pollen, pollution, and other particulates that may be required to obtain a positive 
result for EIA 3) the cost of the compressed gas mixture (5% C02,21% 02) required for 
EVH test makes the relative cost of an EVH test far greater than other challenges 4) 
EVH equipment is not widely available and skilled technicians are required to construct 
an EVH system. Further studies are required to investigate whether exercise or EVH 
should be used as the main challenge for testing athletes for EIA. An algorithm (figure 
2.8) presented recently by Harries and Dickinson (2005) suggests a sport specific 
exercise should be the first test conducted, followed by an EVH challenge if the initial 
test is negative and the athlete continues to complain of symptoms. Exercise was 
suggested as the initial test because of the low cost, specificity and accessibility of the 
test. 
Osmotic Challenges 
Osmotic challenges are designed to induce airway hyperosmolarity and hypertonicity 
without the need to exercise or hyperventilate. They are thought to produce similar 
levels of hyperosmolarity and hypertonicity to exercise and EVH challenges (Holzer 
and Brukner, 2004). The two main osmotic challenges are hypertonic saline and inhaled 
mannitol. The hypertonic saline challenge involves increasing doses of hypertonic 
saline, either by duration or concentration. Thee mannitol challenge involves the 
inhalation of increasing doses of a dry powder of mannitol via a Spin Inhaler"'. The 
mannitol challenge may be preferable, as it can be implemented in an office, whereas 
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the saline challenge must take place in a laboratory. The disadvantage of both tests is 
that patients are not exposed to exercise or environmental triggers, therefore reducing 
the test specificity. 
I Interview with patient. Obtain past history of asthma and any asthma symptoms (e. g. 
wheezing, coughing... ) 
L 
patient suspccted to suffer from modere¢c to 
scrvcrc chronic r thiua 
rfronchodllhil 
it challenge 
+ve 
+ve 
+ve 
Medicate patient 
appropriately 
+ve 
I Patient suspected to be suffenng from mild 
asthma or EI A 
-ve Exercise Challegc 
-ve 
Patient still reporting symptoms 
-ve 
FIVII cihancnge 
-ve 
Psdwnt still reporting symptom. 
Methecholine/Seline Challenge 
Figure 2.8: Algorithm for EIA Diagnosis 
-ve 
Patient boot Aslhnwlic 
-ve 
Due to the cost and lack of portability of EVH equipment, a protocol to test an athlete 
for EIA may consist of first completing a sport specific exercise challenge in those 
individuals who are already asthmatic or complain of asthma symptoms during or after 
exercise. If the exercise challenge is negative then an EVH test may be administered on 
a separate day. (From Harries, M and Dickinson, J. (2005). 'Exercise Induced Asthma'. 
In Whyte, C. Harries, M. and William, C. ABC of Sports Medicine 2005. Blackwell 
publishing, Abingdon UK. P36-39) 
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2.8 Diagnostic Criteria 
Use of FEVi vs Mid-Expiratory Flow Measurements in the diagnosis of asthma 
In all EIA tests described above, FEVI is the parameter by which changes 
in maximal 
expiratory air flow are assessed. To date, however, no 'gold standard' criterion measure 
of airway function exists for athletes, or non-athletes (Godfrey, 1999). Previous studies 
using FEV i to diagnose EIA have suggested a magnitude of cut off criteria ranging 
from 7-20% falls in FEVi (Anderson et al., 1971; Eggleston et al., 1979; Helenius et al., 
1996). Despite the absence of a `gold standard' criterion measure for diagnosis of EIA 
in athletes, the International Olympic Committee - Medical Commission (IOC-MC) has 
ruled that an exercise or EVH challenge is positive for EIA when the FEVI falls >_10% 
from the baseline measurement. The work carried out by Helenius et al. (1996) suggests 
that a fall of 10% in FEV1 following an exercise test is not sensitive enough to diagnose 
EIA in elite athletes. It is possible that the addition of other measurements of expiratory 
lung function may provide greater sensitivity and specificity in the diagnosis of EIA. 
For example, forced expiratory flow between 25-75% of vital capacity (FEFzsas) has 
been used in conjunction with FEV1 to aid the diagnosis of EIA in children (Custovic et 
al., 1994; Fonseca-Gouedes et al., 2003) and athletes (Rundell, 2001). 
Implicitly, FEV1 measures expiratory flow at high and mid-lung volumes, whereas 
FEF25-75 and forced expiratory flow at 50% of vital capacity (FEFso) are markers of 
expiratory flow through middle lung volumes. It has been suggested that FEF25-75 and 
FEF50 are more sensitive indicators of airway obstruction in the small airways than 
FEVI (McFaden and Linden, 1972; Lebecaque et al., 1993). Custovic et al. (1994) noted 
that cut off points for EIA in children (defined as the normal group mean value -2 SD) 
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occurred with a >10% fall in FEV1 and >26% fall in FEF25_75. In this study, the 
combined application of FEV1 and FEF25_75 criteria enabled detection of all subjects 
with EIA. Furthermore, using both FEV1 and FEF25_75 criteria, none of the subjects with 
allergic rhinitis or dermatitis presented with EIA. The fall in FEV1 after exercise in 
children with allergic rhinitis was within the normal range (2SD), but with a 
significantly lower mean value than control subjects. Thus, the Custovic et al. (1994) 
study provides promising evidence supporting the addition of mid-expiratory flow-rates 
to FEVI in the diagnosis of EIA in children that might also be applied to the diagnosis 
of EIA in adults and athletes. To date, there is no literature investigating the sensitivity 
and specificity of mid-expiratory flow in the diagnosis of EIA in athletic populations. 
2.9 Therapy 
At present there is no therapy available to cure asthma However, there are a range of 
pharmacologic and non-pharmacologic therapies available for asthmatics that reduce the 
severity of asthma (table 2.3). Highly trained athletes commonly use pharmacologic 
medication to attenuate EIA. In a recent study of Finnish elite summer-sport athletes, 
the most commonly used drug was inhaled 02-agonists (Helenius and Haahtela, 2000). 
However, despite the widespread use of inhaled pharmacologic therapy by athletes, few 
randomised, controlled studies have been conducted on their effects on asthma-like 
symptoms, bronchial responsiveness, or airway inflammation (Helenius et al., 2005). 
Recommendations for Therapy 
The British Thoracic Society (BTS) has a5 step guideline (Table 2.4) for asthma 
treatment in the general population (BTS, 2004). Despite the lack of evidence regarding 
the treatment of EIA, the BTS (2004) currently recommends inhaled corticosteroids and 
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inhaled 02-Agonists as the first line treatments for individuals with EIA. According to 
the BTS guidelines (2004) inhaled short acting 02-Agonists should be used in the 
first 
instance for mild intermittent EIA (Step 1). If symptoms are not controlled then inhaled 
corticosteroids should be used in addition (step 2) and then inhaled long-acting 
132- 
Agonists (step 3) if symptoms are not controlled by the use of both short-acting ß2- 
Agonists and corticosteroids. 
Phannacologic Non-Pharmacologic 
Inhaled short acting ß2-Agonists Refractory period (Warm-up) 
Inhaled long acting ß2-Agonists Change training environment 
Inhaled corticosteroids Breathing exercises 
Oral anti-histamines Low salt diet 
Oral anti-leukotrienes Poly-unsaturated fatty acids (e. g. fish oils) 
Inhaled cromolyn sodium Anti-oxidants (Vitamin C and E) 
Table 2.3: Interventions for EIA 
Inhaled /12-Agonists 
In the case of acute break through episodes of asthma, corticosteroids and other similar 
treatments are ineffective and bronchodilator therapy in the form of 32-agonists is 
recommended (Rundell and Jenkinson, 2002). In addition to their use following an 
acute episode, it is recommended that the short acting p2-agonist should be inhaled 30 
minutes before exercise. This type of treatment has been shown to improve pulmonary 
function in 90% of individuals with EIA (Anderson et al., 1979). The degree of 
attenuation to EIA observed following short-acting 32-agonist administration has ranged 
38 
from 50-100% in clinical trials using both adults and children (Anderson et al., 1976; 
Boulet et al., 1989; Woolley et al., 1990). 02-agonists relax smooth muscle, increase 
airflow, decrease vascular permeability and moderately inhibit mediator release 
(Williams and Shapiro, 1995). Short acting ß2-agonists are not recommended as the 
only source of treatment for EIA if they are inhaled more than three times a week (BTS, 
2004). Further, Anderson and Brannan (2004) suggests that 1) daily use of inhaled 132- 
agonists can result in the development of tolerance and reduction in the duration of their 
protective effect, 2) the severity of EIA may increase when exercise is performed 
between 8-12 hours following the last inhaled dose and 3) prolonged recovery of lung 
function after an asthma attack. These responses are believed to be due to 
desensitisation of the 02-receptors on mast cells leading to greater mediator release. 
Since inhaled ß2-agonists are used by a large number of asthmatics in the UK, these 
findings may have implications for initial therapy given to individuals diagnosed with 
mild EIA (table 2.4). 
Inhaled Corticosteroids 
Chronic asthmatic and exercise induced asthmatic individuals who exercise regularly 
can take medication that controls inflammatory processes and reduces the occurrence of 
symptoms. A number of studies have demonstrated that treatment with inhaled 
corticosteroids reduces the number of airway inflammatory cells including mast cells, 
eosinophils and lymphocytes (Ward et al., 2002), Furthermore, inhaled corticosteroids 
have been shown to reduce the number of mononuclear cells, CD4+ type 2 T-helper 
cells (Bocchino et al., 1997). Most studies conducted on inhaled corticosteroids suggest 
that these effects are usually seen after 2 weeks of treatment (Chanez et al., 2004). 
Several studies have demonstrated asthmatics using inhaled corticosteroids have an 
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improved airway epithelium (Lundgren et al., 1988; Laitinen et al., 1992; Heino et al., 
1988). However, no single study has demonstrated that inhaled corticosteroids are able 
to fully restore normality to the airway epithelium layer (Lundgren et al., 1988). 
Step Medication 
1- Mild Intermittent Asthma Inhaled short-acting 02-agonists 
2- Introduction of regular preventer Corticosteroids 
therapy 
3- Add on therapy Increase current medication, Inhaled long 
acting 02-agonists, theophylines, 
leukotrienes receptor antagonists, anti- 
histamines 
4- Poor control on moderate dose of Add forth drug from list above 
corticosteroid and add on therapy 
5- Continuous or frequent use of oral Oral corticosteroids 
corticosteroids 
Table 2.4: The British Thoracic Society 5 Step asthma medication guidelines (British 
Thoracic Society. (2004). `British Guidelines on the Management of Asthma: A national 
clinical guideline) 
Despite corticosteroids controlling airway inflammation and remodelling, they do not 
provide full attenuation to acute airway hyperresponsiveness in all individuals with 
EIA. For example, it has been demonstrated that treatment with inhaled corticosteroids 
attenuated acute airway hyperresponsiveness in over 50% of people with EIA 
(Henriksen and Dahl, 1983; Henriksen, 1985; . Vathenen et al., 1991; Farrero et al., 
1995). Sue Chu et al. (2000) demonstrated that the corticosteroid budesonide 400mcg, 
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inhaled twice daily for 12 weeks, had no effect on cellular inflammation in the bronchial 
mucosa or tenascin expression. However, within the budesonide group, there was a 
decrease in IL-2 receptor-activated T-helper lymphocytes and an improvement in FEV1, 
but asthma symptoms were unchanged in 17 (68%) skiers and methacholine 
provocation test was negative in 15 subjects, but remained positive in five subjects in 
each group. However, the improvement in bronchial responsiveness occurred in both 
treatment and placebo groups and was not accompanied by a decrease in cellular 
inflammation. In contrast recent studies have shown benefits from regular use of inhaled 
steroids in patients with mild asthma, even in those whose FEV1 is >90% predicted 
(O'Bryne et al., 2001; Pauwels et al., 2003). 
2.10 International Olympic Committee - Medical Commision (IOC-MC) 
There are conflicting views in recent literature regarding the ergogenic effects of 132- 
agonists. Signorile et al. (1992) demonstrated an increase in power output during 
maximal 15 second efforts on a cycle ergometer after an acute inhalation of the 02- 
agonist Albuterol. Bedi et al. (1988) reported an increase in sprint duration at the end of 
an endurance run after acute inhalation of Albuterol. Another 02-agonist, Salbutamol, 
has been shown to increase muscle strength in young men (Martineau et al., 1992). The 
above studies show that f32-agonists may be of more benefit to improve performance in 
short duration high power events (e. g. sprinting, weight lifting) as no improvements in 
endurance tests have been noted. The research that has specifically looked into the 
endurance effects of 02-agonists (Goubault et al., 2001; Meeuwisse et al., 1992) has 
found no ergogenic effect in elite athletes. Further research is required in this area to 
clarify the potential ergogenic effects of (32-agonists as the argument as to the ergogenic 
effects of the (32-agonist continues. 
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Despite the conflicting views on the performance enhancing effects of inhaled 32- 
agonists, an asthmatic athlete who competes at the Olympic Games must apply for 
therapeutic use exemption (TUE) to be allowed to use therapeutic doses of asthma 
medication (appendix 1 and 2). Prior to the 2002 Salt Lake City Winter Olympic Games 
an asthmatic athlete only required a doctor's note with an explanation of the athlete's 
symptoms and the doctors diagnosis and signature. As discussed above, symptoms 
based diagnosis is neither a sensitive nor a specific diagnosis of EIA and inhaled ß2- 
agonists are potentially performance enhancing. Due to these reasons, and others listed 
in table 2.5, the IOC-MC has stated that a simple notification from the team medical 
officer stating the athlete has EIA is no longer acceptable (IOC-MC 2002). Indeed, a 
more rigorous testing regime including bronchial provocation and maximal voluntary 
flow-volume loops is now required (Anderson et al., 2003). 
- Large increase in the number of athletes notifying the need to inhale a 132- 
Agonist 
- Some athlete's may have been mis-diagnosed and did not have asthma/EIA 
- Endurance sports seemed to have a higher prevalence of EIA than other sports 
- Some evidence that daily use of inhaled 02-Agonists may result in tolerance to 
medication 
- Geographic distribution of notifications was skewed 
I Me z. a: i ne reasons for IUC-MU change in asthma criteria 
(From: Weiler, J. (2003). `Why must Olympic athlete's prove that they have asthma to 
be permitted to take inhaled /12-agonists? '. Journal of Allergy and Immunology. Vol. 
111, pp. 36-37) 
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2.11 Summary 
In summary asthma is a condition that limits expiratory flow, which is a result of 
inflammation, smooth muscle contraction and mucosal gland hyper-secretion within the 
small airways. It is important that individuals who suffer from acute asthma (e. g. 
exercise induced) obtain accurate diagnosis and optimum therapy to reduce the potential 
for airway remodelling and worsening of asthma severity. At present reports suggest 
asthma prevalence within the elite athletes is higher than the general population. 
Furthermore, the prevalence can vary depending on the training and competitive 
environment of the sport. However, asthma prevalence data from British elite athletes 
does not exist. 
EIA can be diagnosed by a variety of tests which can be either direct or indirect airway 
challenges, although, indirect airway challenges are thought to be more sensitive and 
specific. The IOC-MC accepts data from several different provocation challenges 
however, it is not clear which indirect challenge is optimal to diagnose EIA within elite 
athletes. The IOC-MC has criteria for the diagnosis of EIA (AFEV1>10% following 
either exercise or EVH challenge), which has not been derived from reports on elite 
athletes and other measures of expiratory flow may provide a more sensitive and 
specific measure for the diagnosis of EIA in these individuals. 
At present there is no therapy available to eliminate asthma. Therefore, there is a range 
of pharmacologic and non-pharmacologic therapies available for asthmatics that reduce 
the severity of EIA. BTS guidelines suggest inhaled corticosteroids and ß2-agonists 
should be used as first line therapy to attenuate EIA. Despite these recommendations 
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there are limited controlled studies on pharmacologic therapy and attenuation of EIA, in 
elite athletes. 
2.12 Hypotheses 
1. H1 The prevalence of asthma within the British Olympic Team will be reduced 
at the Athens 2004 Summer Olympic Games when compared to the prevalence 
at the Sydney 2000 Summer Olympic Games associated with the introduction of 
the IOC-MC requirement for objective evidence of asthma 
2. Hl The addition of FEF50 will provide a greater sensitivity and specificity in the 
diagnosis of EIA in elite athletes 
3. H, EVH challenges will have a greater sensitivity than exercise challenges in the 
diagnosis of EIA in elite athletes 
4. Hi Combination therapy in the form of inhaled corticosteroid and long acting 32- 
agonist will provide the greatest attenuation to EIA in elite athletes compared 
with corticosteroids and long acting ß2-agonist used as individual therapy. 
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Chapter 3 
General Methods 
3.1 Spirometry - Maximal Flow Volume Loop 
Spirometry is a medical test that measures the volume of air an individual inhales or 
exhales as a function of time flow. It is an effort dependent manoeuvre that requires co- 
operation, coordination and understanding by the subject. For these reasons the 
American Thoracic Society (ATS) has published spirometry guidelines (American 
Thoracic Society, 1995), which were taken into consideration when spirometry 
measurements were performed. The ATS guidelines ensure there is a global standard for 
the manoeuvre and the equipment used to test flow volume that is reliable and specific. 
Spirometer 
In this following collection of studies all maximal flow volume loops were collected 
using a MicroLab ML3500 Spirometer (MicroMedical Ltd, Rochester, UK), which met 
the ATS guidelines for diagnostic spirometers. The volume accuracy of the spirometer 
was checked daily using a three litre syringe. 
Measurement of Maximal Flow Volume Loop 
The maximal flow volume manoeuvre (figure 3.1) was conducted as follows. The test 
was explained to the participant. In preparation for the test the subject was asked about 
recent illness, medication use, smoking and training they had completed that day. The 
participant's data was entered into the spirometer and a forced vital capacity manoeuvre 
was selected. Throughout the whole manoeuvre the participant was asked to remain in a 
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seated position. Verbal instruction (see table 3.1) and a correct demonstration of the 
manoeuvre was given. The participant was asked to attach a nose clip and inhale 
completely. They then placed the mouth piece in there mouth and exhaled maximally 
until they felt they had reached residual volume. Once they had reached residual volume 
they were instructed to inspire maximally to total lung capacity. This manoeuvre was 
completed a minimum of 3 times and no more than 8 times. The maximal flow-volume 
loop with the best FEV, was recorded as long as the second highest FEV1 was within 
0.2L. Each individual maximal flow volume loop effort was accepted if they met the 
criteria listed in Table 3.2. 
Figure 3.1: Spirometry Measurement 
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1. Sit up straight and try to be relaxed 
2. Place nose clip on 
3. Hold the mouth piece to the side of you head 
4. Inhale until your lungs are full 
5. Place the mouth piece in your mouth and exhale as fast as possible 
6. Keep breathing out until you feel your lungs are empty 
7. Following complete exhalation keep the mouth piece in your mouth and inhale 
maximally until your lungs are completely full. 
Table 3.1: Verbal instruction given to participant 
Within-manoeuvre criteria 
Individual maximal flow-volume loops were accepted if 
They are free from 
Cough during the first second of exhalation 
Early termination or cutcut - off 
Effort that is not maximal throughout 
Leak 
Obstructed mouth piece 
They show satisfactory exhalation 
Duration of >6 seconds or a plateau in volume time curve 
Table 3.2: Criteria for acceptance of maximal flow-volume loops (Adpated from 
Brusasco, RV. Crapo, R and Viegi, G. (2005). `Standardisation of Sprirometry'. European Respiratory Journal, vol. 26, pp. 319-338) 
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3.2 Bronchoprovocation Challenge 
Bronchoprovocation challenges are used to make the diagnosis of EIA in athletes. In 
preparation for all bronchoprovocation challenges athletes were instructed to stop 
pulmonary medications as indicated in table 3.3. The athletes were told not to exercise 
within 4 hours of the challenge as this may exert a protective effect against EIA 
(Edmunds et al., 1978; Anderson, 1993). On the day of the test the athletes completed a 
questionnaire stating any other medication they are using and whether they were 
suffering from any illness or injury. If an athlete is suffering from an illness or injury 
that may limit the results of the test, they should be told to return when they are well 
and fit to complete the test. The athlete was also told not to drink coffee, tea, cola drinks 
or eat chocolate on the day of the test (Henderson et al., 1993). Following the 
bronchoprovocation challenge the athlete was not allowed to leave until their FEV i was 
within 10% of their baseline FEV,. If an athlete had not returned to within 10% of FEV1 
within 15 minutes after stopping the challenge, bronchodilator therapy was offered in 
the form of inhaled ß2-agonist (e. g. 200mcg Salbutamol). 
Bronchoprovocation challenges such as methacholine and histamine were not used to 
test for EIA as they are not specific to EIA (Mahler, 1993; Haby et al., 1994,1995; 
Clough., 1991; Rundell et al., 2002; Holzer et al., 2002). Two challenges that are 
thought to be specific to diagnose EIA in athletes are: exercise and eucapnic voluntary 
hyperpnoea (EVH). A positive test for EIA was regarded as a fall of 10% in FEV1 
following either exercise or EVH (ATS, 2000; IOC-MC, 2002). 
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Medication Minimum time interval Reference 
from last dose to challenge 
Inhaled Short Acting 32- 8 hours Ahrens et al. 1984; 
Agonist Greenspon et al 1984 
Inhaled Long Acting ß2- 48 hours Derom et al. 1992; 
Agonist Cockcroft and Swystun 
1997 
Cromolyn Sodium 8 hours ATS 2000 
Leukotriene modifiers 24 hours ATS 2000 
Inhaled corticosteroids 24 hours Anderson et al 2001 
Table 3.3: Time scales for stopping Pulmonary Medication (adapted from: American 
Thoracic Society. (2000). 'Guidelines for Methacholine and Exercise Challenge Testing 
-1999' ' 
American Journal of Respiratory Critical Care Medicine, vol. 161, pp. 309- 
329) 
Exercise challenge 
Prior to exercise the athlete was instructed to complete three maximal voluntary flow 
volume loops with the best FEVI taken as their baseline value. The athlete then 
completed exercise in a mode that was sport specific to the athlete (Rundell et al., 2000; 
2002). This involved the exercise challenge taking place out side of the laboratory. 
During the exercise challenge the athlete was asked to work at an exercise intensity that 
achieved a target heart rate between 80-90% of their max heart rate (HRmax) for 
approximately 8 minutes. The intensity of exercise during the last four minutes was 
conducted at > 85% of HRmax (ATS, 2000; Joos, 2003). After exercise had stopped the 
athlete completed maximal voluntary flow-volume loops at 3,5,10 and 15 minutes post 
exercise. 
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Eucapnic Voluntary Hyperpnoea (EVH) challenge 
The EVH challenge (figure 3.2) is a surrogate for exercise to identify EIA in athletes 
(Anderson et al., 2001). Before the athlete starts the EVH challenge they completed 3 
maximal voluntary flow-volume loops with the best FEV 1 being recorded as their 
baseline measurement. The athlete was then asked to ventilate at a target minute 
ventilation of 85% of their maximal voluntary ventilation rate (MVV). This was 
calculated by multiplying their baseline FEV 1 by 30. The air which is inspired during 
the EVH challenge consists of 21% 02,5% CO2 and 74% N2 and was delivered via a 
gas cylinder (see figure 3.3). There is a 5% CO2 concentration present to prevent 
syncope during the test. The hyperventilation lasts for 6 minutes during which verbal 
feedback and encouragement is given to the athlete. During the EVH challenge minute 
ventilation (V,:, ) was monitored by calculating the volume of air passing through the dry 
gas meter every minute. This allowed the athlete to know whether to increase, maintain 
or decrease Vi.,. After stopping the EVH challenge maximal voluntary flow-volume 
loops are taken at 3,5,10 and 15 minutes. 
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Figure 3.2: EVH Challenge 
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Chapter 4 
The Impact of the Changes in the IOC-MC asthma criteria: A British Perspective 
4.1 Introduction 
Exercise induced asthma (EIA) causes expiratory flow limitation following exercise. It 
can be triggered by an increase in the volume of `unconditioned' air inspired through 
the mouth. During increased levels of activity `unconditioned' air cools and dries the 
upper and lower airways inducing inflammation and smooth muscle contraction, which 
leads to bronchial narrowing (Anderson and Daviskasm 2000) that is readily reversible 
with inhaled short-acting ß2-Agonists. The prevalence of EIA within athletic 
populations has been shown to vary between 9%-55% (Hallstrand et at., 2002; Mannix 
et al., 1999), depending on the type of sport, competitive environment and diagnostic 
test used. Participants in winter sports generally show a higher prevalence of EIA than 
those engaged in summer sports (Weiler et al., 1998; Weiler and Ryan, 2000; Wilber et 
al., 2000; Rundell et al., 2000). 
A number of studies have demonstrated that therapeutic doses of inhaled short-acting 
ß2-Agonists have no performance enhancing effects (Goubault et al., 2001; Collomp et 
al., 2002; Meeuwisse et al., 1992; Morton et al., 1996). Despite the absence of a proven 
ergogenetic effect the International Olympic Committee - Medical Commission (IOC- 
MC) have stated that a simple notification from the team medical officer stating the 
athlete has EIA is no longer acceptable (IOC-MC, 2002). Indeed, a more rigorous 
testing regime including maximal voluntary flow-volume loops is now required 
(Anderson et al., 2003). 
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One of the main reasons the IOC-MC has given for the enhanced level of evidence 
required for the use of 32-Agonists is an apparent increase in the prevalence of asthma 
observed in athletes since the 1984 Olympic Games (Anderson et al., 2003). At the 
1984 Los Angles Olympics, 11% of the United States Olympic team were using 
inhalers (Voy, 1984). The prevalence of asthma reported within the United States team 
at the 1996 Olympics in Atlanta was 14% (Weiler et al., 1998), and by 1998 at the 
Winter Olympics in Nagano this figure had reached 17% (Weiler and Ryan, 2000). 
Whilst there seems to be a progressive rise in EIA within the United States Olympic 
teams, there are limited reports of asthma prevalence from other nations' Olympic 
teams. What remains unclear is whether the observed increase in the prevalence of 
asthma in the United States teams is an indication of a global trend at elite athletic level. 
Further, limited data exists examining sport specific prevalence (Rundell, 2004). 
Many studies have reported asthma prevalence through the sole use of questionnaires 
and symptoms (Weiler et al., 1998; Weiler and Ryan, 2000; Voy, 1984; Nysted et al., 
2000; Turcotte et al., 2003; Kippelen et al., 2004; Alaranta et al., 2004). This approach, 
however, is regarded as a poor method of assessment. For example, Rundell et al. 
(2001) examined the accuracy of symptom-based diagnosis compared to an exercise 
challenge to diagnose EIA in elite winter athletes by comparing results from an asthma 
symptoms questionnaire, with those from exercise challenges. Of the 26% participants 
who tested positive for EIA in response to the exercise challenge, only 40% reported 
more than one symptom of EIA in the questionnaire. Post-exercise cough was the most 
common symptom reported by both EIA-positive athletes and EIA-negative athletes. 
The high number of false positives and false negatives from questionnaire diagnosis 
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highlights the need for a bronchoprovocation test and supports the IOC-MC requirement 
for athletes to produce quantitative evidence of their asthma. 
The relative paucity of sport-specific data examining asthma/EIA prevalence, together 
with the IOC-MC criteria changes for asthma diagnosis, provide the rationale 
for this 
study. Accordingly the purpose of this study was to compare the prevalence of EIA 
within the Great British Olympic Team (Team GB) at the 2000 and 2004 Summer 
Olympic Games, to quantify sport-specific differences in EIA prevalence and to 
examine the implications of changes made in the IOC-MC guidelines. 
4.2 Methods 
2004 Team GB 
Following local ethics committee approval, British athletes (165 males, 106 females), 
selected to compete in the 2004 Team GB, were recruited. All athletes were volunteers 
and provided written, informed consent. Athletes were only tested for asthma if they 
had a previous diagnosis of EIA or reported symptoms of EIA or were referred for 
testing by a team medical officer. 
IOC-MC Criteria 
Diagnosis of asthma for the 2004 Team GB members was made according to the IOC- 
MC requirements, which included a positive bronchodilator, or bronchoprovocation 
test. The IOC-MC criteria for positive diagnosis in a bronchodilator challenge were met 
if the forced expiratory volume in one second (FEV1) increased 15% or greater 
following a therapeutic inhaled dose (200mcg) of a short-acting ß2-agonist 
(Salbutamol). The IOC-MC criteria for positive diagnosis in a bronchoprovocation 
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challenge were met if the post-challenge FEV 1 dropped 10% or greater from the pre- 
challenge FEV1 measurement. Both bronchodilator and bronchoprovocation responses 
were assessed using maximal effort flow-volume spirometry, measured with an 
electronic spirometer that met American Thoracic Society guidelines (MicroLab 
ML3500, Micro Medical, Rochester, UK). The best of three criteria were applied for 
selection of recordings. 
All asthma drug therapy, including inhaled corticosteroids and long acting (32-agonist 
therapy, were withdrawn for a minimum of 72 hours before each bronchial challenge. 
Athletes were advised to use short-acting ß2-agonists if they required any asthma relief 
during this period. 
Bronchodilator Challenge 
The bronchodilator challenge involved measuring maximal voluntary flow-volume 
loops before and 10 minutes following a therapeutic dose (200mcg) of inhaled 32- 
agonist (Salbutamol). 
Bronchoprovocation Challenges 
The Bronchoprovocation challenges consisted of either an exercise challenge or 
eucapnic voluntary hyperpnoea (EVH) challenge (Anderson et al., 2001). 
(i) Exercise 
An exercise challenge involved measuring maximal flow-volume loops pre-exercise and 
at 3,5,10 and 15 minutes after stopping exercise. The exercise challenges were 
conducted for a minimum of 4 minutes and were designed to be as sport-specific as 
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possible, so could involve running, cycling, rowing or swimming. The target heart rate 
during the exercise challenge was between 80-90% of maximum heart rate (220-age). 
(ii) Eucapnic Voluntary Hyperpnoea 
The EVH challenge involved measuring a maximal voluntary flow-volume loops pre- 
EVH (best of three) and at 3,5,10, and 15 minutes after stopping hyperventilation 
(single effort). The EVH challenge required the athlete to hyperventilate for six minutes 
at a rate of 30 times their baseline FEV 1 per minute. To prevent hypocapnia during 
hyperventilation, subjects inspired a gas mix containing 5% C02,21% 02 and 74% N2 
(Anderson et al. 2001). 
2000 Team GB asthma prevalence 
Competitors' Medical Forms (120 females; 152 males) from the 2000 Team GB were 
used to obtain the reported prevalence of asthma before the IOC required quantitative 
evidence of asthma. Data obtained from these forms included the athletes' asthmatic 
status and event. 
Analysis 
The prevalence of asthma within each sport for 2000 Team GB and 2004 Team GB is 
reported descriptively by sport, gender and overall prevalence. 
4.3 Results 
Seventy-seven athletes who were members of 2004 Team GB were tested for asthma 
using a test recognised by the IOC. All athletes required to provide evidence of asthma 
were tested. Sixty-two of these athletes had been previously diagnosed asthmatic and 
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were prescribed asthma medication. Thirteen of the 62 (21%) failed to produce a 
positive test for asthma under IOC criteria. Of these 13 athletes all reported symptoms 
of EIA with post exercise cough (n=10), wheezing (n=10) and chest tightness (n=10) 
the most popular. In addition to the 62 medicated athletes, a further 15 athletes, referred 
by a team medical officer, were tested. Seven of these 15 athletes (47%) tested positive 
for asthma under IOC guidelines, these athletes had no previous history or diagnosis of 
asthma. Four of these seven athletes reported symptoms of EIA with post exercise 
cough (n=3), wheezing (n=3) and chest tightness (n=3) the most common. The athletes 
who met the criteria to use asthma medication at the 2004 Olympic Games (56 athletes) 
won a total of 17 medals (7 Gold, 7 Silver, 3 Bronze). The athletes who failed to meet 
the IOC-MC criteria and were subsequently removed from asthma medication (13 
athletes) at the 2004 Olympic Games won a total of two medals (2 Gold). 
Of the 56 IOC-MC positive athletes only two athletes provided evidence of asthma 
through bronchodilator challenge; all other athletes required a bronchoprovocation 
challenge. The fall in FEV 1 elicited by the positive exercise challenges ranged from 
10.5% to 23.3%. The fall in FEV1 elicited by positive EVH challenges ranged from 
10.0% to 61.3%. All athletes who had a positive bronchoprovocation challenge 
demonstrated reversibility. The prevalence of asthma in the British Olympic Squad at 
both the 2000 and 2004 is reported in Table 4.1 by gender, sport and overall prevalence. 
Swimming had the third highest prevalence of asthma in 2000 (41%) and the highest in 
2004 (44%). Sports whose asthma prevalence also remained similar between 2000 and 
2004 included canoeing (8% vs 11%), rowing (20% vs 19%) and cycling (44% vs 
39%). Sports in which there was a fall in asthma prevalence from 2000 to 2004 
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included athletics (25% vs 16%), badminton (15% vs 9%), diving (43% vs 14%) and 
judo (20% vs 13%). Sports that observed an increase in the prevalence of asthma from 
2000 to 2004 include archery (33% vs 50%), men's hockey (13% vs 31%), shooting 
(0% vs 17%) and Tae Kwon Do (0% vs 25%). Sports that had no asthmatics in either 
2000 or 2004 included boxing, gymnastics, modern pentathlon, sailing, tennis, triathlon, 
weightlifting, and wrestling. 
2000 2004 
n 
No. 
Asthmatic 
% 
Asthmatic n 
No. 
Asthmatic 
% 
Asthmatic 
Athletics 28 7 25 58 9 16 
Badminton 13 2 15 11 1 9 
Canoe/Kayak 12 1 8 9 1 11 
Cycling 27 12 44 23 9 39 
Diving 7 3 43 7 1 14 
Gymnastics 14 0 0 9 0 0 
Hockey 31 3 10 16 5 31 
Judo 10 2 20 8 1 13 
Rowing 41 8 20 36 7 19 
Sailing 17 0 0 18 0 0 
Shooting 6 0 0 6 1 17 
Swimming 41 17 41 36 16 44 
Triathlon 8 0 0 6 0 0 
Other 19 3 16 28 5 18 
Male 152 29 19.1 165 34 20.6 
Overall Female 122 29 23.8 106 22 20.8 
Overall 274 58 21.2 271 56 20.7 
Table 4.1: British Olympic Squads asthma prevalence at the 2000 and 2004 Olympic 
Games 
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4.4 Discussion 
The main finding of this study was that the prevalence of EIA in Team GB athletes was 
unchanged between the 2000 and 2004, whereas within the US Olympic team it appears 
to be rising (Weiler et al., 1998; Weiler and Ryan, 2000; Voy, 1984). Unfortunately, it 
is impossible to determine precisely how the US Olympic team diagnoses of asthma 
were made, as they were conducted at a time when a range of different (unspecified) 
methods were employed. Data from this study demonstrates that 21% of athletes 
previously diagnosed with asthma and using inhalers did not meet the IOC-MC criteria. 
This indicates that a large number of British Olympic athletes were receiving 
medication for which there was no clinical indication. The percentage of athletes in the 
2004 Team GB squad who did not meet IOC-MC criteria is similar to the percentage of 
athletes whose application was declined by the IOC-MC at the 2002 Winter Olympics 
(Anderson et al., 2003). Eighteen percent (29 out 159) of those athletes who submitted 
an application to use 02-agonists at the 2002 Winter Olympics were refused by the IOC- 
MC. We support the IOC-MC contention that a large number of athletes may be mis- 
diagnosed and inappropriately medicated. The new IOC-MC asthma/EIA guidelines 
may, therefore, improve athlete care. 
Despite identifying inappropriately medicated athletes and their subsequent withdrawal 
from medication, there was no overall change in the prevalence of asthma within Team 
GB between 2000 and 2004. This outcome is likely due to the identification of the small 
number (7) of athletes with no previous history, but who presented with a positive 
response to bronchoprovocation. If diagnosis in the 2004 team had been based upon 
symptoms alone, the prevalence would have been 27% ([62+12]/271), which is higher 
than the actual prevalence, and higher than the rate reported in 2000 (21 %). This finding 
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is consistent with previous studies that have demonstrated a continued rise in the asthma 
prevalence at Olympic Games (Weiler et al., 1998; Weiler and Ryan, 2000; Anderson et 
al., 2003; Voy, 1984). This data requires substantiation by data from future Olympics 
using the new IOC-MC criteria. 
The results from the present study demonstrate that there is inter-sport variation in the 
asthma prevalence of Team GB Olympic Teams, with swimming having one of the 
highest at both the 2000 and 2004 Olympics (>40%). It has been suggested that the high 
asthma prevalence in swimming may be due to the environment in which swimmers 
train and compete. The swimming environment has a high concentration of chlorine, 
which may act as a potent trigger for EIA (Thickett et al., 2002; Nemery, 2002). Other 
sports such as figure-skating and cross country skiing have also reported a similarly 
high prevalence of asthma (35%, and 50%, respectively) that has been associated with 
training and competing in cold and dry, and/or polluted environments (Wilber et al., 
2000; Mannix et al., 1996; Rundell et al., 2004). This suggests that athletes who 
compete in certain sports may be more susceptible to EIA development than others. 
Data from the present study indicates that the overall prevalence of asthma is higher in 
elite athletes than it is in the general UK adult population (7.8%) (Asthma UK, 2001). 
The factors underlying this observation require urgent attention, since they have 
implications not only for elite athletes, but also for the many recreational athletes in the 
UK and internationally. 
The small number of athletes within some of the Team GB squads (archery, boxing, 
fencing, modem pentathlon, shooting, tae kwon doe, triathlon) makes it difficult to 
obtain an accurate impression of the prevalence of EIA asthma by sport. Indeed, the 
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prevalence data for triathlon appears to be in opposition to other 
findings. At the 2000 
and 2004 Olympic Games the Team GB triathlon squad did not 
have one athlete 
diagnosed with asthma, yet swimming and cycling were amongst the sports with the 
highest asthma prevalence at both the 2000 and 2004 Olympic Games. It is possible that 
the absence of asthmatic triathletes within Team GB may be due to the small squad size, 
and may not be a true representation of triathlon as a whole. Future investigations could 
overcome this by polling prevalence data from the Olympic Teams of several countries. 
Multi-centre data collection is indicated to support collection of prevalence data. 
In a unique study by Alaranta et al. (2004) sports were classified into four main groups 
and prevalence of EIA was reported on the basis of whether the sport was endurance, 
team, speed/power or motor skill. Prevalence of EIA was highest in endurance sports 
(22.2%) and team sports (14.5%) when compared to speed/power sports (8.8%), and 
motor skill sports (8.2%). Unfortunately, the study relied solely on physician diagnosis 
and lacked individual sport prevalence data. Data from the present study used 
recognised EIA tests to gain the prevalence data at the 2004 Olympics and also 
examined the individual sports. It is difficult to make a direct comparison with the data 
from the Alaranta et at. (2004) study, as sports such as swimming and athletics have 
many different events ranging from sprinting to endurance events. Sub-dividing events 
into groups based on their aerobic requirement seems to suggest that events with a 
longer exposure to inhalation of `unconditioned' air (e. g. endurance events) could have 
a higher EIA prevalence than events that involve shorter exposure to `unconditioned' air 
(e. g. sprint events) supporting the implication of the study by Alaranta et al. (2004). 
Furthermore, sports/events that take place in environments that have a high potency for 
triggering EIA (e. g. dry/polluted air) may have the highest prevalence of asthma 
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regardless of the duration of the activity (e. g. winter sports/swimming). This 
interpretation suggests that the development of EIA may be exacerbated, or even 
caused, by a process of airway remodelling in response to training and competing in an 
environment that triggers EIA. This remodelling process may occur at different speeds, 
depending on the individual, type of event and environment. 
The introduction of more rigorous testing procedures for the diagnosis of EIA/asthma 
resulted in 21% of athletes who were thought to be EIA-positive being confirmed as 
EIA-negative. This rate of mis-diagnosis is not as high as that reported by Rundell et al. 
(2001) in their comparison of questionnaire diagnosis and diagnosis via exercise 
challenges (60%). One of the reasons for this could be the variety of different methods 
used to diagnose asthma in previous Team GB athletes. Thus, not all of the athletes who 
took part in our study would have received previous diagnosis through symptom based 
diagnosis alone. At present no systematic program exists for diagnosis of EIA/asthma in 
Team GB athletes. Such a program could reduce the chance of false positive diagnosis, 
and reduce the needless use of medication, which may have potentially damaging side 
effects, such as down-regulation of airway ß2 receptors (Anderson and Brannan, 2004). 
Perhaps more importantly, this study identified seven athletes with no previous history 
or diagnosis of asthma, three of which reported no symptoms of EIA on questioning. 
Some of these presented with falls in FEV1 of greater than 40% following EVH 
challenge. The implications of untreated EIA/asthma for the performance, health and 
wellbeing of these athletes can only be speculated upon and argues strongly for the 
routine screening of all athletes. 
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4.5 Conclusion 
The prevalence of asthma in 2004 Team GB athletes remained similar to 2000 Team 
GB despite changes in IOC-MC requirements. The improved diagnostic techniques, 
however, identified a large number of false positive diagnoses, as well as identifying a 
number of previously unknown asthmatics. These athletes were either removed from 
unnecessary treatment, or placed on appropriate medication, and therefore received an 
improved level of care. Screening for EIA within elite athletic populations using 
bronchoprovocation challenges such as EVH and exercise appears warranted, not only 
to assist athletes in preparing for major sporting events, but also to ensure the best 
possible level of care. 
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Chapter 5 
Mid-Expiratory Flow vs FEVI Measurements in the Diagnosis of Exercise Induced 
Asthma in Elite Athletes 
5.1 Introduction 
Exercise-induced asthma (EIA) occurs in approximately 90% of chronic asthmatics 
(Lacroix, 1999) and has previously been reported to occur in 7-50% of athletic 
populations (Weiler et al., 1998; Wilber et al., 2000; Larsson et al., 1993; Helenius et 
al., 1998). Data presented in chapter 4 demonstrated a prevalence of 21% in Team GB 
athletes at the 2004 Olympic Games. Asthmatic elite athletes, currently require evidence 
of asthma to obtain a Therapeutic Use Exemption Certificate, which enables the athlete 
to use therapeutic doses of inhaled 02-agonists in and out of competition (IOC-MC 
2002). EIA has previously been diagnosed through a variety of challenge methods 
including; exercise (Rundell et al., 2000; Anderson et al., 1982); eucapnic voluntary 
hyperpnoea (EVH) (Rundell et al., 2004; Anderson et al., 2003); methacholine (Scanlon 
and Beck, 1994; Wagner and Jacoby, 1999); histamine (Anderton et al., 1979); 
hypotonic saline (Smith and Anderson, 1990) and mannitol (Anderson et al., 1997; 
Brannan et al., 1998). The International Olympic Committee's Medical Commission 
(IOC-MC) considers positive tests from exercise, EVH, hypotonic saline, histamine and 
methacholine challenges as evidence of EIA. Methacholine and histamine however, 
have been shown to be less specific than exercise for EIA diagnosis (Anderson et al., 
1997; Avital et al., 1995; Bhagat and Grunstein, 1984). Exercise and EVH challenges 
are regarded as the most specific methods of EIA diagnosis in elite athletes (Anderson 
et al., 2003). 
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In all EIA tests recognised by the IOC-MC, forced expiratory volume in one second 
(FEV1) is the parameter by which changes in maximal expiratory function are assessed. 
At present no 'gold standard' measure exists for the diagnosis of EIA in athletes, or 
non-athletes (Godfrey, 1999). Previous studies that have used FEV1 to diagnose EIA 
have suggested cut off criteria ranging from 7-20% falls in FEV1 post provocation 
(Anderson et al., 1971; Eggleston et al., 1979; Helenius et al., 1996). The work carried 
out by Helenius et al. (1996) suggested that a fall of 10% in FEVI following an exercise 
test is not sensitive enough to diagnose EIA in elite athletes. Despite the absence of a 
`gold standard' measure for the diagnosis of EIA in athletes, the IOC-MC has ruled that 
an exercise or EVH challenge is positive for EIA when the FEV1 falls >10% from the 
baseline measurement. 
It is possible that the addition of other measurements of expiratory lung function may 
provide greater sensitivity and specificity in the diagnosis of EIA. For example, Forced 
Expiratory Flow between 25-75% of vital capacity (FEF25.75) has been used in 
conjunction with FEV1 to aid the diagnosis of EIA in children (Custovic et al., 1994; 
Fonseca-Guedes et al., 2003) and athletes (Rundell et al., 2000; Rundell et al., 2001). 
Implicitly, FEV 1 measures expiratory flow at high and mid-lung volumes, whereas 
FEF25.75 and Forced Expiratory Flow at 50% of vital capacity (FEFSO) are markers of 
expiratory flow through middle lung volumes. It has been suggested that FEF25_75 and 
FEF50 are more sensitive to airway obstruction in the small airways than FEV1 
(McFadden and Linden, 1972; Lebecaque et al., 1993). Custovic et al. (1994) noted that 
cut off points for EIA in children (defined as the normal group mean value -2 SD) 
occurred with a >10% fall in FEV1 and >26% fall in FEF25.75. In this study, the 
combined application of FEV1 and FEF25.75 criteria enabled detection of all subjects 
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with EIA. Furthermore, using both FEVI and FEF25.75 criteria, none of the subjects with 
allergic rhinitis or dermatitis presented with EIA. The fall in FEV 1 after exercise 
in 
children with allergic rhinitis was within the normal range (52SD), but with a 
significantly lower mean value than control subjects. Thus, the Custovic et al. (1994) 
study provides promising evidence supporting the addition of mid-expiratory flow-rates 
to FEV1 in the diagnosis of EIA in children that might also be applied to elite athletes. 
The measurements FEF50 and FEF25-5o are highly correlated and the ratio of the two is 
reasonably constant. Based on this finding, Bar-Yishay et al. (2003) suggested that 
reporting both measurements is unnecessary, and suggested that FEF50 be the preferred 
measure. This preference was based upon the argument that FEF50 is easily and directly 
determined, whilst FEF25-5o is a calculated parameter that is affected by the spirometer 
manufactures' choice of algorithm. 
At present limited data is available examining the inclusion of mid-expiratory flow for 
the diagnosis of EIA in elite athletes. The purpose of the present study was to examine 
the role of FEF50 as an adjunct to FEV1 in the diagnosis of EIA in elite athletes 
following a bronchoprovocation challenge. 
5.2 Methods 
Following local ethical committee approval, 66 male (Mean±SD, age 25.1±4.9 years, 
stature 180.7+7.8 cm, body mass 77.3±12.5 Kg) and 50 female (age 24.3+5.4 years, 
stature 168.2+7.9 cm, body mass 62.6+9.9 Kg) elite summer and winter athletes, who 
held either a Gold or Silver British Olympic Association passport (indicating current or 
potential Olympic competitive standard), volunteered and provided written informed 
consent for the study. Of the athletes who participated in this study, 83 had a previous 
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diagnosis of EIA and were using asthma medication. The other 33 athletes had reported 
symptoms of EIA to a sports physician who had referred them to be tested 
for EIA. The 
testing took place at the Olympic Medical Institute, Harrow, between June 2003 and 
June 2004. Athletes were not tested within two weeks following a respiratory infection 
or within 12 hours of a training session. 
Each athlete completed either an exercise (n=62) or EVH (n=54) challenge. Exercise 
challenges involved exercising at an intensity of >85% of maximal heart rate for 6-10 
minutes in a sport-specific environment (American Thoracic Society 2000). EVH 
challenges consisted of hyperventilating for 6 minutes at a rate of 85% maximal 
voluntary ventilation (30 x baseline FEV1). The gas inspired during the EVH challenge 
was a medical gas containing 21% 02,5% CO2 and 74% N2 (Anderson et al., 2001). For 
both exercise and EVH challenge maximal flow volume loops were measured before 
and at 3,5,10 and 15 minutes after stopping exercise or EVH using a digital spirometer 
(MicroLab ML3500, Micro Medical Ltd, Rochester, UK) which met ATS guidelines. 
The lowest values of FEV1 and FEF50 following either exercise or EVH were recorded 
and the change from baseline was calculated (0). A tFEV1 of >-10% and AFEF50 of >- 
26% were considered cut off criteria for EIA diagnosis (Custovic et al 1994). 
Pearson's correlation was used to calculate the relationship of OFEVI and AFEF50. 
Specificity, sensitivity, predictive value of positive test and efficiency were calculated 
for FEF50 cut-off criteria of 26% and 14%. 
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5.3 Results 
There was a strong positive correlation between tFEV1 and AFEF50 following 
bronchoprovocation (r=0.94, p=0.000) (see figure 5.1). Sixty athletes (52%) 
demonstrated a AFEV1 of ? 10% leading to the diagnosis of EIA (see figure 5.1). Using 
the FEF50 criteria alone led to 21 (35%) asthmatic athletes receiving false negative 
diagnosis; thus, 39 athletes met both FEV1 and FEF50 criteria. The lowest AFEF50 in an 
athlete with a >_10% fall in FEV1 was -14.3%. Reducing the FEF50 criterion to a ? -14% 
fall included 13 athletes whose AFEV 1 was not 2_10% (mean tFEV 1= 5.7, range -8.9 to - 
1.5) (see figure 5.1). Only one athlete had a 226% fall in FEF50 in the absence of a 
210% fall in FEV I (OFEV 1= 8.9%) 
Of the 83 athletes with a previous diagnosis of EIA, 33 athletes failed to present 
evidence for the diagnosis of EIA (OFEV 1<10%) following the bronchoprovocation 
challenge. Of the 33 athletes who had been referred for testing but had no previous 
diagnosis of EIA, 10 athletes presented with EIA following bronchoprovocation 
The values for FEF50 and FVC pre and post bronchoprovocation challenge for the 
asthmatic and non-asthmatic groups are reported in table 5.1. FEF50 (p=0.000) and FVC 
(p=0.000) are significantly lower post bronchoprovocation in the asthmatic athletes. 
There was no significant change in FEF50 or FVC pre and post bronchoprovocation 
challenge in non-EIA athletes (AFEV 1 <10%). 
The specificity, sensitivity, predictive value of positive test and efficiency for FEFso 
cut-off criteria of 26% and 14% are reported in tables 5.2,5.3 and 5.4, respectively. 
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Figure 5.1: Delta FEV 1 vs. Delta FEF50 
FEF50 (1/s) FVC (1) 
Pre 
(mean+SD) 
Post 
(mean+SD) 
Pre 
(mean+SD) 
Post 
(mean±SD) 
Asthmatic 3.86±0.92 2.39±0.84** 4.99+1.00 4.45±1.16** 
Non-Asthmatic 4.79+1.37 4.43±1.31 4.81±1.03 4.65±1.04 
l able changes in HI S0 and rVU following bronchoprovocation challenge 
Asthmatic athlete defined as having a> 10% fall in FEV 1 following bronchoprovocation. 
**= significantly different (p<0.05) from pre test value 
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True positive True Negative Total True 
39 55 94 
False Negative False Positive Total False 
21 1 22 
Total with EIA Total without EIA Total 
60 56 116 
Table 5.2: True and false positive diagnoses based on FEF50 cut-off 26% 
True Positive = OFEV 1 of >_ 10% and a fall in FEF50 of >26% 
True Negative = OFEV 1 of <10% and did not have a fall in FEF5o of >_26% 
False Positive = AFEV 1 of <10% and a fall in FEF50 of >_26% 
False Negative = EFEV 1 of >_10% and a fall in FEF50 of <_26% 
True positive True Negative Total True 
51 43 94 
False Negative False Positive Total False 
9 13 22 
Total with EIA Total without EIA Total 
60 56 116 
Table 5.3: True and false positive results based on FEF50 cut-off 14% 
True Positive = AFEV 1 of ? l0% and a fall in FEF50 of >_14% 
True Negative = AFEV 1 of <10% and did not have a fall in FEF50 of >_l4% 
False Positive = EFEV 1 of <10% and a fall in FEF50 of >_14% 
False Negative = EIFEV I of >_10% and a fall in FEF50 of : 514% 
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Cut-off criteria of 26% Cut-off criteria of 14% 
Specificity 98 77 
Sensitivity 65 85 
Predictive value of positive 
test 
98 80 
Efficiency 81 81 
Table 5.4: The Effectiveness of FEF50 cut-off criteria of 26% and 14%. 
*=True Negativei (True negative + True positive) 
&=True Positive / (True positive + False Negative) 
-=True Positive / (True positive + False Positive) 
*= (True Positive + True Negative) / Total Number of tests 
5.4 Discussion 
Data from the present study demonstrates that the addition of FEF50 reduces the 
sensitivity of EIA diagnosis, following exercise or EVH challenge. Of the 60 athletes 
who were diagnosed with EIA using IOC-MC criteria of a >_10% fall in FEV1,21 (35%) 
athletes would have received false negative diagnosis if a combination of FEV1 and 
FEF50 falls were required for diagnosis. Furthermore, only one athlete exceeded the 
criterion for FEF50, but not for FEV1. Our study therefore suggests FEF50 does not 
improve the sensitivity or specificity for the diagnosis of EIA in elite athletes via the 
IOC-MC criteria (OFEV>10%). 
In previous studies, measurements of FEF25_75 have been employed to supplement FEVI 
in the diagnosis of EIA in children (Custovic et al., 1994; Fonseca-Guedes at al., 2003) 
and athletes (Rundell et al., 2000; Rundell et al., 2001). The studies conducted on 
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children have supported the addition of FEF25_75 measurements to improve the 
diagnosis 
of EIA. It has been suggested FEF25.75 is a more sensitive measure of obstruction 
in the 
small airways than FEV1 (McFadden and Linden, 1972). Thus, EIA may be a 
disease 
that consistently affects expiratory flow through the small airways. Fonseca-Guedes et 
al. (2003) noted that only 60% of children with `intermittent' EIA compared to 94.4% 
of children with `severe persistent' EIA met the criteria for both FEVI and FEF25-75" 
Fonseca-Guedes et al. (2003) suggest FEF25_75 was more likely to fall significantly than 
FEV 1 in children with mild EIA. In contrast, our data are inconsistent with this 
finding 
and suggest that FEV1 is more likely to fall significantly in athletes with mild asthma. 
Indeed, only 1 athlete had a significant fall in FEF50 (? 26%) in the absence of a 
significant fall in FEV1, compared to 21 athletes who had a significant fall in FEVI 
(? 10%) in the absence of a significant fall in FEF50 (? 26%). Only 39 athletes met both 
criteria for FEF50 and FEV1, which would have resulted in 21 (35%) of athletes (who 
met FEV1 criteria) receiving a false negative diagnosis for EIA. The reduced sensitivity 
demonstrated following the inclusion of FEF50 measurement suggests that, in elite 
athletes with mild EIA, expiratory airflow is just as likely to be restricted in the larger 
airways as it is in the smaller airways. Thus, it is most appropriate to assess expiratory 
flow using an index of function for both the larger and smaller airways of the lung, i. e. 
FEV 1. 
There have been a number of studies conducted examining the diagnosis of EIA in 
athletes; however, these have not specifically used mid-expiratory flow rates as a 
criterion measurement to diagnose EIA. Rundell et al. (2000) suggested that a fall in 
FEF25.75 of 14% is significant in the diagnosis of EIA in winter athletes. This lower 
limit was calculated by taking the mean post exercise change from baseline spirometry 
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and subtracting 2 standard deviations. Lowering the FEF50 cut-off criterion in our data 
to >_14% resulted in an increase in the sensitivity, however, this came at a cost of a 
lower specificity of the measurement, from 98% to 77%. Using a >14% criterion, 13 
athletes would have been diagnosed EIA who did not meet the IOC-MC criterion of a 
10% fall in FEV1 from baseline values. 
A further problem associated with the use of FEF50 as a criterion measurement is that its 
reliability is dependent upon constancy of FVC. The data from this study demonstrate 
that the mean fall in FEF50 following bronchoconstriction was accompanied by a mean 
fall in FVC in EIA athletes. Therefore, the fall in FEFSO that is evident in some of the 
athletes following a bronchoprovocation test may be partially attributable to a reduction 
in FVC. Small falls in FVC will not effect the FEV1 measurement. The reduction of 
FVC in asthmatic athletes may be due to the prolongation and discomfort associated 
with exhaling to residual volume during bronchoconstriction. Despite standard controls, 
this may cause the athlete to stop exhaling prior to reaching residual volume. This 
shortcoming further undermines the potential value of FEF50 for diagnosis of EIA. 
5.5 Conclusion 
The addition of FEF50 to FEV1 reduces the sensitivity of EIA diagnosis in elite athletes. 
Our data suggest that a more global measure of maximal expiratory airflow (FEV1) 
provides the most sensitive and specific diagnosis of EIA, especially when the severity 
of the disease is thought to be mild. This would suggest that EIA is a disease that is 
associated with expiratory flow limitation in the larger and smaller airways of elite 
athletes. However, methodological issues associated with assessment of FEF50 (reliance 
upon FVC) mean that this interpretation should be viewed cautiously. Future studies 
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should investigate the efficacy of the IOC-MC criterion of a 10% fall in FEV1 to define 
a more statistically justified cut-off point for EIA diagnosis in elite athletes and examine 
the most appropriate diagnostic tool i. e. EVH vs exercise either based in the lab or sport 
specific environment to establish EIA in elite athletes. 
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Chapter 6 
Screening Elite Winter Athletes for Exercise-Induced Asthma: A Comparison of 
Three Challenge Methods 
6.1 Introduction 
The reported prevalence of exercise induced asthma (EIA) in winter athletes ranges 
from 9% to 50% (Wilber et al., 2000), which is higher than that of the general 
population (e. g., approximately 8% in the UK), but in line with estimates for elite 
summer sports athletes (see chapter 4). At both the 2002 Salt Lake City Winter 
Olympics and the 2004 Athens Summer Olympics, athletes who wished to use inhaled 
02-agonists therapeutically were required to provide evidence of asthma through 
bronchodilator or bronchial provocation challenges. At present, there is no `gold 
standard test' for EIA, however the International Olympic Committee-Medical 
Commission (IOC-MC) accepts the results of a number of different airway challenges, 
including exercise, eucapnic voluntary hyperpnoea (EVH), methacholine and saline 
challenges (Anderson et al., 2003). 
Exercise is an indirect airway challenge that has a high level of specificity (Anderson et 
al., 2003), but its sensitivity is affected by environmental conditions (Rundell et al., 
2000). Accordingly, exercise challenges in sport-specific (SS) environments may be 
more sensitive than exercise challenges conducted in laboratory (LB) settings (Rondell 
et al 2000). This is most likely because the air-conditioned laboratory environment has a 
relatively high temperature and water vapour content (i. e. Temperature c. 20°C, 
Humidity c. 50%). Airway drying (Anderson, 1984; Anderson and Daviskas, 2000; 
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Evans et al., 2005; Hahn et al., 1984; Holzer et al., 2002) and airway cooling 
(McFadden et al., 1986) have been proposed as mechanisms in the aetiology of EIA. 
Therefore, an air conditioned LB environment may not be sufficiently provocative, 
especially for winter athletes, who train and compete at sub-zero temperatures, where 
the water vapour content of the air is very low. Despite this limitation, LB exercise 
challenges are still used to assess elite athletes for EIA. 
Eucapnic voluntary hyperpnoea (EVH) is a laboratory based indirect airway challenge 
that enables minute ventilation and environmental conditions to be controlled. The EVH 
challenge has been reported to be the most suitable method for the diagnosis of EIA. in 
cold weather athletes (Mannix et al., 1999; Rundell et al., 2004). However, over half of 
the requests for therapeutic use exemption (TUE) for 02-Agonists submitted for the 
2002 Salt Lake City Winter Olympics employed direct airway challenges to establish 
EIA (i. e. methacholine and histamine) (Anderson et al., 2003). The sensitivity and/or 
specificity of these methods have been challenged. Holzer et al. (2002) screened 50 
athletes for EIA using methacholine and EVH challenges and found only 9 (18%) 
athletes presented with a positive challenge to methacholine, whereas 25 (50%) athletes 
(including the 9 methacholine positive athletes) presented with a positive EVH 
challenge. The authors concluded that an EVH challenge was more sensitive and 
specific than a methacholine challenge for the diagnosis of EIA in athletes. Thus, 
evidence suggests that direct airway challenges are not sufficiently sensitive or specific 
for the diagnosis of EIA in athletes. 
Due to the lack of sensitivity and specificity of symptom based diagnosis (Rundell et 
al., 2001) and direct airway challenges (Holzer et al., 2002) several groups have 
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recently suggested that athletes should be screened for ETA using either EVH challenge, 
or exercise challenges (Bokulic, 2002; Holzer and Brukner., 2004; Helenius et al., 1996; 
Kukafka et al., 1998; Rupp et al., 1992; Rupp et al., 1993). At present, however, limited 
evidence exists examining the sensitivity and specificity of eucapnic voluntary 
hyperventilation challenge and laboratory based and sport specific exercise challenges 
in elite athletes. The aims of this study were to establish whether an asthma screening 
program would be beneficial for elite British winter athletes and examine the role of the 
EVH challenge and laboratory based (LB) and sport specific (SS) exercise challenges in 
the evaluation of elite winter athletes. 
6.2 Methods 
Following ethical approval from Harrow Local Research Ethics committee, 14 athletes 
(mean±SD; age 22.6+5.7years, height 177.2+7.0cm, weight 68.9+16.9kg) from the 
Great Britain Short-track Speed Skating (n=10) and Biathlon (n=4) teams volunteered 
and provided written informed consent. 
Each athlete completed a laboratory based challenge (LB), a sport-specific challenge 
(SS), and a eucapnic voluntary hyperventilation challenge (EVH) in a random order. All 
asthma drug therapy, including inhaled corticosteroids and long acting p2-agonist 
therapy, were withdrawn for a minimum of 72 hours before each bronchial challenge. 
Athletes were advised to use short-acting ß2-agonists if they required any asthma relief 
during this period, until 8 hours before the challenge. 
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Laboratory based exercise (LB) challenge 
The LB challenge required the athlete to run continuously on a treadmill for 8 min 
(Temperature 18°C, Humidity 56%). Exercise intensity was set to illicit a HR greater 
than 90% HR. for the final four minutes of exercise (Joos and O'Conner, 2003). 
Sports Specific exercise (SS) challenge 
The SS challenge for the speed skaters involved skating for 6 min (pace ranged between 
11-12 seconds per 250m lap) on the ice-rink (Temperature 8°C, Humidity 35% H2O 
content). The SS challenge for the biathletes involved a 20min simulated race in 
Vaukati, Finland (Temperature. 1-2°C, Humidity 31-34% H20). 
Eucapnic Voluntary Hyperventilation (EVII) 
The EVH challenge was conducted in the laboratory and required each athlete to 
hyperventilate for 6 min (30 x baseline FEV1) breathing a gas mixture containing 5% 
C02,21% 02,74% N2 (Inspired Air Temperature 19.1°C, Humidity <2%) (Anderson et 
al., 2001). 
A MicroLab ML3500 (Micro Medical Ltd, Rochester, UK) spirometer was used to 
collect all spirometry measurements. Maximal effort voluntary flow-volume loops were 
measured before and at 3,5,10 and 15 minutes after stopping each challenge. Forced 
expiratory volume in one second (FEV1), peak expiratory flow (PEF), forced vital 
capacity (FVC), forced expiratory flow at 50% of FVC (FEFSQ) and FEV1 as a 
percentage of FVC (FEV1%) were recorded at each time point. 
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The percentage change (A) in FEV1, PEF, FVC, FEF5o and FEV1% were calculated for 
each challenge by taking the lowest value recorded in the 15 minutes following each 
challenge and expressing the difference between this and the baseline value measured 
immediately before each challenge as a percentage. A fall in FEV1 of 10% or greater 
from the baseline value was deemed positive for EIA. 
Statistics 
Repeated measure analysis of variance (ANOVA) tests were used to compare the 
changes in OFEVI, iPEF, OFVC, AFEF50 and OFEV1% for each challenge. Planned 
unpaired t-tests were used to analyse the difference between positive and negative 
athletes for each challenge. AP value of <0.05 was regarded as significant. All values 
are presented as mean + SD. 
6.3 Results 
All 14 athletes completed every challenge. Of 14 athletes, 2 athletes had a previous 
history of asthma and were currently medicated with beclomethasone and salbutamol 
inhalers. Baseline lung function and OFEV1 for each challenge are reported for every 
athlete in table 6.1. 
Based on a >_10% fall in FEV1,10 of the 14 athletes (including two athletes with a 
previous history of asthma) had a positive test to at least one of the challenges (see 
Table 6.1). There was no difference for percent predicted baseline FEV1 values between 
positive (102.9+11.43%) and negative (110.3+12.6%) EIA athletes. Ten athletes had a 
positive response to EVH; of these, only 3 also had a positive response to the SS 
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challenge. No athletes had a positive test to the LB challenge (see figures 6.1,6.2 and 
6.3). 
After the assumption of sphericity was met, repeated measures ANOVA revealed 
AFEV 1 (P=0.001), APEF (P=0.001), AFEF50 (P=0.001) and AFEV 1% (P=0.001) 
changes were significantly greater following EVH than either the LB or SS challenge. 
The average falls for positive (AFEV1 >10% for at least one challenge) and negative 
athletes following LB, SS and EVH challenges are reported in table 6.2. 
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Figure 6.1: LB challenge vs EVH challenge 
80 
Athlete No. 
Baseline 
FEV 1(1) 
% of predicted 
FEV 1(%) 
SS OFEV1 
(%) 
LB OFEVI 
(%) 
EVH 
OFEV 1(%) 
1 4.8 104 -13.9 -5.52 -20.3 
2 4.0 126 -2.5 2.48 -8.8 
3 4.5 113 -20.7 -5.77 -35.8 
4 4.5 104 -3.4 -3.34 -11.0 
5 4.5 96 -1.1 -3.15 -14.0 
6- 4.8 100 -14.7 -8.78 -11.8 
7 4.0 113 -2.5 -3.72 -10.8 
8 4.1 97 2.4 0.97 -3.4 
9 4.0 114 -7.2 0.53 -3.5 
10- 3.6 79 -9.1 -5.01 -12.5 
11 4.7 104 -4.1 0.20 -11.4 
12 5.1 104 -8.2 0.38 -4.7 
13 5.1 120 -2.9 4.38 -18.4 
14 4.1 96 -1.5 0.70 -23.7 
Mean +SD 4.4+0.4 105+11.8 -6.4+6.4 -1.8+3.7 -13.6+8.7 
Table 6.1: Athlete responses to each challenge 
LB tFEV1= change in FEV1 following Laboratory Based exercise challenge 
SS tFEV 1= change in FEV 1 following Sport Specific exercise challenge 
EVH tFEV1= change in FEV1 following Eucapnic Voluntary Hyperventilation 
challenge 
EIA positive athlete identified by bold print 
-= past history of asthma and regular therapy using bechlomethosone and salbutamol #= Member of the British Biathlon Team 
Predicted values = European Community for Coal and Steel (1993) 
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LB SS EVH 
No. A No. 0 No. A 
FEVI *+ 
Positive 0 3 -16.4±3.73 10 -16.9+7.99 
Negative 14 -1.83+3.73 11 -3.6+3.39 4 -5.1+2.51 
PEF 
Positive 0 3 -14.4+4.38 10 -14.9+7.49 
Negative 14 -2.32+4.39 11 -2.9±5.87 4 -7.08+7.09 
FVC 
Positive 0 3 -7.7+2.08 10 -3.1+3.37 
Negative 14 -2.44+2.26 11 -3.9±4.00 4 -1.7+2.59 
FEFso + 
Positive 0 3 -24.6+_3.79 10 -30.7+_10.13 
Negative 14 -2.44+13.38 11 -2.9+17.90 4 -14.2+9.93 
FEVI% *+ 
Positive 0 3 -9.5+2.17 10 -14.4+6.56 
Negative 14 0.65+3.96 11 0.4±4.09 4 -3.41+2.69 
Table 6.2: Comparison of mean percentage changes for EIA-positive and EIA-negative 
athletes for the EVH and SS challenges. 
*= Significant difference (P<_0.05) between positive and negative athletes following SS 
Significant difference (P<_0.05) between positive and negative athletes following 
EVH 
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6.4 Discussion 
Data from the present study suggests that screening elite athletes for EIA is warranted. 
In addition to the 2 athletes who had a previous history of EIA, screening identified 8 
athletes, with no previous history of EIA, who presented with significant (>10% fall in 
FEVI) bronchial hyperresponsiveness to EVH. This finding concurs with previous 
studies and chapter 4 that suggest many athletes fail to report and/or recognise 
symptoms of EIA (Rundell et al., 2001; Bokulic, 2002; Holzer et al., 2004). 
Results from the present study demonstrate that the EVH challenge resulted in the 
greatest number of athletes presenting with bronchial hyperresponsiveness (EFEV1>- 
10%) commensurate with the diagnoses of EIA. Results from this study are similar to 
studies that have compared exercise and EVH challenges in winter athletes (Mannix et 
al., 1999; Rundell et al., 2004) and suggest that the EVH challenge provides a more 
sensitive diagnosis of EIA in elite winter athletes than any other routinely used, non- 
pharmacological challenge. In the present study all athletes who presented with EIA did 
so through the EVH challenge. In contrast, Rundell et al. (2004) demonstrated that 19 
out of 38 winter athletes presented with EIA. Two of these athletes had a positive 
exercise challenge but did not present with EIA following EVH. Had the present study 
recruited a larger number of athletes the study may also have found that the SS 
challenge identified athletes who did not respond to EVH. However, it is clear that EVH 
is a sensitive and specific challenge for the diagnosis of EIA in elite athletes. 
The superiority of the EVH challenge is primarily due to the greater degree of control 
over the two main contributors to the airway response, viz., inspired air water content 
and minute ventilation. The enhanced control over the condition of the inhaled air and 
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breathing rate during the EVH challenge allows greater confidence that the airways are 
being adequately stimulated to trigger bronchoconstriction in susceptible athletes. 
In line with the greater control of inspired air water content during the EVH challenge, 
findings from the present study are more consistent with the hyperosmolarity theory of 
EIA pathogenesis (Anderson, 1984; Anderson and Daviskas, 2000; Evans et al 2005; 
Hahn et al 1984; Holzer et al 2002) rather than the airway re-warming theory (Anderson 
and Daviskas, 2000; Anderson and Holzer, 2002; McFadden et al., 1986). Despite the 
colder inspired air temperature during the SS challenge (1°C Biathlon, 8°C Speed 
Skaters) compared with the LB challenge (18°C), only a limited number of athletes (3) 
presented with EIA following the SS challenge. The EVH challenge, which had the 
greatest number of positive tests (10 athletes), was conducted with inspired air 
temperatures (19.1°C) similar to that of the LB challenge, however the relative humidity 
(RH) of the inspired air (RH<2% H2O content) was lower than either the LB 
(RH=c. 60% H2O content) or SS (RH=31-35% H2O content) challenge. The more 
provocative nature of dry air inhalation, compared to cold air lends support to the notion 
that the underlying mechanisms for the development of EIA are not temperature-related. 
The lower number of athletes who presented with EIA following SS and LB challenges 
may be a result of the 10% FEV1 criterion not being sensitive enough to detect EIA 
following LB or SS challenge. Work by Helenius et al. (1996; 1998) has suggested that 
the 10% cut-off criterion for FEV1 may be insufficiently sensitive to detect EIA in elite 
athletes and argue that it is not statistically justified. They suggest a fall in FEV1 of 
6.5% as a suitable cut-off criterion for elite runners. Similarly, Rundell et al. (2000) 
suggest a fall in FEV1 of 7.1% is a justified value to diagnose EIA in elite athletes. 
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These studies calculated the FEV1 cut-off criteria on the basis of the 95th percentile 
(defined as two standard deviations) of the post-exercise decline in FEV1 observed in a 
non-asthmatic population. 
In line with Rundell et al. (2000) recommendation, we assessed a reduction in the cut- 
off criterion for OFEVI to 7%. This resulted in a further two athletes being classified as 
positive in response to the SS challenge, and one in response to the LB challenge (see 
figures 6.1 and 6,2). Thus, a reduction in the criterion fails to improve the sensitivity of 
the SS and LB challenges to the extent that no false negative responses are observed. 
Further work is required to establish standardised cut-off criteria for falls in FEV1 
following various challenges. This may reveal that the criterion for exercise challenges 
should be lower than the criterion (FEVI >-10%) for an EVH challenge. 
6.5 Conclusion 
The observations in the present study support the role of screening elite athletes for EIA 
and suggest that EVH is a more sensitive challenge for the detection of EIA in 
asymptomatic athletes compared with SS and LB challenges. Therefore, if sporting 
governing bodies were to implement screening programmes to test athletes for EIA, it is 
recommended that EVH should be the challenge of choice. 
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Chapter 7 
Athletes, Exercise Induced Asthma and Optimal Medication 
7.1 Introduction 
Exercise-induced asthma (EIA) affects approximately 20% of elite athletes (see chapter 
4). Chapters 5 and 6 have demonstrated that a fall in FEV1 of >10% following a 
eucapnic voluntary hyperpnoea (EVH) challenge is a specific and sensitive diagnostic 
test of EIA in elite athletes. If an athlete presents with EIA following a recognised test it 
is important that he/she receives optimal management and pharmaceutical treatment. In 
the absence of efficacious pharmacologic therapy, there may be deteriorations in well- 
being and performance. At present, few controlled studies examining the efficacy of 
asthma drugs in elite athletes are available (Helenius et al., 2005). 
There are a number of medications that have been reported to attenuate EIA, however, 
at present, inhaled corticosteroids and inhaled ß2-agonists are recommended as the first 
line treatment for individuals with asthma by the British Thoracic Society (BTS, 2004). 
In accordance with the BTS guidelines, inhaled short acting ß2-agonists should be used 
in the first instance for mild intermittent EIA (step 1). If symptoms are not controlled, 
inhaled corticosteroids should be used in addition (step 2) and then inhaled long-acting 
I32-agonists (step 3) if symptoms are not controlled by the use of both short-acting 3- 
agonists and corticosteroids (table 2.4). 
Since 1976 it has been accepted that inhaled 02-agonists are effective in the prevention 
of EIA (Anderson et al., 1976). Within the elite athlete population the number of 
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submissions for inhaled ß2-agonists has increased at each Olympic Games since 1984 
(IOC-MC 2002). However, Anderson and Brannan (2004) have recently suggested that 
the long-term use of inhaled ß2-agonists may lead to a worsening of asthma severity. 
Kaira et al. (1996) and Van Veen et al. (2003) have both reported that only a small dose 
of inhaled long-acting ß2-agonists can cause the bronchial smooth muscle to become 
more sensitive to a provocative stimulus. Furthermore, once daily use of long-acting 02- 
agonists results in a reduction in the duration of its protective effect upon the airway 
from bronchoconstriction (Hancox et al., 2002; Simons et al., 1997). Therefore, sole use 
of (32-agonist therapy to attenuate EIA should be undertaken with caution, as this 
treatment does little to attenuate the underlying airway inflammatory and remodelling 
processes that may occur (Anderson and Brannan, 2004). 
Corticosteroids have previously been reported to be associated with a reduction in 
inflammatory cells in the airway (Schleimer, 1983), as well as an improvement in 
symptoms, lung function and asthma exacerbation frequency (Dompeling et al., 1993). 
Therefore, the use of corticosteroids should attenuate the potential airway remodelling 
processes that may occur within individuals who have EIA. Recent studies have 
reported that the addition of long-acting inhaled ß2-agonists to corticosteroid therapy 
leads to better symptomatic asthma control and lower frequency of exacerbations 
(Shrewsbury et al., 2000; Koopmans et al., 2005; Masoli et al., 2005). However, Aziz et 
al. (2000) reported that patients preferred the combination therapy, despite the fact that 
it provided no greater effect on inflammatory markers (exhaled nitric oxide and serum 
eosinophilic cationic protein) than corticosteroid therapy alone. 
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Inhaled corticosteroid and long-acting ß2-agonist therapy may attenuate the signs and 
symptoms of EIA compared to short-acting medication and single medication alone in 
non-athletes. It remains unclear at present however, which pharmaceutical interventions 
are optimal for elite athletes with EIA. Accordingly the purpose of the present 
investigation was to examine the effects of corticosteroid (fluticasone propionate) and 
long-acting p2-agonist (salmeterol) therapy in the control of EIA in athletes. 
7.2 Methods 
Following approval from Harrow Local ethics committee, elite athletes who had a 
previous positive (FFEVI >-10%) eucapnic voluntary hyperpnoea (EVH) test were 
approached to take part in the study. Three male and 5 female elite athletes (mean+SD; 
age 21.8±4.0 years; height 171.0+11.2cm; body mass 66.0+12.3kg), who had previous 
diagnosis of EIA, volunteered and provided written informed consent. Athletes came 
from a range of sports: 4 athletics, I slalom canoe, 1 swimming, 1 rowing and I short 
track speeding skating. 
Athletes were prescribed the following inhaled pharmaceutical therapies, in a 
randomised double blind design, for a three week period with a two week washout 
between each intervention: (a) 200mcg fluticasone propionate (FLU), (b) 50mcg 
Salmeterol (SAL), (c) 250mcg fluticasone propionate and salmeterol in combination 
(FXS) or (d) placebo (PLA). Each medication was given to the athlete as a inhaler 
labelled either A, B, C or D. Neither the athlete nor the researcher knew what 
medication was being used. At the cessation of the study the athlete discovered what the 
medications were through consultation with the English Institute of Sport doctor. 
Athletes using long term therapy (e. g corticosteroids, long acting ß2-agonist) at the 
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initiation of the study ceased medication two weeks before they began the first 3 week 
course of test treatment (figure 7.1). Throughout this period and following 18 weeks of 
the study, athletes were prescribed inhaled salbutamol to use when required. Athletes 
were also asked to keep a daily diary that included: 1) recording the use of treatment 
medication (am and pm), 2) number of hours of aerobic training 3) the number of 
salbutamol inhalations required each day. 
A3 week intervention was thought to be the most suitable time to allow all the 
medications to reach their optimum protective effect following consultation with 
English Institute of Sport Doctors and the ethical committee. A two week wash was 
thought an appropriate time to allow all medication to leave the body before the next 
medication was started. This time period was suggested by the drug manufactures and 
deemed acceptable by the ethics committee. 
Following each three week period of treatment medication the athlete completed an 
EVH challenge (Anderson et al., 2001) with maximal voluntary flow volume loops and 
exhaled nitric oxide (eNO) analysis measured before and 3,5,10 and 15 minutes after 
the EVH challenge (see chapter 3.4 for EVH methods). 
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Starts 3 weeks medication trial 
T T-- 
Initialion of trial Exhaled nitric oxide measured and eucapnic voluntary hyperventilation challenge completed 
=2 week Washout period 
=3 week medication trial 
II= consultation with doctor 
Figure 7.1: Schematic of medication trial 
Exhaled Nitric Oxide (eNO) was measured using an online analyser (NOA-280i Nitric 
Oxide Analyser, NO Analysis software Version 3.21, Sievers Instruments, Boulder) 
according to American Thoracic Society guidelines (ATS, 1999). The procedure for 
eNO analysis was: 1) maximal inhalation to total lung capacity and 2) immediate 
exhalation against a resistance for at least 6 seconds to obtain a NO plateau lasting at 
least 3 seconds. During exhalation subjects were instructed to monitor a visual computer 
display to maintain a flow rate of 50 mLs I± 10% at a pressure of 16 cmH2O. Three 
measurements of eNO were taken at each time point and the mean of the three 
measurements was recorded. All eNO measurements were taken before spirometry at 
each time point. 
Statistics 
Repeated measures ANOVA were used to compare the means of resting FEVI and eNO 
and percent changes in FEV1 and eNO following the EVH challenge for each treatment. 
Significance was assumed when p<0.05. Mauchly's Test was used to test for the 
assumption of sphericity. Sphericity was assumed if p>0.05. If sphericity was not 
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assumed (p<0.05) the Greenhouse-Geisser correction factor was applied to assess within 
subjects effects. A Pearson's correlation was used to investigate the relationship 
between baseline eNO and percentage fall in FEV 1 following the EVH challenge. 
7.3 Results 
Six athletes completed all 4 treatments. One athlete was able to complete resting 
measurements during FXS, but was unable to undertake the EVH challenge; a second 
athlete was unable to complete the PLA trial due to illness. Both athletes completed all 
other assessments, however, data from their EVH and eNO measurements were 
excluded from repeated measures ANOVA. Individual measurements for baseline 
FEV 1, eNO and percentage change in FEV 1 following EVH challenges are reported in 
table 7.1. Repeated measures ANOVA revealed no significant difference for the number 
of salbutamol inhalations taken, or hours of aerobic training across the different 
treatment periods of the study. 
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Repeated measures ANOVA demonstrated a significant difference (p=0.03) between 
the means of the total expired air following the EVH challenge after the four treatments 
(table 7.2). Post hoc Pairwise comparisons demonstrated that the total amount of air 
expired during the EVH challenge following FXS was significantly greater (p=0.05) 
than that expired following FLU, SAL and PLA. Repeated measures ANOVA however, 
did not identify any significant difference in the FEV1 change (AFEVI) following EVH 
challenge between the 4 treatments. Repeated measures ANOVA identified a difference 
between the means of baseline FEV I for the 4 treatments (table 7.2) that approached 
significance (p=0.07), suggesting FXS treatment resulted in greater baseline FEV 1 
values compared with FLU and PLA treatments (figure 7.2). The greatest fall in FEV1 
from baseline occurred at 5 minutes post-EVH challenge for all treatments (figure 7.3). 
The FEV1 improved at the 10 minute post-EVH measurement, with a similar 
improvement shown at 15 minute post-EVH measurement. However, FEV1 did not 
return to the baseline values. Forced vital capacity measures were similar at baseline 
and reduced to a similar level following EVH challenge for all treatment groups. 
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Figure 7.2: Baseline FEV 1 
mSAL 
Figure 7.2 shows the means (±SE) values for each treatment. Repeated measures 
ANOVA identified a difference between the means of baseline FEV 1 for the 4 
treatments that approached significance (p=0.07). 
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Figure 7.3: FEV 1 before and after EVH Challenge 
Figure 7.3 demonstrates the AFEV1 (mean +SE) at each time point following EVH 
challenge. Repeated measures ANOVA did not identify any significant difference in the 
max AFEV1 following EVH challenge between the 4 treatments 
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Baseline 5 10 15 
Treatment Baseline 
FEV1 
(litres) 
OFEVI post 
EVH (%) 
Baseline 
eNO (ppb) 
DeNO post 
EVH (%) 
EVH total 
expired air 
(litres) 
FXS 4.2±0.8 -14.2±7.7 20.3+8.2+ -45.0±21.0 737.7±210.8 
FLU 4.0±0.9 -13.0+10.0 19.7+9.2+ -33.8+15.1 640.8+138.6 
SAL 4.2±1.0 -18.0+16.4 39.3±26.7 -45.0+17.9 669.0+163.2 
PLA 4.0±0.8 -18.2+16.4 46.3±26.8 -23.2+35.5 650.7+148.9 
Table 7.2: Mean values for FEVI, eNO and EVH 
Value reported mean + SD 
+= significantly lower than PLA 
*= significantly lower than SAL 
$= significantly greater than PLA, SAL and FLU 
AFEV1= max change in Forced Expiratory volume in one second 
DeNO = max change in exhaled nitric oxide 
Repeated measures ANOVA demonstrated a significant difference (p=0.01) between 
the means of baseline eNO (table 7.2). Post-hoc pairwise comparisons demonstrated 
that baseline eNO was significantly different between FXS and PLA (p=0.03), FLU and 
PLA (p=0.04) and FLU and SAL (p=0.04). Pearson's correlation revealed that there was 
no significant relationship between eNO and iFEV 1 following an EVH challenge 
(figure 7.4). eNO was lower following EVH challenge for all treatments when 
compared with the baseline measurement (figure 7.5). This fall was greatest at the 5 
minute measurement. Repeated measures ANOVA revealed no significant difference 
between the changes in eNO post EVH challenge between treatment groups. 
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Figure 7.4: Correlation between baseline eNO and change in FEV1 post EVH challenge 
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Figure 7.5: eNO Before and After EVH Challenge 
*= significantly greater than FLU; **= significantly greater than FLU and FXS 
Following the completion of the study each athlete had a consultation with an English 
Institute of Sport doctor to review the results. Athletes were prescribed ongoing 
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medication based on the results of the tests and the symptoms athletes reported during 
each drug trial. Four athletes were prescribed FLU, two athletes were prescribed FXS 
and two athletes were prescribed SAL (table 7.1). 
7.4 Discussion 
This study demonstrates that there is heterogeneity of response in elite athletes with EIA 
to the three medication regimes employed in the present study. The heterogeneity is 
highlighted by the medications prescribed to the athletes on a long term bases following 
the 5 month trial (4 Fluticasone Propionate: 2 Salmeterol: 2 Fluticasone Propionate and 
Salmeterol in combination). The heterogeneity of the responses suggests that the 
pathogenesis of EIA may vary between individuals. Anderson and Kippelen (2005) 
suggest that the pathogenesis of bronchoconstriction is associated with several cascades 
(figure 7.6). Some of these cascades may involve more inflammatory mediators than 
others. The Anderson and Kippelen (2005) model of EIA pathogenesis, suggests that 
the individual pathology resulting in bronchoconstriction may vary between individuals 
with EIA. Therefore, environment, EIA severity, sport and individual physiological 
profiles should be considered before pharmaceutical intervention to attenuate EIA as 
opposed to following general population guidelines (BTS, 2004). 
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Figure 7.6: Flow-diagram of the pathogenesis of EIA 
Flow chart describing the acute events leading to EIA in the classic asthmatic (left) and 
the events leading to the development of EIA in the athlete (right) (From Anderson, S. 
& Kippelen, P. (2005). 'Exercise Induced Bronchoconstriction-Pathogenesis'. Current 
Asthma and Allergy Reports, vol. 5, pp. 116-122) 
There is obviously a potential for the heterogeneity of response to the medications to be 
due to inter-individual pathogenic differences, however the observed heterogenity may 
also be due to the significant difference between the ventilation rates achieved during 
the EVH challenges. One of the advantages of an EVH challenge is that minute 
ventilation (VE) can be monitored and controlled (Anderson et al., 2001). In the present 
study the total expired air volume differed between the FXS and other trials. 
Fluctuations in the ventilation rate can alter the observed bronchoconstriction response 
(O'Cain et al., 1980). Therefore, the larger volumes of air expired during the FXS EVH 
challenge may have resulted in greater reductions in FEV 1 following EVH. Thus, the 
bronchoconstriction observed following the FXS EVH challenge may have been smaller 
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had the athletes VE during each EVH challenge been similar under all conditions. This 
may have been achieved by using 85% of maximal minute ventilation (MVV) during 
exercise rather than calculating 85% of MVV from baseline FEV1 before each EVH 
challenge (Spiering et al., 2004). The greater VE observed following FXS trial however, 
may be a result of improved respiratory function, therefore, resulting in greater 
VE. This 
would suggest the FXS trial resulted in the greatest observed functional improvements 
when compared to the other medication trials (FLU, SAL and PLA). 
Long-acting 02-agonist therapy in the form of Salmeterol provided greater protection 
against EIA in 4 athletes, than the use of corticosteroids alone. Two of these athletes 
benefited from the sole use of Salmeterol as opposed to using it in combination with 
corticosteroid. Previous research suggests the addition of long-acting 02-agonist 
medication is more effective in attenuating EIA than increasing the dose of 
corticosteroids (Shrewsbury et at, 2000; Koopmans et at, 2005; Masoli et at, 2005). It 
was surprising however, to observe that Salmeterol in isolation was more beneficial to 
some athletes than in combination with corticosteroids, or corticosteroids alone in the 
present study. The results of this study therefore suggest that BTS (2004) and 
International Asthma Guidelines (GINA 2002), may need to be adapted to 
accommodate elite athletes with EIA. These recommendations should be interpreted 
with caution however, given the spectrum of results observed during the present study. 
Further investigations are indicated examining the sole use of ß2-agonists in athletes in 
whom EIA is not attenuated by corticosteroids alone. As previously discussed however, 
long-term use of 02-agonists may result in down regulation of (32-receptors in the lung 
(Barnes 1995) and the stimulation of chloride secretion and movement across the 
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epithelial cells to the airway surface leading to the dehydration of the airway submucosa 
(Boucher, 1994), thereby increasing EIA severity. Anderson and Brannan (2004) 
suggest that long-acting (32-agonists in the form of salmeterol and formoterol should 
be 
used intermittently to reduce the potentially deleterious effects described above. 
It may 
therefore be useful to investigate other potential therapies that may be more suitable for 
long-term treatment of EIA, but do not increase asthma severity. 
In this study, airway inflammation was monitored using online eNO analysis. eNO has 
previously been demonstrated to correlate positively with induced sputum eosinophilia 
(Jatakanon et al 1998) and be greater in asthmatics compared with non-asthmatics 
(Kharitonov et al.; 1995; Persson et al., 1994). Previous studies have demonstrated a 
reduced eNO following treatment with corticosteroids in patients with asthma (Massaro 
et al., 1995; Alving et al., 1999; Kharitonov et al., 1994,1996; Silkoff et al., 2001). The 
findings in the present study concur with previous studies and demonstrate eNO was 
significantly lower when athletes were using medications that contained corticosteroids 
(FXS and FLU) compared with athletes using medications that did not contain 
corticosteroids (SAL and PLA). This suggests that EIA in elite athletes has an 
inflammatory component in the pathogenesis that is attenuated by inhaled 
corticosteroids. In the present study however, athletes 6 and 8 (table 7.1) had lower eNO 
levels following SAL trial compared with FXS and FLU trials, which highlights the 
heterogeneity in response to medication and the need to assess individuals physiological 
markers of airway function. 
Reducing the level of inflammation within the airway will reduce the potential for the 
airway to undergo airway remodelling thereby decreasing asthma severity. Previous 
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studies have demonstrated a reduced EIA severity when eNO was reduced (Massaro et 
al., 1995; El Halawani et al., 2003; Deykin et al., 1998,2003). In contrast, the present 
study demonstrated no relationship between eNO and the level of bronchoconstriction 
following EVH challenge. This observation suggests that eNO is a poor predictor of 
EIA severity in elite athletes. This suggestion however, must be viewed with caution as 
one of the limitations to this study was the 5 months time period over which it was 
conducted. Not only did the duration of the study result in potential participants 
declining to take part, but the trial also ran over different seasons of the year. This 
inevitably resulted in environmental changes caused by a change in season and it is 
possible that eNO levels were affected during the pollen season. Aronsson et al. (2005) 
demonstrated greater levels of eNO in asthmatic individuals during the pollen season 
than during the `off season'. Therefore, eNO measurements taken during the pollen 
season may have been affected and may not be a true representation of efficacy of the 
medication used at the time of the test. In this study two athletes reported an atopic 
response during the pollen season. During their 5 months trials each athlete used three 
out of four treatments were over the months of May, June and July when the pollen 
levels are typically at their greatest (National Pollen and Aerobiology Unit, 2005). 
Interestingly, both athletes reporting atopy were subsequently prescribed Fluticasone 
Propionate and Salmeterol, which suggests that the optimal treatment for atopic athletes 
with EIA may involve combination therapy. However, although two athletes reported 
atopic reactions to pollen, no skin prick tests were conducted on any of the participants 
in this study, therefore future studies should employ skin prick tests to identify all atopic 
participants. Furthermore, future studies should attempt to avoid running therapeutic 
trials over the pollen season to eliminate its impact on inflammatory markers in the 
peripheral airways. 
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A limitation of this study is the small sample size. The small sample size in the present 
study is partly due to the duration of the study, as many athletes with EIA declined to 
participate as they could not commit to a5 month study. The author recognises that type 
I and II error can not be ruled out because of the small sample size. Future 
investigations in this area should increase participation, from elite athletes, by reducing 
the duration of the study. This may be achieved by reducing the number of medications 
involved in each study. 
A further limitation was that the athletes who participated in the present study came 
from a variety of sports. Chapter 4 reported the prevalence of asthma in the British 2004 
Athens Olympic Squad varied between sports (0-44%). It was suggested that the 
observed variation in asthma prevalence in chapter 4 was due to the different 
environments in which each sport took place. Exercising in different environments may 
result in the main trigger for EIA differing depending on the environment. Athletes' 
optimal treatment may therefore vary depending on the sporting environment. Future 
studies may consider recruiting more athletes that come from sports whose environment 
is similar. 
7.5 Conclusion 
This study is the first to investigate inhaled corticosteroids and inhaled long-acting ß2- 
agonists therapy in the control of EIA in elite athletes. Corticosteroids either in 
combination or in isolation attenuated EIA in 75% of the elite athletes in this study. In 
contrast to the BTS and international guidelines, a small number of athletes experienced 
the greatest attenuation of EIA with the sole use of long acting-02-agonists. These 
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results suggest the mechanisms for EIA in elite athletes may differ between individuals, 
which should be taken into consideration before medication is prescribed. Due to the 
small sample size and the long duration of this study further investigations into optimal 
medication for elite athletes should be conducted before findings from this study can be 
adopted into clinical practise. 
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Chapter 8 
General Discussion 
The change in the International Olympic Committee Medical Commission (IOC-MC) 
asthma criteria in 2001 (IOC-MC, 2002) initiated the research for this thesis. 
Accordingly the data presented is the first research investigating asthma in elite British 
athletes. A key finding from this thesis was that 20% of British elite athletes presented 
with asthma/exercise induced asthma (EIA) following an IOC-MC recognised test. This 
confirms that the asthma prevalence in elite British athletes is greater than that of the 
British general population of 8% (Asthma UK, 2001) and supports previous studies 
suggesting greater asthma prevalence in athletes when compared to the general 
populations (Voy, 1986; Wilber et al., 2000). Furthermore, the asthma prevalence in 
elite British athletes is greater than the asthma prevalence rates reported from the United 
States of America Olympic Teams from the 1996 Atlanta Olympic Games (14%) and 
1998 Nagano Winter Olympic Games (17%) (Weiler et al., 1998; Weiler and Ryan, 
2000). In a recent report of submissions for the use of inhaled P2-agonists at the 2004 
Athens Olympic Games (Anderson et al., 2005), Great Britain had the second highest 
number of submissions (54) behind Australia (67) and submitted a greater number than 
countries including the United States of America (53), France (27) and Germany (22). 
Anderson et al. (2005) did not report the asthma prevalence within each team (due to 
submissions via the International Association of Athletics Federation), but it is likely 
the 20% asthma prevalence rate within the Great Britain squad represented one of the 
highest asthma prevalence rates at the 2004 Athens Olympic Games. 
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Between the 2000 Sydney Olympic Games and 2004 Athens Olympic Games the 
asthma prevalence within the Great British Olympic team remained approximately 20%. 
This is an interesting result as the IOC-MC expected asthma prevalence to reduce due to 
the introduction of objective data to identify EIA positive athletes, as studies suggesting 
symptom based diagnosis were not accurate for EIA diagnosis (Rundell et al., 2001). 
One explanation for the relatively high asthma prevalence within the Great British 
Olympic team is that Great Britain submitted the greatest number of EVH challenges 
(31) to the IOC-MC. Chapter 6 demonstrated that EVH challenges had a greater 
sensitivity than exercise challenges in the diagnosis of EIA in elite athletes, supporting 
the work from two earlier studies (Mannix et al., 1996; Rundell et al., 2004). Despite 
this evidence, many countries predominantly used direct airway challenges (e. g. 
methocholine) to identify asthmatic athletes for the 2004 Athens Olympic Games 
(Anderson et al., 2005) and 2002 Salt Lake City winter Olympic Games (Anderson et 
al., 2003). Direct airway challenges such as methacholine have been shown to have a 
lower sensitivity and specificity than an EVH challenge (Holzer et al., 2002) and 
therefore may have led to a lower number of athletes from other countries presenting 
with EIA, following objective testing using direct airway challenges, when compared 
with Great British athletes. Further research in this area should use a global multi-centre 
approach employing similar methods and diagnostic criteria in the diagnosis of EIA. 
This approach would allow a more representative evaluation of EIA prevalence and 
identify whether elite Great British athletes do actually have the highest asthma 
prevalence among international athletes, or whether the difference in prevalence is due 
to the different methods of EIA diagnosis adopted by different countries. 
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In addition to the sensitivity and specificity of EVH vs exercise, Chapter 5 
demonstrated that a fall in FEV 1 following either an exercise or EVH challenge 
provided greater sensitivity and specificity in the diagnosis of EIA than measures of 
mid-expiratory air-flow (FEF50). The fall in FEV1 required by the IOC-MC however, 
may not be a justified cut-off point for the diagnosis of EIA in elite athletes. Currently 
an athlete must present with a fall in FEV 1 of 10% or greater following either an EVH 
or exercise challenge. Studies focusing specifically on athletic populations suggest that 
the cut-off criterion following an exercise challenge should be a 7% fall in FEVI 
(Helenius et al., 1996,1998; Rundell et al., 2000). Lowering the cut-off criterion 
however, would only serve to increase the number of athletes presenting with EIA, as 
demonstrated in chapter 6 where the reduced cut-off criterion resulted in a greater 
number of athletes meeting the positive cut-off point. This increases the potential for 
false positive diagnosis of EIA. Other studies have demonstrated that the cut-off should 
be increased to 11% (Elliasson et al., 1992), however work by Hurwitz et al., (1995) 
suggests a cut-off criterion of a fall in FEV 1 of 10% provides 90% specificity for 
identifying subjects with asthma. As Helenius et al. (1996; 1998) and Rundell et al. 
(2000) are the only studies that have previously investigated cut-off criteria specifically 
in athletes further research is required to justify the IOC-MC criterion of a fall in FEV1 
> 10% for the diagnosis of EIA in elite athletes. What may be of greater value in the 
diagnosis of EIA in elite athletes however, is the evidence of airway reversibility 
following the inhalation of a ß2-agonist such as salbutamol. Evidence of a marked 
improvement in airflow following inhalation of salbutamol may provide further 
evidence of the presence of a pathologically mediated bronchoconstriction. 
Furthermore, evidence of reversibility may be crucial in an athlete who presents with 
borderline EIA (AFEV1 =-7-11%) following bronchoprovocation. A significant (e. g. 
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15%) rise in FEV1 following inhalation of salbutamol in an athlete with borderline EIA 
could result in them being confirmed EIA positive, whereas a borderline athlete who did 
not show reversibility would not be confirmed EIA positive. 
The greater prevalence of EIA observed in elite British athletes compared to other 
nation's elite athletes may be associated with genetic differences. Asthma is known as a 
"complex" heritable disease. Accordingly, a number of gene candidates contributing to 
individual susceptibility to EIA have been identified, including: ADAM33, DPP 10, 
PHF11 and GPRA (Yamada and Ymamoto, 2005). The relative roles of these genes in 
asthma predisposition are unclear. To date, no studies have examined genetic profiles of 
elite athletes presenting with EIA. Given the similar general population prevalence rates 
of asthma between Great Britain and other countries the role of genetics in the high 
prevalence rates observed in elite athletes remains unclear. A global multi-centre 
research study investigating specific EIA genes within elite athletes would help to 
clarify the role of genetics in the high prevalence of EIA in elite athletes. Furthermore, 
the identification of the genes responsible for mild asthma/EIA will assist in the early 
diagnosis of affected individuals and inform treatment algorithms. 
The prevalence of asthma within the British general population is similar to worldwide 
asthma prevalence, which reduces the potential for the genetic contribution to EIA 
development to differ between nations (Asthma UK, 2001). The differences in 
prevalence are more likely due to the variety of methods used to diagnose EIA between 
nations. In addition, the environment in which individual sports take place may have 
affected the overall prevalence of EIA within the Great British Olympic Team at the 
2004 Athens Olympic Games. Competitors from cycling, rowing and swimming made 
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up over a third of the 2004 Great British Olympic team. These sports had the greatest 
absolute and relative asthma prevalence within the 2004 Great British Olympic squad. 
Cycling, rowing and swimming could be thought of as `high risk asthma' sports as they 
are endurance based and require the athlete to train and compete within environments 
that may be more likely to trigger a bronchoconstriction. For instance, the swimmers are 
likely to train in a chlorinated pool for at least 2 hours daily and long term exposure to 
the environment of a chlorinated pool has been shown to increase asthma severity 
(Fjellbirkedland et al., 1995; Mustchin and Pickering, 1979; Penny, 1983; Zwick et al., 
1990; Helenius et al., 1998). Rowing involves training outdoor in the early morning 
which, during the mornings in the winter months, can result in large quantities of dry 
cold air being inspired during several hours of training. The majority of the cyclists that 
made up the British team at the 2004 Olympics were based on the track and therefore 
spent long hours training and competing in dry, dusty velodromes. In these sports, 
where athletes have high ventilation rates in `high risk asthma' environments, there may 
be a greater potential for airway remodelling. Future screening programmes should 
target these `high risk' asthma sports including swimming, rowing and cycling to ensure 
EIA is treated whilst the severity is still mild to reduce the potential for airway 
remodelling in athletes competing in these sports. Further research should investigate, 
whether there is a potential for athletes within these sports to be at a greater risk of 
airway remodelling than other sports with the same aerobic requirements and examine 
ways of reducing the environmental load placed on the lungs during training. 
The atopic status of an elite athlete with EIA may also have an impact on the potential 
for airway remodelling and increased EIA severity. Helenius et al. (1998) compared 
falls in FEVI after an exercise challenge between those who suffered from EIA in the 
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winter and those who suffered during the pollen season. The results demonstrated that 
more athletes presented with a fall in FEV1 post exercise in the cold, however, those 
who demonstrated falls in FEVI during the pollen season had larger post exercise 
changes. These observations suggests that athletes who present with EIA following a 
bronchoprovocation and have a history of atopy may have a greater risk of airway 
remodelling and increased EIA severity. Atopy status was not measured in the studies 
presented in this thesis. Accordingly, future studies examining EIA should investigate 
the link between atopy and EIA. The benefits of this approach may lead to a differential 
approach in the treatments of atopic and non-atopic athletes with EIA. 
General guidelines for the treatment of EIA suggest that individuals with mild EIA or 
asthma should be given short-acting inhaled 02-agonists as first line treatment with 
corticosteroids given if the symptoms persist (BTS, 2004). These guidelines were 
constructed for the general population and are not specifically targeted at elite athletes. 
Chapter 7 is the first study to examine the optimal treatment of elite British athletes with 
EIA. The results indicate that the BTS guidelines are suitable for half of the athletes 
included in the study. In contrast, half of the athletes benefited from either combination 
therapy or sole use of long acting ß2-agonists. These results, suggest that consideration 
should be given to the therapy offered to elite athletes with EIA rather than following 
the national general population guidelines. Furthermore, the results from chapter 7 
support the use of individual assessment of EIA to optimise medication efficacy. The 
findings from chapter 7 may lead to a separate treatment algorithm for elite athletes, 
which may include atopy, genetics and sporting environment. Due to the heterogeneity 
of response to the different medications used in chapter 7 other forms of therapy that are 
110 
not included in the BTS guidelines may be beneficial in the treatment of elite athletes 
with EIA. 
Despite chapter 4 reporting no change in asthma prevalence in the 2004 British Olympic 
team compared with the 2000 British Olympic team, 20% of the athletes reporting using 
asthma medication failed to present with EIA following bronchoprovocation challenges. 
Athletes presenting negative for EIA following a bronchoprovocation challenge but 
who continued to report breathing difficulty either during or after exercise suffer were 
thought to suffer from unexplained inappropriate breathlessness (UIB) likely associated 
with inspiratory stridor and/or hyperventilation. 
Inspiratory Stridor (IS) is a condition that is characterised by high-pitched inspiratory 
noise that is often mistaken for the wheeze of asthma (Brugman and Simons, 1998; 
Corren and Newman, 1992; Niven et al., 1992; Heiser et al., 1990; Baughman and 
Loudon, 1989; Kivity et al., 1986; Lakin et al., 1984; Christopher et al., 1983). The 
presence of IS is associated with vocal cord dysfunction (Brugman and Simons, 1998; 
Corren and Newman 1992; Niven et al 1992; Heiser et al., 1990; Baughman and 
Loudon, 1989; Lakin et al., 1984) that can be diagnosed by laryngoscopy. 
Laryngoscopy however, is very invasive and the patient must be symptomatic, which is 
problematic if the IS is caused by high intensity exercise, thus, symptom based 
diagnosis is a more common and practical method. 
The prevalence of IS is unknown, however, it has been estimated at 2-3% of the general 
population with the majority of cases reported in adolescent females (Sullivan et al., 
2001; Kenn and Schmitz, 1997). The prevalence in elite athletic populations has been 
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reported to be 5%; with 53% of IS suffers also presenting with EIA (Rundell and 
Spiering, 2003). Rundell and Spiering (2003) also reported that it is common for IS to 
be mis-diagnosed as EIA, reporting 7 out of 19 athletes who were diagnosed with IS 
had a previous diagnosis of EIA. At the time of data collection for chapter 4 there was 
no intervention readily available for athletes to attenuate their UIB during training and 
competition. Future research should consider investigating diagnostic procedures for 
IS/hyperventilationlhypoventilation in elite athletes that is more practical than 
laryngoscopy and investigate specific treatments for individuals with 
IS/hyperventilation/ hypoventilation that may be specific to the individual, sport or elite 
athletes in general. 
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8.1 Conclusion 
This thesis was the first research to investigate EIA in elite British athletes. The 
prevalence of asthma within elite British athletes at the 2000 and 2004 Olympic Games 
was 20%, greater than that of the general population (8%). British elite athletes may 
have the greatest prevalence of asthma when compared with elite athletes from other 
nations. This difference may be due to genetics, method of diagnosis or the predominant 
sports within Great British Olympic team. 
Measures of mid-expiratory flow (FEFSO) should not be used in the diagnosis of EIA in 
elite athletes. Our data suggest that a more global measure of maximal expiratory 
airflow (FEV1) provides the most sensitive and specific diagnosis of EIA, especially 
when the severity of the disease is thought to be mild. This would suggest that EIA is a 
disease that is associated with expiratory flow limitation in the large and small airways 
of elite athletes. 
Elite athletes should be screened for EIA, especially those from `high risk' asthma 
sports including swimming, cycling and rowing. Eucapnic voluntary hyperpnoea (EVH) 
is a more sensitive challenge for the detection of EIA in asymptomatic athletes 
compared with SS and LB challenges. Therefore, if sporting governing bodies were to 
implement screening programmes to test athletes for EIA, it is recommended that EVH 
should be the challenge of choice. 
The British Thoracic Society guidelines failed to provide optimal therapy for all athletes 
and therefore guidelines specific to elite athlete may be beneficial to improve treatment 
of EIA with in this population. The addition of alternative treatments, including dietary 
113 
supplementation, may help reduce symptoms and severity of asthma in elite athletes 
greater than the sole use of pharmaceutical therapy. 
A large number of athletes with a previous diagnosis of asthma failed to present with 
EIA following a recognised bronchoprovocation challenge. Despite failing to present 
with EIA following bronchoprovocation these athletes still reported symptoms during 
exercise. It is possible these athletes suffer from conditions such as vocal cord 
dysfunction, inspiratory stridor and/or inappropriate hyperventilation. Further research 
examining the diagnosis of these conditions and optimal treatments is required to assist 
athletes who fail to present with EIA but report breathing symptoms during exercise. 
8.2 Hypotheses - accepted or rejected 
1. H1 The prevalence of asthma in the British Olympic Team will be reduced at the 
Athens 2004 Summer Olympic Games when compared to the prevalence at the 
Sydney 2000 Summer Olympic Games associated with the introduction of the 
IOC-MC requirement for objective evidence of asthma - rejected 
2. Ht The addition of FEFso in the diagnosis of EIA will provide a greater 
sensitivity and specificity - rejected 
3. H1 EVH challenges will have a greater sensitivity than exercise challenges in the 
diagnosis of EIA in elite athletes - accepted 
4. H1 Combination therapy in the form of inhaled corticosteroid and long acting 02- 
agonist will provide the greatest attenuation to EIA in elite athletes - rejected 
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APPENDIX 1 
IOC-MC guidelines for asthma medication use at Olympic Games 
Beta2 adrenoceptor agonists and the Olympic Games in Turin 
1. INTRODUCTION 
Article 4 of the World Anti-Doping Code refers to the Prohibited List as the international standard. This List, 
which came into force on 1 January 2005, stipulates that: 
All beta-2 agonists including their D- and L- isomers are prohibited. Their use requires a Therapeutic Use 
Exemption. 
As an exception, formoterol, salbutamol, salmeterol and terbutaline, when administered by inhalation to 
prevent and/or treat asthma and exercise-induced asthmalbroncho-constriction require an abbreviated 
Therapeutic Use exemption. 
A simple notification from a respiratory or team physician stating that the athlete has asthma and/or exercise- 
induced asthma (or exercise-induced bronchoconstriction) WILL NO LONGER BE ACCEPTABLE as evidence 
for that athlete to inhale a permitted betat agonist at the 2006 Olympic Winter Games in Turin. 
Athletes who request permission to inhale a permitted betat agonist during the Olympic Winter Games in 2006 
in Turin will be required to submit test results in support of that athlete having objective evidence of asthma 
and/or exercise-induced asthma (EIA) or exercise-induced bronchoconstriction (EIB). 
Requests must be addressed to the IOC Medical and Scientific Department using the on-line Therapeutic Use 
Exemption request form. 
As for every edition of the Games since 2000, the doping control laboratory will report the presence in urine of 
any betat agonist. For any athlete who has not received an authorisation from the IOC Medical Commission to 
inhale betat agonists, or who has not respected the notifications related to the use of these products, the 
result of the doping control will be considered positive. The procedures in place for positive doping control 
cases will then be applied. 
For any question related to the on-line form, please contact the IOC Medical and Scientific Department, 
preferably by e-mail at beta2@olymoic. orq or by telephone on +41216216111. 
BACKGROUND to the decision to require documented evidence of asthma and/or EIA/EIB: 
In May 2001, the IOC (Medical Commission IOC-MC) convened a workshop to examine asthma, beta 
agonists and the Olympic Games. The workshop concluded that: 
At recent Olympic Games, there had been a large increase in the number of athletes notifying the 
need to inhale a betat agonist 
> Some athletes may have been misdiagnosed and did not have asthma and/or exercise induced 
asthma (EIA) or bronchoconstriction (EIB) 
¢ There is no scientific evidence to confirm that inhaled betat agonists enhance performance in doses 
required to inhibit E1A/EIB 
A skewed distribution of notifications of betat agonists by sport was observed with a higher prevalence 
in endurance sports 
The geographic distribution of notifications of inhaled betat agents was markedly skewed but 
correlated well to the reported prevalence of asthma symptoms in those countries 
> There is some evidence that daily use of an inhaled betat agonist may result in tolerance to the 
medication 
¢ Inhaled corticosteroids may be under-used in athletes notifying the use of betat agonists 
> Eucapnic voluntary hyperpnoea (EVH) was considered to be the optimal laboratory based challenge 
to confirm that an athlete has EIA/EIB 
Betat agonists when administered systemically do have anabolic effects 
In October 2001, the IOC-MC appointed an Independent Panel of experts who established the necessary 
criteria for an athlete to be granted permission to inhale a permitted betat agonist at the Olympic Games in 
Salt Lake City. The results obtained further to the application of these criteria at the Salt Lake City Games 
have been published, c. f. J Allergy & Clinical Immunology 2003: 111: 45-50. Due to the success of the 
application of these criteria, the IOC has decided to use this rule again at the next edition of the Winter Games 
in Turin. 
Recommendation for withholding medications prior to tests 
To provide the optimal test circumstances, some medications must be withheld for 8 to 96 hours before the 
bronchial provocation test. No short-acting bronchodilators, sodium cromoglycate, nedocromii sodium, or 
ipratropium bromide for 8 hours. No long-acting bronchodilators or antihistamines for 48 hours. No leukotriene 
antagonists for four days. Steroids should not be inhaled on the day of the test. No caffeine should be taken 
on the morning of the test. Avoid vigorous exercise for at least four hours prior to the start of the test and avoid 
any exercise on the day of testing. 
b) Exercise challenge in the laboratory or an exercise test in the field 
The response to the exercise challenge is considered positive when there is a fall in FEV1 of 10% or more 
compared to baseline during the first 30 minutes post exercise. 
To maximise the opportunity for a positive test the exercise test should be performed breathing dry air for 8 
minutes with the intensity of exercise close to maximal for the last 4 minutes. 
Recommendation for withholding medications prior to tests 
To provide the optimal test circumstances, some medications must be withheld for 8 to 96 hours before the 
bronchial provocation test. No short-acting bronchodilators, sodium cromoglycate, nedocromil sodium, or 
ipratropium bromide for 8 hours. No long-acting bronchodilators or antihistamines for 48 hours. No leukotriene 
antagonists for four days. Inhaled corticosteroids should not be administered on the day of the test. No 
caffeine should be taken on the morning of the study. Avoid vigorous exercise for at least four hours prior to 
the start of the test, and avoid all exercise on the day of testing. 
c) Hypertonic aerosol 
Hypertonic solution: a test is considered positive when there is a fall in FEV, of 15% or more from baseline 
after a dose of 22.5 ml of 4.5 gm% saline (e. g. 4.5 g NaCl /100 ml water) has been inhaled. The response is 
usually reported as the dose required to provoke a 15% fall in FEV, (PD15) but can also be reported as the 
maximum fall after the final dose administered. 
Recommendation for withholding medications prior to tests 
To provide the optimal test circumstances, some medications must be withheld for 8 to 96 hours before the 
bronchial provocation test. 
No short-acting bronchodilators, sodium cromoglycate, nedocromil sodium, or ipratropium bromide for 8 hours. 
No long-acting bronchodilators or antihistamines for 48 hour. No leukotriene antagonists for 4 days. Inhaled 
corticosteroids should not be administered on the day of the test. No caffeine should be taken on the morning 
of the study. Avoid vigorous exercise for at least four hours prior to the beginning of the test, and avoid all 
exercise on the day of testing. 
d) Methacholine test 
A test is considered positive if there is a fall in FEV, of 20% or more from baseline at a dose less than or equal 
to 2 micromoles, 400 micrograms (PD20), after inhalation of a solution with a concentration less, or equal to, 4 
Mg/Ml (PC20), or after inhalation of a maximum of 40 breath units when the subject is not taking inhaled 
corticosterolds. 
For applicants taking inhaled steroids for at least three months, the PD20 should be equal to or less than 
6.6 micromoles, 1320 micrograms or PC20 equal to or less than 13.2 mg/ml, or inhalation of a maximum of 130 
breath units, to be accepted as proof of airway hyperresponsiveness (AHR) (2,7). 
It should be noted that a negative response to methacholine does not exclude exercise-induced asthma in an 
athlete, and in the event of a negative response, an alternative bronchial provocation test is recommended. 
If values for PC20 or PD20 , or breath units during the Methacholine challenge are in access of the thresholds 
mentioned above, the athlete may undergo an EVH test or an exercise test on site in Turin * prior to the start 
of the Games. 
* Please contact Dr Carlo GULOTTA, Pneumologia li - Fisiopatologia Respiratoria, ASO San Luigi, Regione Gonzole, 10,10043 Orbassano, Torino, Italie, tel. +39 011 9026 332,372,733, tel. /fax + 39 011 9026 371, 
portable +39 335 7609 007, c. Qulottalc-sanluiai. piemonte. it, fprosanluigi. piemonte. it. 
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2. PROCEDURE 
The on-line Therapeutic Use Exemption request form for inhaled betat agonists for the Games in Turin must 
reach the IOC Medical and Scientific Department as soon as possible before 31 January 2006. 
Requests will be examined by a group of independent experts. The independent panel's decision will be 
notified by e-mail to the doctor in charge of the request. It will be his/her responsibility to inform the athlete of 
the status of his/her request. The NOC's chief physician will also be informed in writing of the independent 
panel's decision. 
Any athlete whose request is refused will have the chance to be retested in Turin. 
Please contact Dr Carlo GULOTTA, Pneumologia 11 - Fisiopatologia Respiratoria, ASO San Luigi, Regione 
Gonzole, 10,10043 Orbassano, Torino, Italie, t6l. +39 011 9026 332,372,733, tel. /fax + 39 011 9026 371, 
portable +39 335 7609 007, c. aulotta sanluigi. piemonte. it, fpr sanluiai. piemonte. it. 
These tests may take up to 1 hour and 30 minutes. 
The cost of the test in Turin will be ¬300 and payable by the NOC. 
The results of such investigation shall be final. 
Athletes having received an authorisation at oast editions of the Olympic Games (Salt Lake City or Athens). 
For athletes who received the IOC Medical Commission's authorisation to inhale betat agonists at the XIX 
Olympic Winter Games in Salt Lake City in 2002 (or the Games of the XXVIII Olympiad in Athens in 2004), the 
authorisation will be carried over for the XX Olympic Winter Games in Turin in 2006, with no additional tests 
needed. However, so that the IOC Medical Commission can clearly identify these athletes, the on-line 
Therapeutic Use Exemption request form must imperatively be completed. 
3. METHODOLOGY 
A measure of forced expiratory volume (FEV, ) at rest, as well as changes in FEV, in response to an inhaled 
bronchodilator or further to a bronchial provocation test, are the indispensable elements that [rust appear on 
the on-line Therapeutic Use Exemption request form for betat agonists (see below for further details on these 
tests). 
Peak Expiratory Flow (PEF) measurements are unacceptable. 
In the request form, information must be provided for at least one of the tests below. 
Only tests performed after February 2002 will be taken into consideration by the independent panel. 
Spirometry recordings need not be forwarded but must retained and the independent panel reserves the right 
to request to view them before issuing any approval. 
BRONCHODILATOR TEST: 
A bronchial reversibility test is considered positive if there is an increase in FEV, of 12% or more of the 
baseline FEV, and exceeds 200 ml after administering an inhaled permitted beta2 agonist by inhalation. 
Recommendation for withholding medications prior to bronchodilator test 
To provide the optimal test circumstances, short acting bronchodilators (e. g. salbutamol, terbutaline, 
ipratropium bromide) should be withheld for 8 and long acting bronchodilators (salmeterol, formoterol, 
tiotropium bromide) for 24 hrs or longer. 
BRONCHIAL PROVOCATION TESTS: 
Various bronchial provocation tests may be used: 
a) eucapnic voluntary hyperpnea test 
b) exercise challenge in the laboratory or an exercise test in the field 
c) Hypertonic aerosol 
d) Methacholine test 
a) Eucapnic voluntary hyDerDnea test 
The eucapnic voluntary hyperpnea test is considered positive when a fall in FEV, of 10% or more from 
baseline is recorded after a6 minutes period of hyperpnea in dry air. To overcome the problem of any post- 
test respiratory muscle fatigue, the FEV, should be recorded three minutes at least after challenge. It would be 
usual for the reduction sustained over the next five minutes to be consistent with hyperpnea-induced bronchoconstriction. 
2 
Important note 
The results of bronchial provocation tests using pharmacological agents other than methacholine (e. g. 
carbachol, histamine or adenosine monophosphate) will not be accepted. 
Recommendation for withholding medications prior to tests 
To provide the optimal test circumstances, it is recommended that some medications be withheld for 8 to 96 
hours before the bronchial provocation test. 
No short-acting bronchodilators, sodium cromoglycate, nedocromil sodium, or ipratropium bromide for 8 hours. 
No long-acting bronchodilators or antihistamines for 48 hours. No leukotriene antagonists for 4 days. Inhaled 
corticosteroids should not be administered on the day of the test. No caffeine should be taken on the morning 
of the study. Avoid vigorous exercise for at least four hours prior to the start of the test, and avoid all exercise 
on the day of testing. 
WELL-CONTROLLED ASTHMA with negative response to all the tests 
In the case of an athlete with known, but well-controlled, asthma recording a negative result to the bronchial 
provocation test, but still seeking approval for the use of inhaled beta2-agonists, the following documentation 
must be included in the file, (in addition to negative results obtained in the bronchial provocation test(s) sent 
electronically): consultations with their physician for treatment of asthma, hospital emergency department 
attendance or admission for acute exacerbations of asthma or treatment with oral corticosteroids. 
Additional information that may assist includes: the age of onset of asthma; detailed description of the 
athlete's asthma symptoms, both day and night; trigger factors; medication use; past history of atopic 
disorders and/or childhood asthma; and physical examination, together with results of skin prick test or RAST 
to document the presence of allergic hypersensitivity. 
At the time of the submission of this type of request, please indicate clearly in the "Comments' section 
underneath the bronchial provocation test(s) with a negative response, that the athlete's asthma is well 
controlled. Please also inform us that you are sending a file, in order to avoid your request being automatically 
refused. 
Should the athlete wish to submit a second bronchial provocation test result, the opportunity for further testing 
will be available in Turin. Please contact: Dr Carlo GULOTTA, Pneumologia I1- Fisiopatologia Respiratoria, 
ASO San Luigi, Regione Gonzole, 10,10043 Orbassano, Torino, Italie, tel. +39 011 9026 332,372,733, 
tel. /fax + 39 011 9026 371, portable +39 335 7609 007, c. aulotta(cäsanluic aiemonte it, 
fpr(sanluigi. piemonte. it. 
, The files must imperatively be sent by recorded delivery to the following address: International Olympic Committee, Medical and Scientific Department, Chateau de Vidy, CH - 1007 Lausanne, Switzerland. 
For any further information or assistance, please contact the IOC Medical and Scientific Department, 
preferably by e-mail at betat olympic. org or by telephone on +412162161 11. 
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APPENDIX 2 
Abbreviated Therapeutic Use Exemption Form 
Identification of Anti-Doping Organization 
(Logo or Name of the ADO) Appendix 2 
Abbreviated 
Therapeutic Use Exemptions 
ATUE 
Please complete all sections in capital letters or tvoina 
beta-2 agonists by inhalation Q glucocorticosteroids by Q 
non-systemic routes * 
* All routes other than orally, rectally, intravenously and Intramuscularly. 
Dermatological glucocorticosteroids do not require any TUE 
1. Athlete Information 
Surname: ..................................... Given Names:............................................. 
Female Q Male Q Date of Birth (d/m/Y) :........................................... 
I Ad d ress : .............................................................................................................. . 
City: ......................... Country :........................... Postcode: ......................... 
Tel.: ..................................................................... 
E-mail ....................................................................... 
(Wth international code) 
Sport:................................. Discipline/Position: ...................................................... 
International or National Sporting Organization: .......................................................... 
2. Medical information 
Diagnosis* ..................................................................................................................................................... 
........................................................................................................................................................................... 
........................................................................................................................................................................... 
......................................................................................................................................................................... . 
N. B. Any ATUE may be reviewed at any time, by the ADO and/or WADA 
1 
STRICTLY CONFIDENTIAL 
Prohibited substance(s): 
Generic name 
Dose Route Frequency 
1. 
2. 
3. 
Intended duration of treatment: 
(Please tick appropriate box) 
once only Q emergency Q 
or duration (week/month) 
3. Medical practitioner's and athlete's declaration 
I certify that the above-mentioned treatment is medically appropriate and that the use of 
alternative medications not on the Prohibited List would be unsatisfactory for this condition. 
Name: ........................................................................................................................ 
Medical Speciality: ..................................................................................................... 
Address: ...................................................................................................................... 
Tel.: ............................................................ Fax:....................................................... 
E-mail: ......................................................................................................................... 
Signature of Medical Practitioner: ................................... Date: ............................ 
I, ....... ................................................................. certify that the information under 1. is accurate 
and that I am requesting approval to use a Substance or Method from the WADA Prohibited 
List. I authorize the release of personal medical information to the Anti-Doping Organization 
(ADO) as well as to WADA staff, to the WADA TUEC (Therapeutic Use Exemption Committee) 
and to other ADO under the provisions of the Code. I understand that if I ever wish to revoke 
the right of these organizations to obtain my health information on my behalf, I must notify 
my medical practitioner and my ADO in writing of that fact. 
Athlete's signature: .............................................. Date: ...................................... 
Parent's/Guardian's signature: ............................ Date: ...................................... (if the athlete is a minor or has a disability preventing him/her to sign this form, a parent or guardian 
shall sign together with or on behalf of the athlete) 
IncomDiete Applications will be returned and need to be resubmitted. 
Please submit the completed form to the ADO and keep a copy for your records. 2 
STRICTLY CONFIDENTIAL 
APPENDIX 3 
Abstracts presented at International Conferences 
Presented at the British Association of Sports and Exercise Science 2004 Annual 
Conference. 
Resting Maximal Voluntary Flow Volume Loops in Elite Athletes: Asthmatics vs 
Non Asthmatics 
The International Olympic Committee has restricted asthma medication for the 2004 
Athens Summer Olympic Games. Athletes must produce quantitative evidence of their 
asthma in order to permit use of their asthma medication. At present there are no 
published data describing resting lung function in elite athletes, or how resting lung 
function differs between asthmatic and non-asthmatic elite athletes. The aim of this 
study was to characterise the maximal flow volume loops of elite athletes with and 
without asthma. 
The study was carried out at the Olympic Medical Institute and at squad training 
camps around the UK. Ethical approval was obtained from the Harrow Local Research 
Ethics Committee. Athletes who held either a British Olympic Association Gold or 
Silver passport were approached to take part in the study. Athletes (males; 171 non 
asthmatic, 28 asthmatic: females; 137 non asthmatic, 28 asthmatic) volunteered and 
completed a consent form. All asthmatic athletes were confirmed as such by a positive 
bronchoprovication test and were instructed not to use asthma medication for up to three 
days before the testing. Three maximal flow volume loops were obtained using a 
Spirometer (MicroLab ML3500, Micro Medical, Rochester, UK), which met European 
Respiratory Society guidelines. The flow volume loop with the best Forced Expiratory 
Volume in one second (FEV1) was recorded. One-Way ANOVA was carried out to 
compare the means between asthmatics and non-asthmatics in males and females. 
The assumption of homogeneity of variance was met (P>0.05) for all ANOVA. 
In males and females age, height and weight were not significantly different (P>0.05) 
between asthmatic and non-asthmatic groups. In males, all maximal flow volume loop 
measurements were significantly greater (P<0.05) in non-asthmatics than in asthmatics 
(See Table 1). However, in females only Forced Expiratory Flow at 50% of vital 
capacity (FEF50) and percent of predicted FEF50 (ECCS predicted values) were 
significantly greater (P<0.05) in non-asthmatics than in asthmatics (See Table 1) 
Table 1. Maximal lung function parameters for male and female asthmatic and non- 
asthmatic elite athletes (mean+S). NA = non-asthmatic; A= asthmatic; % Predicted = 
percentage of predicted normal value (ECCS predicted values) 
Sex Group FEVI (1) % Predicted FEVI (%) 
FEF50 (1. s" 
1) 
% Predicted 
FEF50 (%) 
FEV1/FVC 
(%) 
Male NA 4.73+0.82 105.98+12.43 5.21+1.35 93.15+23.69 83.66+7.05 
A 4.14+0.74 94.82+12.52 3.88+0.97 69.26+16.11 77.01+6.5 
Female NA 3.53+0.63 105.78+13.84 4.37+1.00 94.84+21.42 87.21+7.67 
A 3.50+0.49 104.30+11.02 3.67+0.88 79.53+14.66 86.05+7.06 
The results from this study demonstrate that at rest the maximal voluntary flow volume 
of an asthmatic elite athlete is lower than that of a non-asthmatic elite athlete. This 
difference is more pronounced in males than in females. The study also highlights the 
need for athletes to be tested for asthma through bronchoprovication and bronchodilator 
challenges, as at rest elite asthmatic individuals have FEV 1 values that appear normal 
(FEV1 > 90% predicted). 
Presented at the American Thoracic 2005 Annual Conference 
Fall in FEF50 (l. s'1) is a more sensitive indicator of bronchial constriction than 
FEVI (1) of PEFR (l. s'1) following eucapnic voluntary hyperventilation (EVH) 
The IOC criterion to diagnose EIA is a 10% fall in FEVI following an EVH challenge. 
We have shown that FEF50 is a more sensitive indicator of bronchoconstriction than any 
other spirometry measure. 
One hundred and fifteen elite athletes, 59 asthmatic (who met IOC criteria), 56 
non-asthmatics, underwent an EVH challenge requiring each athlete to hyperventilate at 
30 x FEV 1 for 6 minutes (Anderson et al. 2001). Maximal voluntary expiratory flow 
volume measurements were taken before and 5,10 and 15 minutes after EVH. A one- 
way analysis of variance was used to compare means at baseline and following 
bronchoprovication. 
FEF50 was the only measurement that was significantly (P<0.05) different at 
baseline between the asthmatic group and the non-asthmatic group, which was 
maintained following scaling for FVC. FEF50 and ISO50 fell significantly (P<0.05) 
greater than FEV 1 following the EVH challenge (Table 1). 
Table 1. Spirometry measurements before and after EVH challenge in asthmatic (A) and 
non-asthmatic (NA) elite athletes 
FEVI litres PEFR 1. s" FEFSQ 1. s ISOSO FEF50/FVC 
A NA A NA A NA A NA 
Pre 3.9 4.09 8.84 9.18 3.86* 4.79 0.79* 1.02 
Post 3.07* 3.9 6.81* 8.66 2.39* 4.42 0.53* 0.97 
*= Value is significantly (P<V. 05) lower in the A group. 
In conclusion, FEF50 has been shown to be the only spirometry measurement that 
distinguishes elite EIA athletes at rest from non-asthmatics. Furthermore, FEF50 shows a 
larger fall than FEV1 following bronchoprovication challenge in EIA positive athletes 
even after accounting for changes in FVC. Therefore FEFSo maybe a more sensitive 
measure for diagnosing EIA at rest and following an EVH challenge. 
Presented at the American College of Sports Medicine 2005 Annual Conference 
Impact of the IOC-MC change in asthma diagnosis -A British Perspective 
Introduction: Since 2001 the International Olympic Committee-Medical Commission 
(IOC-MC) has required athletes, who suffer from asthma, to provide evidence of their 
condition to use inhaled ß2-Agonists. The purpose of this study was to compare the 
prevalence of asthma at the 2000 and 2004 Olympic Games in the Great British 
Olympic team (Team GB). 
Method: Following local ethics committee approval, athletes (165 males, 106 females) 
from 2004 Team GB volunteered and signed informed consent. An athlete was 
confirmed asthmatic if they had a positive bronchoprovication or bronchodilator test 
recognised by the IOC-MC. Pre-Olympic medical forms from the 2000 Team GB were 
examined to discover the prevalence of asthma at the 2000 Olympic Games. 
2000 2004 
No. No. Asthmatic 
% 
Asthmatic No. 
No. 
Asthmatic 
% 
Asthmatic 
Male 152 29 19.08 165 34 20.6 
Female 122 29 23.77 106 22 20.8 
Overall 274 58 21.17 271 56 20.7 
Results: The asthma prevalence of Team GB is reported in table 1. 
Table 1: Team GB asthma prevalence at the 2000 and 2004 Olympics 
13 out of 62 (21.0%) athletes with a previous diagnosis of asthma tested negative. A 
further 7 athletes with no previous diagnosis of asthma tested positive. Swimming (41% 
vs 44%) and cycling (44% vs 39%) had the highest prevalence of asthma at both 2000 
and 2004. 
Conclusion: The IOC-MC requirement that asthmatic athletes must submit documented 
evidence of asthma has highlighted that 19.35% of athlete's previously diagnosed 
asthmatic where unable to provide positive evidence of asthma. Despite this the overall 
asthma prevalence of Team GB remained unchanged between 2000 and 2004. The more 
rigorous procedure used in 2004 also provided a number of athletes who tested positive 
for asthma that had no previous history, symptoms or diagnosis of asthma. It is 
recommended that all Elite athletes should be screened for asthma regardless of 
previous history, symptoms or diagnosis of asthma. 
Presented at the British Association for Sports and Exercise Science 2005 Annual 
Conference 
Screening elite winter athletes for exercise-induced asthma: a comparison of three 
challenge methods 
Exercise-induced asthma (EIA) is defined as an acute transient narrowing of the airways 
that occurs following exercise. The reported prevalence of EIA with in elite winter 
athletes has ranged from 9% to 50% (Wilber, R. et al. 2000: Medicine and Science in 
Sport and Exercise, 32,732-737). At present there is no `gold standard' test for EIA, but 
the International Olympic Committee accepts the results of a number of different 
challenges, including exercise, eucapnic voluntary hyperventilation (EVH), and 
inhalation of hypertonic substances. In the case of the exercise and EVH, they stipulate 
a minimum requirement for changes in forced expiratory volume in 1 sec (OFEV1) of 
10%. The purpose of this study was to compare the response of elite winter athletes to 
eucapnic voluntary hyperventilation (EVH) and two exercise challenges (laboratory- 
based [LB] and sport-specific [SS]). 
Following ethical approval from Harrow Local Research Ethics committee, 14 athletes 
(mean +_SD; age 22.6±5.7years, height 177.2±7.0cm, weight 68.9+_16.9kg) from the 
British Short-track Speed Skating (n=10) and Biathlon (n=4) teams volunteered and 
provided written informed consent. Each athlete completed an LB challenge, a SS 
challenge, and an EVH challenge in a random order. The LB challenge required the 
athlete to run continuously on a treadmill for 8 min (Temperature 18°C, Humidity 
40%); during the last 4 min their heart rate (HR) was above 85% HR".. The SS for the 
speed skaters involved skating for 6 min at race pace on the ice-rink (Temperature 8°C, 
Humidity 35%). The SS challenge for the biathletes involved a 20 minutes race in 
Finland (Temperature. 1°C, Humidity 34%). The EVH challenge was conducted in the 
laboratory (Temperature 18°C, Humidity 40%) and required each athlete to 
hyperventilate for 6 min (30 x baseline FEV1) breathing a gas mix consisting of 5% 
C025 21% 02,74% N2. Spirometry was measured before and at 3,5,10 and 15 minutes 
after stopping each challenge. A fall AFEV 1 of 10% from the baseline measurements 
was deemed positive for EIA. Repeated measures ANOVA were used to compare the 
AFEV1 for each challenge. AP value of <_ 0.05 was regarded as significant. 
All 14 athletes completed each challenge. Two athletes had a previous history of 
asthma. Ten of the 14 athletes (including the two athletes with a previous history) had a 
positive test to at least one of the challenges. Ten athletes had a positive response to 
EVH (71%); of these, only 3 (21%) also had a positive response to the SS challenge. No 
athletes had a positive test to the LB challenge. The EFEV 1 following EVH was 
significantly greater (P<0.05) than the OFEVI for either the LB or SS challenge (see 
table 1). 
Table I- AFEV i% changes for each different challenge (Mean +5D) 
LB SS EVH 
Positive EIA AFEVI % n=10 -3.0+3.8 -7.4+6.8 -16.9+8.0** 
Negative EIA AFEV1 % n=4 -1.1+1.0 -3.9+4.9 -5.1+2.5 
**= Significant change in AFEVI (P: 50.05) 
Our results suggest that the EVH challenge is more sensitive than an exercise challenge 
to detect EIA in elite winter athletes. The requirement of 10% fall in AFEV1 following 
an exercise challenge may not be sensitive enough to detect all EIA-positive athletes. 
Eight out of the 12 (66%) elite winter athletes tested had no previous history of EIA, but 
had a positive test EVH. An EVH challenge may therefore be considered the most 
suitable challenge to use when screening athletic populations for EIA. 
APENDIX 4 
Information Regarding Fluticasone, Propionate and Salmeterol 
Fim- 
nuEN &HmBuRrs 
Serevent.. 
Inhaler 
salmeterol xinafoate 
Patient Information Leaflet for Serevent Inhaler 
Your doctor has decided to prescribe Serevent Inhaler as part of your treatment. 
This leaflet tells you about Serevent Inhaler and how to use it. Please read it 
carefully before using your inhaler and keep it until you have finished the medicine. 
WHAT IS SEREVENT INHALERV 
Serevent Inhaler delivers your medicine as an aerosol spray for you to inhale 
directly into your lungs where it is needed. Each puff provides 25 micrograms of the 
active ingredient salmeterol (as salmeterol xinafoate). It also contains the 
propellants trichlorofluoromethane and dichlorodifluoromethane, and soya lecithin 
which helps to dissolve the active ingredient. Each canister contains 120 puffs. 
To help identify Serevent Inhaler, there is an embossed letter S on the plastic case. 
There is also a special dimpled 'touch pad' area to distinguish the 'protector' 
inhalers from 'preventer' or 'reliever' inhalers which have different touch pads. 
WHO MAKES " 
Serevent Inhaler is made by Glaxo Wellcome Production, Evreux, France. The product 
Hr en re is hcdd I Allen & H, inburys, '; tot klc't Ptrk Mirldl('u-v l' BI 11 RT 
HOW YOUR MIIEDIICINENORW. ý 
Salmeterol xinafoate is one of a group of medicines called bronchodilators. It 
relaxes the muscles in the walls of the small air passages in the lungs. This helps to 
open up the airways and makes it easier for air to get in and out of the lungs. The 
effects of salmeterol xinafoate usually last for at least twelve hours. When it is taken 
Serevent Inhaler is used to help breathing problems in asthma and other chest 
illnesses such as, in adults, Chronic Obstructive Pulmonary Disease (COPD). 
If you have asthma you should take your Serevent at the same time as your inhaled 
corticosteroid and not on its own. If you are not taking this second medication or if 
you are unsure, ask your doctor. 
Serevent Inhaler should NOT be used as a 'reliever' for a sudden attack of wheeze 
or breathlessness. If you get a sudden attack of wheezing or breathlessness, you 
should inhale from a quick-acting 'reliever' inhaler. If you feel you are getting 
breathless or wheezy more often than normal, you should go to see your doctor. 
MAKE SURE THAT THIS MEDICINE IS SUITABLE FOR YOU 
TELL YOUR DOCTOR BEFORE STARTING TO TAKE THIS MEDICINE 
" if you are pregnant (or intending to become pregnant), 
" if you are breast-feeding a baby, 
" if you have ever had to stop taking this or another medicine for this illness 
because you were allergic to it or it caused problems, 
' if you are allergic to soya or related food products such as soya beans, 
' if you are allergic to lecithin, 
" if you are having treatment for a thyroid condition, 
' if you are having treatment for high blood pressure, 
" if you have an irregular heart beat/rhythm, including a very fast pulse, 
if you are taking any medicines to control an irregular heart beat/rhythm, 
including a very fast pulse. 
Sometimes this medicine may not be suitable and your doctor may want to give you 
something different. Make sure that your doctor knows what other medicines you 
are taking (e. g. other inhalers, treatment to reduce fluid, any other kind of 
bronchodilator tablets, steroid tablets), including any you have bought from the 
chemist. Remember to take these medicines with you if you have to go into 
hospital. 
TAKING YOUR MEDICINE 
Serevent Inhaler produces a fine mi>t ,k, Iý,, u must inhale into your lungs. 
Make sure that you know how to use tI mh. il O ornn- 
HOW TO USE YOUR INHALER 
iu i. d A . At ii IL SNAP'-UN MUL: IiII'IL(L COVER, HOLD BETWEEN THE THUMB 
AND FOREFINGER, SQUEEZE GENTLY 
AND PULL APART AS SHOWN. Check 
inside and outside to make sure that the 
mouthpiece is clean and that there are no foreign objects. 
TESTING YOUR INHALER 
If your inhaler is new or if it has not been used for a week or more, shake' it well 
and release one puff into the air to make sure that it works. 
7 If you are to take another puff, keep the inhaler upright and wait about half a 
minute before repeating steps 2 to 6. 
8 After use, always replace the mouthpiece cover to keep out dust and fluff. 
REPLACE FIRMLY AND SNAP INTO POSITION. 
IMPORTANT 
Do not rush stages 3,4 and 5. 
It is important that you start to breathe in as slowly as possible just before operating your 
inhaler. Practise in front of a mirror for the first few times. If you see 'mist' coming from 
the top of the inhaler or the sides of your mouth, you should start again from Stage 2. 
Some people find it difficult to release a puff of medicine just after they start to 
breathe in. The Volumaticrm large-volume spacer device helps to overcome this 
problem. Your doctor, nurse or pharmacist will be able to advise you about this. 
Young children may need help and their parents may need to operate the inhaler 
for 
them. Encourage the child to breathe out and operate the inhaler just after the child 
starts to breathe in (see picture 5). Practise the technique together. 
Older children or people with weak hands may find it 
easier to hold the inhaler with both hands as shown. Put 
the two forefingers on top of the inhaler and both thumbs 
on the bottom below the mouthpiece. If this does not 
heln a sneci. vl ek"vice 
3 told the inhaler upright place the mouthpiece in 
as shown above with your mouth between 
your thumb on the base your teeth and close below the mouthpiece. your lips around it but 
Breathe out as far as is do not bite it 
comfortable and then..... 
2 Shake the inhaler before use. 
Just after starting to breathe 5 in through your mouth, 
press down on the top of 
the inhaler to release a 
puff while still breathing in 
steadily and deeply. 
liuld sour breath, take the 6 inhaler from your mouth 
and your finger from the 
top of the inhaler. 
Continue holding your 
breath for a few seconds or 
as long as is comfortable. 
The usual starting dose is: 
Adults 
1. For asthma and other chest illnesses: 2 puffs twice a day. Your doctor may 
increase this to 4 puffs twice a day. 
2. For COPD: 2 puffs twice a day. 
Children aged 4 and over: 
1. For asthma and other chest illnesses: 2 puffs twice a day. 
2. For COPD: Not appropriate. 
Serevent Inhaler is not recommended for children under 4. 
* It is very important that you use your Serevent Inhaler every day, twice a day, in the 
morning and again in the evening. This should help to keep you free of symptoms 
throughout the day and night. 
" YOU MUST NOT inhale more puffs or use your inhaler more often than the doctor told 
you to. 
When you start using Serevent Inhaler, it is important to continue using any other 
asthma medication, such as inhaled steroids. Continue in the same way as before, 
unless the doctor tells you otherwise, EVEN IF YOU FEEL MUCH BETTER. 
DO NOT USE THIS MEDICINE TO TREAT A SUDDEN ATTACK OF BREATHLESSNESS. 
You should use a quick-acting 'reliever' inhaler for this purpose. If you have more than 
one type of inhaler, be careful not to confuse them. If you are not sure about this, check 
with the doctor. 
IF YOU MISS A DOSE 
If'you forget to take a dose, do riot worry. Inhale a dose when you remember BUT if 
if is near the time for the next dose, wait until this is due. Then go on as before. 
DO NOT TAKE A DOUBLE DOSE. 
IF YOU TAKE T0646' 
It is important to keep to the dose on the pharm e ii > label. If you accidentally take 
a LARGER DOSE THAN RECOMMENDED, you may notice that your heart is beating 
faster than usual and that you feel shaky. You may also have a headache. The 
potassium levels in your blood may be reduced. Tell your doctor as soon as 
possihie 
IF YOUR BRLAIHWC. ()R WHLLLIN t, LIS WORSE SIRAI( lITAFTER USING YOUR 
INHALER, STOP USING IT IMMEDIATELY AND TELL YOUR DOCTOR AS SOON AS 
POSSIBLE. 
" If the relief of wheezing or chest tightness is not as good as usual or does not last for as 
long as usual, tell your doctor as soon as possible. It may be that your chest condition 
is getting worse and you may need to start or increase using an inhaled steroid. 
SIDE EFFECTS 
Most people do not have any problems when taking this medicine. 
" Some people may be allergic to this medicine. If you develop a rash or swelling 
(usually of the face, mouth or throat), stop using your Serevent inhaler and tell your 
doctor straightaway. 
Some people may occasionally feel a bit shaky or have a headache. 
' Some people who are unusually sensitive may notice that their heart is beating 
faster than usual. This awareness of their heart beating is called palpitations, is 
normally harmless, and usually passes off as treatment continues. Some might 
notice that their heartbeat becomes uneven or their heart gives an extra beat. Tell 
your doctor but do not stop using this medicine unless told to do so. 
' There have been occasional reports of muscle cramps, aching joints, chest pain, 
nausea (feeling of sickness), dizziness, nervousness, insomnia (difficulty in 
sleeping) and mouth and throat irritation. 
' Very rarely, Serevent Inhaler can affect the salt balance of the body. 
If you feel unwell or notice anything unusual which you don't understand, tell your 
doctor as soon as possible. 
STORING " MEDICINE 
Keep your inhaler in a safe place WHERE CHILDREN CANNOT REACH IT. 
* Do not store the inhaler above 30°C. 
* If the inhaler gets very cold, take the metal canister out of the plastic case and 
warm it IN YOUR HANDS for a few minutes before use. NEVER use anything else 
to warm it up. 
* WARNING. The metal canister is pressurised. Do 'not puncture, break or burn it 
even when you think it is empty. 
" Do not use after the date shown as 'EXP' on the carton and label. 
" If you are told to stop taking this medicine, RETURN ANY SEREVENT INHALERS 
TO YOUR PHARMACIST to be destroyed. 
r 
4 
Your inhaler should be cleaned at least once a week. 
1. Pull the metal canister out of the plastic case of the inhaler and remove the 
mouthpiece cover. 
2. Rinse the plastic case and the mouthpiece cover in warm water. A mild detergent 
or a solution of the type used to clean babies feeding bottles may be added to the 
water (your pharmacist will advise you). Then rinse thoroughly with clean water 
before drying. Do not put the metal canister into water. 10. 
3. Leave to dry in a warm place. Avoid excessive heat. 
4. Replace the canister and mouthpiece cover. 
FURTHER INFORMATION 
REMEMBER. This medicine is for YOU. Only a doctor can prescribe it for you. 
Never give it to someone else. It may harm them even if their symptoms are similar. 
This leaflet does not tell you everything about your medicine. If you have any 
questions or are not sure about anything, ask your doctor, nurse or pharmacist. 
You will be able to find more information about prescribed medicine from books in 
public libraries. 
The information in this leaflet only applies to Serevent Inhaler. 
Haleraid, Serevent and Volumatic are trademarks of the Glaxo Wellcome Group of Companies. 
O 2003 Glaxo Wellcome Group of Companies. 
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ALLEN & HANBURYS 
SeretideTM 
EvohalerTM 
1 43111 
Seretide Evohaler delivers your medicine as a pressurised suspension for inhalation 
for you to inhale, which delivers your medicine directly into your lungs where it is 
needed. Each puff provides 25 micrograms of the active ingredient salmeterol (as 
the xinafoate) together with either 50,125 or 250 micrograms of the active 
ingredient fluticasone propionate. It also contains a CFC-free propellant, 
Norflurane (HFA 134a). Each cont, i ncr p1(\ ides 120 puffs. 
Sere urig EvohaIer is manufac turtd lu l , I. nu A%e II(ome Production, Zone Inclu. trielIt, 
N`2,23 Rue Lavoisier, 27000 Evreux, France. The product licence is held by 
Allen & Hanburys, Stockley Park, Middlesex, UBl 11 BT. 
 ""u1f";. 
Patient Information Leaflet for Seretide 50 Evohaler, Seretide 125 Evohaler and 
Seretide 250 Evohaler. This pack contains both a'preventer' and a 'protector' in a 
single inhaler. 
Your doctor has prescribed you a Seretide Evohaler as part of your treatment. 
Seretide Evohaler is available in several strengths. Your doctor will have decided 
which strength you need. Seretide 50 Evohaler is recommended for use in children 
older than 4 years of age. All three strengths are recommended for use in adults 
and adolescents 12 years of age and over. 
This leaflet tells you about your Seretide Evohaler and how to use and clean it. 
Please read the leaflet carefully before using your inhaler and keep it until you 
have finished the medicine. You may find that your inhaler needs cleaning at least 
once a week. Please follow the cleaning instructions given at the end of this leaflet. 
Your medicine contains two active ingredients: 
Salmeterol xinafoate is one of a group of medicines called long-acting 
bronchodilators. It relaxes the muscles in the walls of the small air passages in the 
lungs. This helps to open up the airways and makes it easier for air to get in and out 
of the lungs. The effects of salmeterol xinafoate usually last for at least twelve hours. 
When it is taken regularly, it helps the small air passages to STAY OPEN. This is why 
salmeterol xinafoate is called a 'protector'. 
Fluticasone propionate is one of a group of medicines called corticosteroids which 
are often referred to simply as 'steroids'. Corticosteroids are used to treat asthma 
because they have an anti-inflammatory action. They reduce the swelling and 
irritation in the walls of the small air passages in the lungs, and so ease breathing 
problems. Corticosteroids also help to prevent attacks of asthma. This is why they 
are called 'preventers'. Fluticasone propionate should be taken regularly every day. 
Fluticasone propionate should not be confused with other steroids such as anabolic 
steroids misused by some athletes and taken as tablets or injection. 
Seretide Evohaler contains both a 'preventer' and a 'protector' in a single inhaler. If 
your doctor has prescribed you a Seretide Evohaler, you should not use an 
additional corticosteroid (preventer) inhaler unless your doctor tells you to do so. 
Seretide Evohaler is used for the regular treatment of asthma, in adults and children 
aged 4 and over. Seretide 50 Evohaler should not be used in adults and children 
ý'ith wvere a5thm. i. 
Aa9: P 1: icyTAIAP roIN29LIVIIF_i: 111 ); a'tI 
TELL YOUR DOCTOR BEFORE STARTING TO TAKE THIS MEDICINE 
' if you have ever had to stop taking this or another medicine for this illness 
because you were allergic to it or it caused problems, 
" if you are pregnant (or intending to become pregnant), 
' if you are breast-feeding a baby, 
' if you are being, or have ever been, treated for tuberculosis (TB), 
* if you are having treatment for an overactive thyroid condition, 
* if you have diabetes mellitus, 
' if you have heart disease, 
' if you are having treatment for high blood pressure, 
a if you have an irregular heart beat/rhythm, including a very fast pulse, 
if you have a low level of potassium in your blood. 
Sometimes this medicine may not be suitable and your doctor may want to give 
you something different. 
In some cases, Seretide may not be suitable to use with other medicines so be sure 
to tell your doctor: 
' if you have recently been treated with steroid injections, or if you have been 
taking oral steroids for a long time, 
if you are taking any medicines called 'I++ +G (e. g. atenolol, propranolol, 
sotalol, etc. ), 
f 
4 1,1, . the mouthpiece in 
your mouth between your 
teeth and close your lips 
around it but do not bite it. 
5 Just . ýýtý"ý ýtarting to 
breathe in 
through your mouth, press 
down on the top of the inhaler 
to release a puff while still 
breathing in steadily and 
deeply. 
6 Hold your breath, take the inhaler from your 
mouth and your finger from the top of the 
inhaler. Continue holding your breath for a few 
seconds, or as long as is comfortable. 
7 When you take another puff, keep the inhaler upright and wait about 
half a 
minute before repeating steps 2 to 6. 
8 After use, always replace the mouth Piece cover to 
keep out dust and fluff. 
REPLACE MOUTHPIECE COVER FIRMLY AND SNAP INTO POSITION. 
IMPORTANT 
Do not rush stages 3,4 and 5. 
it is important that you start to breathe in as slowly as possible 
just before operating 
your inhaler. Practise in front of a mirror 
for the first few times. If you see 'mist' 
coming from the top of the inhaler or the sides of your mouth, you 
should start 
again from Stage 2. 
Some people find it difficult to release a puff of medicine 
just after they start to 
breathe in. The VolumaticTM large-volume spacer device helps to overcome this 
problem. Your doctor, nurse or pharmacist will 
be able to advise you about this. 
People with weak hands may find it easier to 
hold the inhaler with both hands as shown. Put 
the two forefingers on top of the inhaler and both 
thumbs on the bottom below the mouthpiece. If 
this does not help, a special device called a 
Haleraid'u may make it easier. Your doctor, nurse 
or pharmacist will be able to advise you. 
If you have been given different instructions 
for 
using your inhaler, please follow them carefully 
Tell your donor, nurse or pharmacist if you 
have z: ' 
CLEANING 
,,,, i ,,,,, blui. 
king up, it is important to clean it at least once a 
week, following the instructions below. If your 
inhaler does block up, the same 
cleaning instructions should be followed. If you notice a 
build up of medicine 
around the mouthpiece, do not attempt to unblock 
it with a sharp object, such as 
a pin. 
To clean your inhaler: 
1. Remove the mouthpiece cover. 
2. Do not remove the container from the plastic casing. 
3. Wipe the inside and outside of the mouthpiece and the plastic casing with a dry 
( loth, tissue or r ottonhud. Do not put the metal container into water. 
4. keplar t' the mouth pier e (over. 
hI MI NIB[ R [his medicine is for YOU. Only a doctor can prescribe it for you. 
Never give it to sorneone else. It may harm them even if their symptoms are similar. 
This leaflet does not tell you everything about your medicine. If you have any 
questions or are not sure about anything, ask your 
doctor, nurse or pharmacist. 
You will be able to find more information about prescribed medicines from 
books 
in public libraries. 
The information in this leaflet only applies to Seretide Evohaler. 
Evohaler, Haleraid, Seretide and Volumatic are trademarks of the GlaxoSmithKline 
group of companies. 
® 2004 GlaxoSmithKline group of companies 
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* if you have ever had to 
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* if you are pregnant (or inte 
* if you are breast-feeding a * if you are being, or have e 
* if you are having treatment 
* if you have diabetes mellit, 
* if you have heart disease, 
* if you are having treatment 
* if you have an irregular he, 
* if you have a low level of f Sometimes this medicine ma 
you something different. 
In some cases, Seretide may n 
to tell your doctor: 
* if you have recently been 
taking oral steroids for a lot 
* if you are taking any medics 
sotalol, etc. ), 
* if you are taking a type of 
-2 " if you are taking any medicines to control an irregular heart beat/rhythm, including 
a very fast pulse. 
Check with your pharmacist or doctor if you are not sure. 
Make sure that your doctor knows what other medicines you are taking (e. g. other 
inhalers, treatment to reduce fluid, any kind of bronchodilators or steroid tablets), 
including those you have bought from a pharmacy (chemist). Remember to take these 
medicines with you if you have to go into hospital. 
If you have just started to use a Seretide Evohaler instead of, or as well as, taking 
steroid tablets, you should carry a 'steroid warning card' (if you have one) until your 
doctor tells you that you don't need to any longer. 
* REMEMBER that Seretide Evohaler produces a fine mist which you must inhale 
through your mouth into your lungs. Make sure that you know how to use the 
inhaler properly. The instructions are given later on in this leaflet. If you have 
problems, ask your doctor, nurse or pharmacist. 
* MAKE SURE YOU KNOW HOW AND WHEN TO USE YOUR INHALER, AND 
HOW MANY PUFFS TO TAKE. Your doctor should have told you and the 
instructions should be on the pharmacist's label. If they are not, or you are not sure, 
. isk our 
doctor or pharm. ( ist. 
1" 
For adults and adolescents 12 years of age and user: 
Seretide 50 Evohaler: Two puffs twice a day 
Seretide 125 Evohaler: Two puffs twice a day 
Seretide 250 Evohaler: Two puffs twice a day 
For children 4 to 12 years of age: 
Seretide 50 Evohaler: Two puffs twice a day 
This medicine is NOT recommended for children below 4 years of age. 
The strength will depend on your condition and will be decided by your doctor. Your 
doctor will prescribe the lowest strength of Seretide Evohaler that will best control 
your symptoms. If your symptoms are very well controlled using Seretide Evohaler 
twice a day, your doctor may decide to reduce your dose to once a day. This may be 
either once a night, if you have night-time asthma symptoms, or once in the morning 
if you usually have daytime symptoms. 
* IT IS VERY IMPORTANT that you keep to your doctors' instructions as to how many 
puffs to inhale and how often to use your Seretide Evohaler. DO NOT USE more 
often than you were told to. 
" It is VERY IMPORTANT THATYOU USE YOUR SERETIDE EVOHALER EVERY DAY. 
DO NOT STOP treatment even if you feel better unless told to do so by your doctor. 
* DO NOT USE THIS MEDICINE TO TREAT A SUDDEN ATTACK OF 
BREATHLESSNESS - it will not help you. You should use a quick-acting 'reliever' 
inhaler (e. g. salbutamol) for this purpose, which you should have available at all 
times. if you have more than one medicine, be careful not to confuse them. 
A spacer device may be used, particularly with young children, if you or your child 
have difficulty co-ordinating breathing in through your mouth and pressing down 
on the top of the inh. tlet In n'le. 3se a puff , it thi' s, inw time 
If YOU TAKE TOO MUCH 
It is important to keep to the dose on the pharmacists lahr'l. It you e dentally take 
a LARGER DOSE THAN RECOMMENDED, you may notice that your heart is beating 
faster than usual and that you feel shaky. You may also have a headache. Contact your 
doctor as soon as possible for advice. 
" MISS A DOSE 
If you forget t dose, do not worry. Inhale a dose when you remember, then go on as 
1w, 
AFTER TAKING YOUR MEDICINE 
OI: A% II! I, I', (, (, Il5 \1't ýf: ýl', I RAIL JIl Al I LR USIN( 
YOUR INHALER, STOP USING IT IMMEDIATELY, AND TELL YOUR DOCTOR 
STRAIGHTAWAY. 
" If your asthma gets worse or is not well-controlled (e. g. you feel wheezy or need 
more of your reliever' inhaler), go and see your doctor. If your 'reliever' inhaler 
does not improve your asthma, you must see your doctor as soon as possible. Your 
chest condition may be getting worse and the doctor may need to increase your 
amount of inhaled steroid. 
If you are being treated for a long time with high doses of any inhaled steroid, you 
may require extra steroids in times of extreme stress or during admission to hospital 
after a serious accident or injury or before a surgical operation. Your doctor may 
decide to give you extra steroid medication during this period as tablets, or 
injection if you are in hospital. 
SIDE EFFECTS 
Most people do not have any problems when taking this medicine. 
Some people may be allergic to this medicine. If you develop a rash or swelling 
(usually of the face, mouth or throat), stop using your Seretide Evohaler and tell 
your doctor straightaway. 
* Some people may occasionally feel a bit shaky or have a headache, but these 
effects usually wear off as treatment continues. 
* Some people who are unusually sensitive may notice that their heart is beating 
f, i'tr'r than ii-, u d '? -i ,f th, ii he. u i' , illed palpitations, is 
nues. Some might 
3- 
* Some people occasionally develop 'thrush' in their mouth and find that their 
tongue becomes sore, their voice becomes hoarse, or their throat becomes 
irritated, after inhaling this medicine. Rinsing the mouth with water and spitting 
it out immediately after each dose may help. Your doctor may prescribe a spacer 
to help you with these side effects. 
* In very rare instances, treatment with Seretide Evohaler may affect the normal 
production of steroids in the body. This is more likely to happen if high doses 
are being used over a long period of time (for example if using more than 2 
inhalations Seretide 50 Evohaler twice daily in children). One of the rare effects 
is that children and adolescents may grow more slowly than others. Children and 
adolescents who are receiving treatment over a long period of time shouldwave 
their height checked regularly by their doctor. Other effects are thinning of the 
bones and certain eye disorders (known as cataract and glaucoma). These effects 
are much less likely to occur than with steroid tablets. If you have just started 
using a spacer with your inhaler then your doctor may reduce your dose to 
decrease the risk of you getting these side effects. 
It is important that if you or your child is on high doses of inhaled steroid and 
becomes unwell with vague symptoms such as tummy ache, sickness, diarrhoea, 
headache or drowsiness you see a doctor immediately. This is more likely to 
happen during an infection such as a viral infection or a stomach upset. It is 
important that your steroid is not stopped suddenly as this could make your asthma 
worse and could also cause problems with the body's hormones. If you or your 
child develops an illness like this, you should make sure that the doctor knows 
you/your child is on inhaled steroids and the daily dose. Check with your doctor if 
you are uncertain. 
Your doctor will help prevent these possible side effects by prescribing the lowest 
dose of Seretide at which your asthma is well-controlled. 
If you feel unwell or notice anything unusual which you don't understand, tell your 
doctor as soon as possible. 
LOOKING AFTER YOUR MEDICINE 
* Keep your Seretide Evohaler in a safe place WHERE CHILDREN CANNOT 
REACH IT. 
* Clean your inhaler on a weekly basis as described under CLEANING. 
* If your inhaler becomes blocked, it should be washed as described under 
CLEANING. 
* Do not store the inhaler above 25°C. 
* If the inhaler gets very cold, take the metal container out of the plastic case and 
warm it IN YOUR HANDS for a few minutes before use. NEVER use anything 
else to warm it up. 
* WARNING. The metal container is pressurised. Do not puncture, break or burn 
it even when apparently empty. 
* Do not use after the date shown as 'EXP' on the carton and label. 
* If you are told to stop taking this medicine, RETURN ANY SERETIDE 
EVOHALERS TO YOUR PHARMACIST to be destroyed. 
I EAFLET PREPARED FEBRUARY 2004 
HOW TO USE YOUR INHALER 
".,, I vii ! !< h'ur doctor, nurse or pharmacist should instruct you in the proper use 
of your Seretide Evohaler. 
1 To remove the snap-on mouthpiece 
cover, hold between the thumb and 
forefinger, squeeze gently and pull 
apart as shown. Check inside and 
Outside to make sure that the mouth- 
pece is clean, and that there are no 
tnreign objects. 
TESTING YOUR INHALER 
If your inhaler is new or if it has not been used for a week or more, shake it well 
and release two puffs into the air to make sure that it works. 
2K. -w before use. Hold thf inhaler upright as 3 shown above with your thumb 
on the base, below the mouth- 
piece. Breathe out as far as is 
comfortable and then..... 
APPENDIX 5 
Peer Review Publications in International Journals 
Downloaded from thorax. bmioumals. com on 4 August 2005 
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629 
Impact of changes in the IOC-MC asthma criteria: a British 
perspective 
JW Dickinson, GP Whyte, AK McConnell, MG Harries 
............................................................................................................................... Thorax 2005; 60: 629-632. dot: 10.1136/thx. 2004.037499 
Background: Since 2001 the International Olympic Committee-Medical Commission (IOC-MC) has 
required athletes using inhaled ß2 agonists to provide clinical evidence of their asthmatic condition. The 
aim of this study was to compare the reported prevalence of asthma at the 2000 and 2004 Olympic 
Games in the Great British Olympic team (Team GB). 
Methods: Following local ethics committee approval, 271 athletes (165 men) from the 2004 Team GB 
oýýý See end l 
article for ffiliations h ' volunteered and provided written 
informed consent. An athlete was confirmed asthmatic if he or she had a 
a aut ors 
,,...... , positive 
broncboprovocation or bronchodilator test as defined by the IOC-MC. Pre-Olympic medical forms 
.,... . from the 2000 Team GB were also examined to establish the prevalence of asthma among the members of Correspondence to' 
Institute 
w Dickinson, English 
Insof Sport Bishom 
Team GB of the 2000 Olympic Games. 
Results: The prevalence of asthma in the two teams at the 2000 and 2004 Olympic Games was similar 
Abbey High Performance (21.2% and 20.7 , respectively). 
In the 2004 Olympic Games 13 of 62 athletes (21.0%) with a previous 
Centre, Bishom, Nr 
A, . dicks SV 1RT, 
dia nosis of asthma tested negative. A further seven with no previous diagnosis of asthma tested positive. 
Conclusions: The prevalence of asthma within Team GB remained unchanged between 2000 and 2004. UK; K; john. dickinsonQ 
eis2win. co. uk The IOC-MC requirement that asthmatic athletes must submit 
documented evidence of asthma has 
highlighted That 13121.0%) previousIy diagnosed as asthmatic failed to demonstrate evidence of asthma 
Received while seven athletes with no previous history or diagnosis of asthma tested positive. Screening for asthma 11 
epted 
er 2004 
Acceptod 29 March h 2005 within elite athletic populations using 
bronchoprovocation challenges appears warranted to assist athletes 
i f 
......... 
ng events. or major sport in preparing more effectively 
xerdse induced asthma (EIA) causes expiratory 
limita- 
tion following exercise. It can be triggered by an increase 
Ein 
the volume of "unconditioned" air inspired through 
the mouth. During increased levels of activity "uncondi- 
tioned" air cools and dries the upper and lower airways 
inducing inflammation and smooth muscle contraction 
leading to bronchial narrowing' that is readily reversible 
with inhaled short acting (1 agonists. The prevalence of EIA 
in athletic populations has been shown to vary between 9% 
and 55%, " depending on the type of sport, diagnostic test 
used, and environment. Participants in winter sports gen- 
craily have a higher prevalence of EIA than those engaged in 
summer sports. '-' 
A number of studies have shown that therapeutic doses of 
inhaled short acting 03 agonists have no performance 
enhancing effects"' yet the International Olympic 
Committee-Medical Commission (IOC-MC) has stated that 
a simple notification from the team medical officer stating 
the athlete has EIA is no longer acceptable. " A more rigorous 
testing regime including maximal voluntary flow-volume 
loops is now required. " 
One of the main reasons the IOC-MC has given for the 
enhanced level of evidence is an apparent increase in the 
prevalence of asthmatic athletes since the 1984 Olympic 
Games. " At the 1984 Los Angles Olympics 11% of the US 
Olympic team were using inhalers. " The prevalence of 
asthma reported within the US team at the 1996 Olympics 
in Atlanta was 14%' and by 1998 at the winter Olympics in 
Nagano this figure had reached 17%' While there seems to be 
a progressive rise in EIA within the US Olympic teams, there 
are limited reports on the prevalence of asthma in the 
Olympic teams of other nations. What remains unclear is 
whether the observed increase in the prevalence of asthma in 
the US teams is an indication of a global trend at the elite 
athletic level. Further, there are few data available on sport 
specific prevalence. " 
Many studies have reported the prevalence of asthma by 
the sole use of questionnaires and symptoms. 4 5 14 1 "9 MS 
approach, however, is regarded as a poor method of 
assessment. For example, Rundell et a? 1° examined the 
accuracy of symptom based diagnosis compared with an 
exercise challenge to diagnose EIA in elite winter athletes by 
comparing results from an asthma symptoms questionnaire 
with those from exercise challenge. Of the 26% of partici- 
pants who tested positive for EIA in response to the exercise 
challenge, only 40% of these reported more than one 
symptom of EIA in the questionnaire. Post-exercise cough 
was the most common symptom reported by both EIA 
positive and EIA negative athletes. The high number of false 
positives and false negatives from questionnaire diagnosis 
highlights the need for bronchoprovocation tests and sup- 
ports the IOC-MC requirement for athletes to produce 
quantitative evidence of their asthma. 
The relative paucity of sport specific data examining the 
prevalence of asthma/EIA, together with the IOC-MC 
changes in criteria for asthma diagnosis, provide the rationale 
for this study. The purpose of this study was to compare the 
prevalence of EIA within the Great British Olympic Team 
(Team GB) at the 2000 and 2004 Summer Olympic Games, to 
quantify sport specific differences in the prevalence of EIA, 
and to examine the implications of changes made in the IOC- 
MC guidelines. 
......................................................... 
Abbreviations: EIA exercise induced asthma; EVH, euco nic voluntary hyperpnoea; FEVI, forced expiratory volume in 1 secondp 
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Table 1 Prevalence of asthma in the British squads at the 2000 and 2004 Olympic 
Games 
2000 2004 
N No (%) asthmatic N No (%j asthnw6c 
Athletics 28 7(25) 58 9(16) 
Badminton 13 2115) 11 1 (9) 
Canoe/kayak 12 1 (8) 9 1 (11) 
Cycling 27 12 (44) 23 9 (39) 
Diving 7 3(43) 7 1 (14) 
Gymnastics 14 0 9 0 
Hockey 31 3(10) 16 5(31) 
Judo 10 2(20) 8 1 (13) 
eng Al 8120) 36 7(19) 
Sailing 17 0 18 0 
Shooting 1 0 
ýýn9 4 (41) 1 7 36 16 (44) 
T, io1+lon 8 0 6 0 
19 3(16) 28 508) 
Overall 
Men 152 29 (19.1) 165 34 (20.6) 
Women 122 29 (23.8) 106 22 (20.8) 
Total 274 58 (21.2) 271 56(20,7) 
METHODS 
2004 Team GB 
Following local ethical committee approval, British athletes 
(165 men, 106 women) selected to compete in the 2004 Team 
GB were recruited. All athletes were volunteers and provided 
written informed consent. Athletes were only tested 
for 
asthma if they had a previous diagnosis of EIA or reported 
symptoms of EIA or were referred for testing by a team 
medical officer. 
IOC-MC criteria 
Diagnosis of asthma for the 2004 Team GB members was 
made according to the IOC-MC requirements, which included 
a positive bronchodilator or bronchoprovocation test. The 
IOC-MC criteria for a positive diagnosis in a bronchodilator 
challenge were met if the forced expiratory volume in 
I second (FEV1) increased by 15% or more following a 
therapeutic inhaled dose (200 µg) of a short acting 52 agonist 
(salbutamol). The IOC-MC criteria for a positive diagnosis in 
a bronchoprovocation challenge were met if the post- 
challenge FEV1 fell 10% or more from the pre-challenge 
FEV1 measurement. Both bronchodilator and bronchoprovo- 
cation responses were assessed using maximal effort flow- 
volume spirometry, measured with an electronic spirometer 
that met American Thoracic Society guidelines (MicroLab 
ML3500, Micro Medical, Rochester, UK). The best of three 
criteria were applied for selection of recordings. 
All asthma drug treatments including inhaled corticoster- 
oids and long acting ßz agonists were withdrawn for a 
minimum of 72 hours before each bronchial challenge. 
Athletes were advised to use short acting ß2 agonists if they 
required any asthma relief during this period. 
Bronchodilator challenge 
The bronchodilator challenge involved measuring maximal 
voluntary flow-volume loops before and 10 minutes after 
a therapeutic dose (200 µg) of an inhaled 02 agonist 
(salbutamol). 
Branch a provocation challenges 
The bronchoprovocation challenges consisted of either an 
exercise challenge or eucapnic voluntary hyperpnoea (EVH) 
challenge. " 
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Exercise 
An exercise challenge involved measuring maximal flow- 
volume loops before exercise and at 3,5,10 and 15 minutes 
after stopping exercise. The exercise challenges were con- 
ducted for a minimum of 4 minutes and were designed to be 
as sport specific as possible, so could involve running, cycling, 
rowing or swimming. The target heart rate (HR) during the 
exercise challenge was 80-90% of HRmax (220 - age). 
Eucapnic voluntary hyperventilation (EVH) 
The EVH challenges involved measuring maximal voluntary 
flow-volume loops before EVH (best of three) and at 3,5,10, 
and 15 minutes after stopping hyperventilation (single 
effort). The EVH challenge required the athlete to hyperven- 
tilate for 6 minutes at a rate of 30 times their baseline FEV1. 
To prevent hypocapnia during hyperventilation, subjects 
inspired a gas mix containing 5% CO2.21% 02, and 74% N2. " 
Prevalence of asthma in 2000 Team GB 
Competitors' medical forms from the 2000 Team GB (120 
women, 152 men) were used to obtain the reported 
prevalence of asthma before the IOC required quantitative 
evidence of asthma. Data obtained from these forms included 
the athletes' asthmatic status and event. 
Analysis of dato 
The prevalence of asthma within each sport for 2000 Team 
GB and 2004 Team GB is reported descriptively by sport, sex, 
and overall prevalence. 
RESULTS 
Seventy seven athletes who were members of 2004 Team GB 
were tested for asthma using a test recognised by the IOC. All 
athletes required to provide evidence of asthma were tested. 
Sixty two of these athletes had been previously diagnosed 
with asthma and were prescribed asthma medication; 13 of 
these 62 (21%) failed to produce a positive test for asthma 
under IOC criteria. Of the 13 athletes, all reported symptoms 
of EIA with post exercise cough (n = 10), wheezing (n = 10), 
and chest tightness (n = 10). In addition to the 62 athletes 
receiving medication, a further 15 athletes referred by a team 
medical officer were tested. Seven of these 15 athletes (47%) 
had no previous history or diagnosis of asthma tested positive 
for asthma under IOC guidelines. Four of these seven athletes 
www. thoroxjnl. com 
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reported symptoms of EIA with post exercise cough 
(n = 3), 
wheezing (n - 3)" and chest tightness (n = 
3) being the most 
common. The athletes who met the criteria to use asthma 
medication at the 2004 Olympic Games (n - 
56) won a total 
of 17 medals (seven Gold, seven Silver, three 
Bronze). The 
athletes who failed to meet the IOC-MC criteria and were 
subsequently removed from asthma medication 
(n = 13) at 
the 2004 Olympic Games won a total of two medals 
(both 
Gold). 
Of the 56 IOC-MC positive athletes, only two provided 
evidence of asthma through bronchodilator challenge; all 
the 
others required a bronchoprovocation challenge. 
The fall in 
FEVI elicited by the positive exercise challenges ranged 
from 
10.5% to 23.3%. The fall in FEVI elicited by positive EVIi 
challenges ranged from 10.0% to 61.3%. 
All athletes who 
had a positive bronchoprovocation challenge 
demonstrated 
reversibility. 
The prevalence of asthma in the British squad at both the 
2000 and 2004 Olympic Games is displayed in table 1 
by sex, 
sport, and overall prevalence. 
Swimming had the third highest prevalence of asthma in 
2000 (41%) and the highest in 2004 (44%). Other sports in 
which the prevalence of asthma also remained similar 
between 2000 and 2004 included canoeing (8% v 11%), 
rowing (20% v 19%), and cycling (44% w 39%). 
Sports in 
which there was a fall in the prevalence of asthma 
from 2000 
to 2004 included athletics (25% v 16%), badminton (15% v 
9%), diving (43% v 14%), and judo (20% v 13%). Sports that 
have seen an increase in the prevalence of asthma from 2000 
to 2004 include archery (33% v 50%), men's hockey (13% v 
31%), shooting (0% v 17%) and tae kwon do (0% v 25%). 
Sports that had no asthmatics in either 2000 or 2004 included 
boxing, gymnastics, modem pentathlon, sailing, tennis, 
weightlifting, and wrestling. 
DISCUSSION 
The main finding of this study was that the prevalence of ETA 
in Team GB athletes was unchanged between the 2000 and 
2004 Olympic Games whereas, within the US Olympic team, 
it appears to be rising. " " Unfortunately, it is impossible to 
determine precisely how the diagnoses of asthma in the US 
Olympic team were made, as they were conducted at a time 
when a range of different (unspecified) methods were 
employed. In the case of our own data, 21% of athletes 
previously diagnosed with asthma and using inhalers 
did not 
meet the IOC-MC criteria. This indicates that a large number 
of British Olympic athletes were receiving medication for 
which there was no clinical indication. The percentage of 
athletes in the 2004 Team GB squad who did not meet IOC- 
MC criteria Is similar to the percentage of athletes whose 
application was declined by the IOC-MC at the 2002 Winter 
Olympics; " 29 of 159 (18%) of those who submitted an 
application to use ßz agonists at the 2002 Winter Olympics 
were refused by the IOC-MC. We support the IOC-MC 
contention that a large number of athletes may be 
misdiagnosed and inappropriately medicated. The new IOC- 
MC asthma/EIA guidelines may therefore improve athlete 
care. 
Despite identifying inappropriately medicated athletes and 
their subsequent withdrawal from medication, there was no 
overall change in the prevalence of asthma within Team GB 
between 2000 and 2004. This outcome is probably due to the 
identification of the small number (n - 7) of athletes with no 
previous history who had a positive response to bronchopro- 
vocation. If diagnosis in the 2004 team had been based on 
symptoms alone, then the prevalence rate would have been 
27% ((62+121/271), which is higher than the actual 
prevalence rate and higher than the rate reported in 2000 
(21%). This finding is consistent with previous studies that 
631 
have shown a continued rise in the prevalence of asthma at 
Olympic Games. ' 1 11 "1 Our data require substantiation by 
data from future Olympics using the new IOC-MC criteria. 
The results from the present study show that there is 
variation between sports in the prevalence of asthma in Team 
GB Olympic teams, with swimming having one of the highest 
at both the 2000 and 2004 Olympics Games (>40%). It has 
been suggested that the high prevalence of asthma in 
swimmers may be due to the environment in which they 
train and compete, with a high concentration of chlorine 
which may act as a potent trigger for EIA. " " Other sports 
such as figure skating and cross country skiing have also 
been reported to have a similarly high prevalence of asthma 
(35%, and 50%, respectively), which has been associated with 
training and competing in cold and dry or polluted 
environments. ' z' " This suggests that athletes who compete 
in certain sports may be more susceptible to the development 
of EIA than others. What is of great concern is that our data 
indicate that the overall prevalence of asthma is higher in 
elite athletes than it is in the general UK adult population 
(7.8%)" The factors underlying this observation require 
urgent attention since they have implications-not only for 
elite athletes-but also for the many recreational athletes in 
the UK and elsewhere. 
The small number of athletes within some of the squads 
(archery, boxing, fencing, modern pentathlon, shooting, tae 
kwon doe, triathlon) makes it difficult to obtain an accurate 
impression of the prevalence of EIA/asthma by sport. Indeed, 
the prevalence data for triathlon appears to be inconsistent 
with our other findings. At the 2000 and 2004 Olympic 
Games the Team GB triathlon squad did not have one athlete 
diagnosed with asthma, yet swimming and cycling were 
among the sports with the highest prevalence of asthma at 
both the 2000 and 2004 Olympic Games. It is possible that 
the absence of triathletes with asthma in Team GB may be 
due to the small size of the squad and may not be a true 
representation of triathlon as a whole. Future investigations 
could overcome this by polling prevalence data from the 
Olympic teams of several countries. Multicentre data collec- 
tion is indicated to support collection of prevalence data. 
In a unique study by Alaranta et all' sports were classified 
into four main groups and the prevalence of EIA was reported 
on the basis of whether the sport was endurance, team, 
speed/power, or motor skill. The prevalence of EIA was 
highest in endurance sports (22.2%) and team sports (14.5%) 
compared with 8.8% for speed and power sports and 8.2% for 
motor skill sports. Unfortunately, the study relied solely on 
physician diagnosis and it lacked individual sport prevalence 
data. Our data used recognised EIA tests to gain the 
prevalence data at the 2004 Olympics and also examined 
the individual sports. It is difficult to make a direct 
comparison with the data from the study by Alaranta et al" 
as sports such as swimming and athletics have many 
different events ranging from sprinting to endurance events. 
Subdividing events into groups based on their aerobic 
requirement seems to suggest that events with a longer 
exposure to inhalation of "unconditioned" air (such as 
endurance events) could have a higher prevalence of EIA 
than events that involve shover exposure to "unconditioned" 
air (such as sprint events), supporting the implication of the 
study by Alaranta et al. " Furthermore, sports/events that take 
place in environments that have a high potency for triggering 
EIA (such as dry/polluted air) may have the highest 
prevalence of asthma regardless of the duration of the 
activity (for example, winter sports/swimming). This inter- 
pretation suggests that the development of EIA may be 
exacerbated, or even caused, by a process of airway 
remodelling in response to training and competing in an 
environment that triggers EIA. This remodelling process may 
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occur at different speeds, depending on the individual, type 
of event, and environment. 
The introduction of more rigorous testing procedures for 
the diagnosis of ELVasthma resulted in 21% of athletes who 
were thought to be EIA positive being confirmed as EIA 
negative. This rate of misdiagnosis is not as high as that 
reported by Rundell of a? ° in their comparison of ques- 
tionnaire diagnosis and diagnosis via exercise challenges 
(60%). One of the reasons for this could be the variety of 
different methods used to diagnose asthma in Team GB 
athletes in the past. Thus, not all of the athletes who took 
part in our study would have received a previous diagnosis 
based on symptoms alone. At present no systematic 
programme exists for the diagnosis of EIA/asthma in Team 
GB athletes. Such a programme could reduce the chance of 
false positive diagnoses and reduce the needless use of 
medication which may have potentially damaging side 
effects, such as downregulation of airway 02 receptors? ' 
Perhaps more importantly, this study identified seven 
athletes with no previous history or diagnosis of asthma, 
three of whom reported no symptoms of EIA on questioning. 
Some of them presented with falls in FEV1 of more than 40% 
following EVH challenge. The implications of untreated EIA/ 
asthma for the performance, health, and wellbeing of these 
athletes can only be speculated upon and argues strongly for 
the routine screening of all athletes. 
In conclusion, the prevalence of asthma in 2004 Team GB 
athletes remained similar to that in 2000 Team GB athletes, 
despite changes in IOC-MC requirements. The improved 
diagnostic techniques, however, identified a large number of 
false positive diagnoses and also identified a number of 
previously unknown asthmatics. These athletes were either 
removed from unnecessary treatment or placed on appro- 
priate medication, and therefore received an improved level 
of care. Screening for EIA within elite athletic populations 
using bronchoprovocation challenges such as EVIl and 
exercise appears warranted, not only to assist athletes in 
preparing for major sporting events but also to ensure the 
best possible level of care. 
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M 
Screening elite winter athletes for exercise induced asthma: 
a comparison of three challenge methods 
JW Dickinson, GP Whyte, AK McConnell, MG Harries 
Br J Sports Med 2006; 40: 179-163. dot: 10.1136/6jsm. 2005.022764 
Background: The reported prevalence of exercise induced asthma (EIA) in elite winter athletes ranges from 
9`X, to 50%. Many elite winter athletes do not report symptoms of EIA At present there is no gold standard 
test for EIA. 
Objective: To establish the efficacy of screening for EIA and examine the role of the eucapnis voluntary 
hyperventilation (EVH) challenge and laboratory based and sport specific exercise challenges in the 
evaluation of elite winter athletes. 
See end of artide for Methods: 14 athletes (mean (SD) age 22.6 (5.7) years, height 177.2 (7.0) cm, body mass 68.9 (16.9) 
kg) 
authors' affiliations korn the Great Britain short-hack speed skating (n - 10) and biathlon looms (n-4) were studied. Each 
athlete completed a laboratory based and sport specific exercise challenge as well as an EVH challenge, in 
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randomised order. 
Results: All 14 athletes completed each challenge. Two had a previous history of asthma. Ten (including 
the two with a Previous history) had a positive test to at least one of the challenges. Ten athletes had a Abbe uc s Abbey, Marlow, abb 
1 RT, UK, john. dickinson@ positive response to EVH; of these, only three also hod a positive response to the sport specific challenge. 
eis2win. co. uk No athletes hod a positive response to the laboratory based challenge. 
Conclusions: Elite athletes should be screened for EIA. EVH is a more sensitive challenge in asymptomatic 
ber 2005 
............. 
athletes than sport specific and laboratory based challenges. IF sporting governing bodies were to 
implement screening programmes to test athletes for EIA, EVH is the challenge of choice. 
E 
xerdse induced asthma (EIA) is defined as a transient 
narrowing of the airways, limiting expiration, following 
a bout of exercise, which is reversible by inhalation off 6 
agonists. ' The reported prevalence of EIA in winter athletes 
ranges from 9% to 50%' which is higher than that of the 
general population (approximately 8% in the United 
Kingdom), but in line with estimates for elite summer sports 
athletes. ' 
At both the 2002 Salt Lake City Writer Olympics and the 
2004 Athens Summer Olympics, athletes who wished to use 
inhaled ß3 agonists therapeutically were required to provide 
evidence of asthma through bronchodilator or bronchial 
provocation challenges. At present, there is no gold standard 
test for EIA; however, the International Olympic Committee- 
Medical Commission (IOC-MC) accepts the results of various 
different airway challenges, including exercise, eucapnic 
voluntary hyperventilation (EVH), methacholine, and saline 
challenges! 
Exercise is an indirect airway challenge that has a high 
level of specitidty, " but its sensitivity is affected by environ- 
mental conditions. ' Accordingly, exercise challenges in sport 
specific environments are more sensitive than challenges 
conducted in laboratory settings' This is probably because 
the air conditioned laboratory environment has a relatively 
high temperature (around 20°C) and water content (around 
50% relative humidity). Airway drying"° and airway cool- 
in '" have been proposed as mechanisms in the aetiology 
of EIA. Therefore an air conditioned laboratory based 
environment may not be sufficiently provocative, especially 
for winter athletes, who train and compete at sub-zero 
temperatures, where the water content of the air is very low. 
Despite this, laboratory based exercise challenges are still 
used to test elite athletes for EIA 
Eucapnic voluntary hyperventilation (EVH) is a laboratory 
based indirect airway challenge that enables minute ventila- 
tion and environmental conditions to be controlled. The EVH 
challenge has been reported to be the most suitable method 
for diagnosing BIA In cold weather athletes. " "" However, 
over half the requests for therapeutic use exemption for jig 
agonists submitted for the 2002 Salt Lake City Winter 
Olympics employed direct airway challenges to establish 
EIA (that is, methacholine and histamine). ` The sensitivity 
and specificity of these methods have been challenged. 
Holzer et al` screened 50 athletes for EIA using methacholine 
and E VH challenges and found that only nine athletes (18%) 
had a positive challenge to methacholine, whereas 25 (50%, 
including the nine methacholine positive athletes) had a 
positive EVH challenge. The investigators concluded that an 
EVH challenge was more sensitive and specific than a 
methacholine challenge for the diagnosis of EIA in athletes. 
Thus evidence suggests that direct airway challenges are not 
sufficiently sensitive or specific for use in athletes. 
Owing to the lack of sensitivity and specificity of symptom 
based diagnosis" and direct airway challenges, " several 
groups have recently suggested that athletes should be 
screened for EIA using either EVH challenge or exercise 
challenges""" Our aim in this study was to establish the 
efficacy of screening for BIA and examine the role of the EVH 
challenge and laboratory based and sport specific exercise 
challenges in the evaluation of elite winter athletes. 
METHODS 
Following ethical approval from Harrow local research ethics 
committee, 14 athletes (mean (SD) age 22.6 (5.7) years, 
height 177.2 (7.0) cm, weight 68.9 (16.9) kg) from the Great 
Abbreviations: EIA, exercise induced asthma; EVH, eucapnic voluntary 
hyperventilation- FEF50, forced expiratory flaw at 50% of forced vital 
capacity; FEV1, 
fýQ 
expirotoryvolume in one second- FEVI%, FEV1 as 
a percentage of forced vital capacit ; FVC forced vita capacity; lOC- 
MC, International Olympic Committee-Medical Commission; PEF, peak 
expiratory Row 
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Table 1 Athlete responses to each challenge 
emelin. FEV1 (W94 % predicted FEv, 55 MFEV1(%) LB AFEV1(%) 'vii eFEv, (%) 
1 4.8 104 -13.9 -7.5 -20.3 
2 4.0 126 -2.5 1.2 -8.8 
3 4.5 113 -20.7 1.02 -35.8 
4 4.5 104 -3.4 -3A -11.0 
5 4.5 % -1.1 -0.4 14.0 
61 4.8 100 -14.7 -7A -11.8 
7 4.0 113 -2.5 2.2 -10.8 
8 4.1 97 2.4 -1.4 -3.4 
9 4.0 114 -7.2 -3.18 -3.5 
10" 3.6 79 -9.1 -1.7 -12.5 
lit 4.7 104 -4.1 0.2 -11A 
12t 5.1 104 -8.2 -8.8 -4.7 
13t 5.1 120 -2.9 3.3 -18.4 
14t 4.1 96 -1.5 2.4 -23.7 
Mean (Sp) 4.4 (0.4) 105 (11.8) -6.4(6.4) -1.8(3.71 -13.6(8.7) 
EIA positive dhl. Ms identified in bold. 
"Past history of asthma and regular treatment with beclomethasone or salbutamol. 
tMember of the British biathlon team- 
EIA, exercise induced asthma; EVH 8FEVI, change in 
forced e, pirabry volume in one second (FEV1) (allowing eucopnic voluntary hyperventilation challenge; LB 
AFEVI, drongs in FEV, following laboratory based exercise challenge; SS AFEY1, change in FEV1 following sport specific exercise challenge. 
Britain short-track speed skating (n = 10) and biathlon 
teams (n = 4) volunteered to participate, providing written 
informed consent. 
Each athlete completed a laboratory based challenge, a 
sport specific challenge, and a eucapnic voluntary hyperven- 
tilation challenge (EVH) in random order. If an athlete was 
using asthma medication they were instructed to stop the 
drug before each test (inhaled corticosteroids, three days 
before; inhaled long acting ßz agonist, two days before; 
inhaled short acting ß2 agonist, on the day of the test). 
Laboratory based exercise challenge 
The laboratory based challenge required the athlete to run 
continuously on a treadmill for eight minutes (temperature 
1890, relative humidity (RH) 56%). Exercise intensity was set 
to elicit a heart rate of more than 90% of maximum (HR. ) 
for the final four minutes of exercise. " 
Sport specific exercise challenge 
The sport specific challenge for the speed skaters involved 
skating for six minutes (pace ranging between 11 and 12 
seconds per 250 m lap) on the ice rink (temperature 89C, RH 
35%). The sport specific challenge for the biathletes involved 
a 20 minute simulated race in Vaukati, Finland (temperature 
I-2t, RH 31-34%). 
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Figure 1 Changes in forced expiratory volume in one second (AFEVI) 
for each athlete during laboratory based challenge (LB) compared with 
eucapnic voluntary h tilation (EVH). The 7% cut off criterion has 
been added to show number of additional athletes who might have 
received a diagnosis of exercise induced asthma had this criterion been 
used for exercise challenges. 
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Figure 2 Changes in forced expiratory volume in one second (AFEV, ) for each athlete during sport sspecific chollengeý (SS) compared with laborarory based challenge_ (LB The 7% cut olf criterion has been added 
to show the number of additional athletes who might have received a diagnosis of exercise induced asthma had this criterion been used for 
exercise challenges. 
Eucapnic voluntary hyperventilation 
The EVH challenge was conducted in the laboratory and 
required each athlete to hyperventilate for six minutes (30 x 
baseline forced expiratory volume in one second (PEV1)), 
breathing a gas mixture containing 5% CO2,21% 02, and 74% 
N2 (inspired air temperature 19.1t, RH >2%). " 
A MicroLab ML3500 spirometer (Micro Medical, Rochester, 
Kent, UK) was used to collect all spirometry measurements. 
Maximum effort voluntary flow-volume loops were mea- 
sured before and at 3,5,10, and 15 minutes after stopping 
each challenge. FEVI, peak expiratory flow (PEF), forced vital 
capacity (FVC), forced expiratory flow at 50% of FVC (PEF5o), 
and FEV1 as a percentage of PVC (FEVI%) were recorded at 
each time point. 
The percentage change (A) in PEVI, PEF, FVC, FEPso, and 
FEV1% were calculated for each challenge by taking the 
lowest value recorded in the 15 minutes following each 
challenge and expressing the difference between this and the 
baseline value measured immediately before each challenge 
as a percentage. A fall in FEV1 of 10% or more from the 
baseline value was deemed positive for EIA. 
Statistical analysis 
Repeated measure analysis of variance (ANOVA) tests were 
used to compare the changes in APEVI, APEF, AFVC, AFEPsa 
and AFEV1% for each challenge. Planned unpaired t tests 
were used to analyse the difference between positive and 
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hic volunbryhypervenMotion (EVH). The 7% cut oft criterion 
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been added to thaw'+s number of additional athletes who might 
have 
received a diagnosis of exercise induced asthma 
hod this criterion been 
used for exercise challenges. 
negative athletes for each challenge. A probability 
(p) value 
of <0.05 was regarded as significant. All values are presented 
as mean (SD). 
RESULTS 
All 14 athletcs completed every challenge. Of the 14 athletes, 
two had a previous history of asthma and were currently 
treated with beclomethasone and salbutamol inhalers. 
Baseline lung function and AFEV1 for each challenge are 
reported for every athlete in table 1. 
Based on a X10% fall in FEV1,10 of the 14 athletes 
(including two athletes with a previous history of asthma) 
had a positive response to at least one of the challenges 
(table 1). There was no significant difference between 
baseline FEV1 predicted values between athletes with positive 
EU (102.9 (11.43)%) and negative EIA (110.25 (12.61)%). 
Ten athletes had a positive response to EVH; of these, only 
three also had a positive response to the sport specific 
challenge. No athletes had a positive test to the laboratory 
based challenge (figs 1-3). 
After the assumption of sphericity was met, repeated 
measures ANOVA showed that AFEV 1, APEF, AFEFso, and 
AFEVI% changes were significantly greater (p<0.05) follow- 
ing EVH than either the laboratory based or sport specific 
challenge. The average reductions for EIA positive (AFEV1 
X 10% for at least one challenge) and EIA negative athletes 
following laboratory based, sport specific, and EVH chal- 
Icnges are reported in table 2. 
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DISCUSSION 
Our study suggests that screening elite athletes for EIA 
appears warranted. In addition to the two athletes who had a 
previous history of EIA, screening elite athletes resulted in 
the identification of eight others with no history of EIA who 
had significant bronchial hyperresponsiveness (>10% fall in 
FEVI). We have therefore highlighted the findings from 
previous studies that suggest that many athletes fail to report 
or to recognise symptoms of EIA. ' "-" 
Our study showed that the EVH challenge resulted in a 
greater number of athletes presenting with bronchial 
hyperresponsiveness commensurate with a diagnosis of EIA 
than either a sport specific or a laboratory based exercise 
challenge. Our results are similar to studies that have 
compared exercise and EVIl challenges" " and suggest that 
the EVH challenge provides a more sensitive diagnosis of EIA 
in elite winter athletes than the other routinely used non- 
pharmacological challenges. In our study all athletes who 
presented with EIA did so through the EVl challenge. In 
contrast, Rundell at al, 14 studying 19 winter athletes with EIA, 
found that two had a positive exercise challenge but did not 
have a positive response to EVH. Had our study recruited a 
larger number of athletes we might have found that EVii did 
not identify all athletes with EIA. Nevertheless it is clear that 
EVii is a sensitive and specific challenge for EIA in elite 
athletes. 
The superiority of the EVH challenge results primarily from 
the greater degree of control over the two main contributors 
to the airway response-the inspired air water content and 
minute ventilation. The enhanced control over the condition 
of the inhaled air and breathing rate during the EVH 
challenge allows greater confidence that the airways are 
being adequately stimulated to trigger bronchoconstriction in 
susceptible subjects. 
In line with the greater control of inspired air water 
content during the EVH challenge, findings from the present 
study are consistent with the hyperosmolarity theory`"' 
rather than the airway rewarming theory' "" of EIA 
development. Despite the colder inspired air temperature 
during the sport specific challenge (l *C biathlon, VC speed 
skating) compared with the laboratory based challenge 
(18C), only a three athletes had a positive response. The 
EVH challenge, which had the largest number of positive 
tests (10 athletes), was conducted with inspired air tempera- 
tures (19.110) similar to those of the laboratory based 
challenge; however, the relative humidity of the inspired air 
(<2%) was much lower than either the laboratory based 
(-60%) or the sport specific challenge (31-35%). The 
Tabb 2 Comparison of moon percentage changes for EIA positive and EIA negative athletes far the eucapnic voluntary 
hyperventilation and sport specific challenges 
La 55 EVH 
- Na ------------------ ------------------------ A No A ------- No -------------------- A 
FEVý'1 
P°'dne 0 ------------------------------------------ - 3 -16.4 (3.73) ----------- 10 --------------------- -16.9 (7.99) Negativ* 14 -1.83 (3.73) 11 -3.6(3.39) 4 -5.1 (2.51) 
PEF- 
Positiv. 0 3 -14.4 (4.38) 10 -14.9 (7.49) 
M 14 -2.32 (4.39) 11 -2.9 (5.87) 4 -7.08 (7.09) 
FVC Positiv@ 0 
3 -7.7(2.08) 10 -3.1 (3.37) Negative 14 -2.44 (2.26) 11 -3.9(4.00) 4 -1.7(2.59) 
Fffýt 
Paili" 0 3 -24.6 (3.79) 10 -30.7 (10.13) 
Nagativo 14 - 2.44 (13.38) 11 -2.9 (17.90) 4 -14.2 (9.93) 
fEVýX"1 P°'dro' 
0 
Negative 14 
---------------------------------------- 
3 -9.5(2.17) 
0.65 (3.96) 11 0.4 (4.09) 
------------------------------------------------ 
10 
4 
----------- 
-14.4 (6.56) 
-3.41 (2.69) 
---------- -------- - 
"Signifioard difsr. c. (p <0.05) bsweu poaitir and negative responses (dbwing sport specific "lange. 
--- - 
tSigni6c d diF6« (p <0.05) bu wcon positive and negative responses (dlvwing sucopnic voluntary hyperventilation. 
. SO , 
force aQi"Bow of 50% of faced v8d fff copociy; FEV , 
forced axpirobry volume in one wcond; FEV1 %, FEV1 as a percentage of forced vitd capacity; 
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provocative nature of dry air inhalation, rather than cold air, 
lends support to the notion that the underlying mechanisms 
EIA are not temperature related. 
The smaller number of athletes who presented with EIA 
following sport specific and laboratory based challenges may 
be because the required 10% fall in FEVI is not sensitive 
enough to detect EIA following laboratory based or sport 
specific challenges. Work by Helenius et aP* ' has suggested 
that the 10% cut off criterion for FEVI may be insufficiently 
sensitive to detect EIA in elite athletes and it is not 
statistically justified. They suggested a fall in FEVI of 6.5% 
as a suitable cut off criterion for elite runners, while Rundell 
ct aP suggested 7.1%. These values were based on the 95th 
centile (defined as two standard deviations) of the post- 
exercise decline in FEVI observed in a non-asthmatic 
population. 
In line with Rundell et a!, ' a reduction in the cut off 
criterion to AFEV1 of 7% in the present study resulted in a 
further two athletes being classified as positive in the sport 
specific challenge, and four in the laboratory based challenge 
(figs 1 and 2). No false negative responses were observed. 
Further work is required to establish standardised cut off 
criteria for the decline in FEVI following various challenges. 
This may show that the criterion for exercise challenges 
should be lower than that for an EVH challenge (FEV, 
- l0%). 
In conclusion, our observations support the role of screen- 
ing elite athletes for EIA and suggest that EVH is a more 
sensitive challenge for the detection of EIA in asymptomatic 
athletes than either sport specific or laboratory based 
challenges. Thus if sporting governing bodies were to 
implement screening programmes to test athletes for EIA 
our recommendation is that EVH should be the challenge of 
choice. 
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Although this work is not novel, it does confirm and support 
previous studies evaluating the efficacy of eucapnic voluntary hyperventilation (EVH) as a tool for identifying exercise 
induced asthma. Previous studies have made similar com- 
parisons with similar results (that is, it is quite well 
established that a laboratory challenge at room temperature 
and 50% relative humidity is not an appropriate provocative 
challenge). The study design is clear and the results solid, 
although a larger number of subjects would strengthen the 
study power. An important point to consider is whether or 
not small falls in FEY1 (-10%) are of functional significance 
(in other words, do these small falls affect competition 
outcomes? ); nonetheless, the IOC has set the liberal cut off 
criterion of a 10% fall in Mi. It is important to note that because of to the potency of EVFI, only qualified laboratories 
with appropriate rescue plans in place should entertain its 
use. 
KW Runden 
Marywood University, Human Performance Laboratory, Scranton, PA, 
USA, rundell@marywood. edu 
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Mid-expiratory flow versus FEV1 measurements in 
the diagnosis of exercise induced asthma in elite 
athletes 
JW Dickinson, GP Whyte, AK McConnell, AM Nevill, MG Harries LINE 
............................................................................................................................... Thorax 2006,, 61: 111-114. doi: 10.1136/ hx. 2005.046615 
Badvound: A fall in FEV1 of > 10% following bronchoprovocation (eucapnic voluntary hyperventilation 
(EVIL) or exercise) is regarded as the gold standard criterion for diagnosing exercise induced asthma (EIA) 
f r f rti l d 
in athletes. Previous studies have suggested that mid-expiratory flow (FEF50) might be used to supplement 
the sensitivit and s ecificit of the dia n i t i A t t FEV d t i th d k ti o o a c e See en 
au s ofitiat`ons 
p y g mprove y os s. s ga 1 o u y was un nves e e er a en to 
response of FEF50 following EVFI or exercise challenges in elite athletes as an adjunct to FEV1. 
''''''''''''''''' Methods: Sixty six male (36 asthmatic, 30 non-asthmatic) and 50 female (24 asthmatic, 26 non-asthmatic) 
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Conclusion: The inclusion of FEF50 in the diagnosis of EIA in elite athletes reduces the sensitivity and does 
16 Oktober 2005 not enhance the sensitivity or specificity of the diagnosis. The use of FEF50 alone is insufficiently sensitive to 
....................... 
diagnose EIA reliably in elite athletes. 
xerdse induced asthma (EIA) occurs in approximately 
90% of chronic asthmatics' and has previously been 
reported to occur in 7-50% of athletic individuals, " 
Asthmatic elite athletes currently require evidence of asthma 
to obtain a therapeutic use exemption certificate which 
enables them to use therapeutic doses of inhaled ßz agonists 
in and out of competition. ' BIA has previously been 
diagnosed by a number of challenge methods including 
exercise, ' I eucapnic voluntary hyperventilation (EVH), '0 " 
methacholine, ' u histamine, " saline, " and mannitoL" " 
The International Olympic Committee's Medical 
Commission (IOC-MC) considers positive tests from exercise, 
EVH, saline, histamine, and methacholine challenges as 
evidence of EIA. Methacholine and histamine, however, have 
been shown to be less specific than exercise for EIA 
diagnosis. " 18 11 Exercise and EVH challenges are regarded 
as the most specific methods of diagnosing EIA in elite 
athletes. " 
In all EIA tests recognised by the IOC-MC, forced 
expiratory volume in I second (FBVI) is the parameter by 
which changes in maximal expiratory function are assessed, 
but no "gold standard" methodology exists for athletes or 
non-athletes'° Previous studies that have used FEV, to 
diagnose BIA have suggested using falls in FEV, ranging 
from 7% to 20% as cut off criteria. "" The work carried out by 
Iielenius et al" suggests that a fall of 10% in FEV, following 
an exercise test is not sensitive enough to diagnose EIA in 
elite athletes. Despite the absence of a "gold standard" 
methodology for diagnosing EIA in athletes, the IOC-MC has 
ruled that an exercise or EVH challenge is positive for EIA 
when the FEV1 falls X10% from the baseline measurement. 
It is possible that the addition of other measurements of 
expiratory lung function may provide greater sensitivity in 
the diagnosis of BIA. For example, forced expiratory flow 
between 25-75% of vital capacity (FEF25... 73) has been used in 
conjunction with FEVI to aid the diagnosis of EIA in 
children"" and athletesO " Implicitly, FEVI measures 
expiratory flow at high and mid lung volumes, whereas 
FEF25-7, and forced expiratory flow at 50% of vital capacity 
(FEFso) are markers of expiratory flow through middle lung 
volumes. It has been suggested that FBF23-7s and FEFso are 
more sensitive to airway obstruction in the small airways 
than FBVI. " 2a Custovic et a? ' noted that cut off points for BIA 
in children (defined as the normal group mean value -2 SD) 
occurred with a fall in FEVI of > 10% and a fall in FEFZ. %-7S of 
>26%. In this study, the combined application of FEV, and 
FEF2S. -75 criteria enabled detection of all subjects with EIA. Furthermore, using both FEVI and FEF=3-7s criteria, none of 
the subjects with allergic rhinitis or dermatitis presented with 
EIA. The fall in FEVI after exercise in children with allergic 
rhinitis was within the normal range (< 2 SD ), but with a 
significantly lower mean value than control subjects. The 
study by Custovic et a? ' therefore provides promising 
evidence to support the addition of mid expiratory flow rates 
to FEVI in the diagnosis of EIA in children that might also be 
applied to elite athletes. FEFso and FEF25-so measurements 
are highly correlated and the ratio of the two is reasonably 
constant. Based on this finding, Bar-Vishay et aP' suggested 
that reporting both measurements is unnecessary, and they 
suggested that FEFso should be the preferred measure. This 
preference was based on the argument that FEFso is easily 
and directly determined while FEF25-50 is a calculated 
Ab6svialions: EIA, exercise induced asthma; EVH, eucapnic voluntary hypene notation; FEFw, forced expiratory Raw at 50% of vital capacity; FEVj, forced expiratory volume in 1 second; FVC, forced vital capacity 
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parameter that is affected by the spirometer manufacturer's 
choice of algorithm. 
The purpose of the present study was to examine the role 
of FEF, 0 as an adjunct to FEVI in the 
diagnosis of EIA in elite 
athletes following a bronchoprovocation challenge. 
METHODS 
Following ethical approval from Harrow local research ethics 
committee, 66 male elite summer and winter athletes of 
mean (SD) age 25.1 (4.9) years, height 180.7 (7.8) cm, body 
mass 77.3 (12.5) kg and 50 female elite athletes of mean 
(SD) age 24.3 (5.4) years, height 168.2 (7.9) cm, and body 
mass 62.6 (9.9) kg who held either a Gold or Silver British 
Olympic Association passport (indicating current or potential 
Olympic competitive standard) provided written informed 
consent and volunteered for the study. Of the athletes who 
participated in this study, 83 had a previous diagnosis of EIA 
and where using asthma medication. The other 33 athletes 
had reported symptoms of EIA to a sports physician who had 
referred them to be tested for EIA. The testing took place at 
the Olympic Medical Institute, Harrow between June 2003 
and June 2004. Athletes were tested at least 2 weeks after a 
respiratory infection and at least 12 hours following a 
training session. 
Each athlete completed either an exercise or EVH 
challenge. Exercise challenges involved exercising at an 
intensity of >85% of maximal heart rate for 6-10 minutes 
in a sport-specific environment. 30 EVH challenges consisted 
of hyperventilating for 6 minutes at a rate of 85% maximal 
voluntary ventilation (30 x baseline FEV1). The gas inspired 
during the EVH challenge was a medical gas containing 21% 
02,5% CO2 and 74% N2. " For both exercise and EVH 
challenges, maximal flow-volume loops were measured 
before and at 3,5,10 and 15 minutes after stopping exercise 
or EVH using a digital spirometer (MicroLab ML3500, Micro 
Table 1 Mean (SD) changes in FEF50 and FVC following bronchoprovocation challenge 
FEFyo Q/s) FVC (1( 
Before After Before AMr 
Asthmatic 3.86 (0.92) 2.39 (0.84)"" 4.99 (1.00) 4.45 (1.16)'" 
Non-asthmatic 4.79 (1.37) 4.43 (1.31) 4.81 (1.03) 4.65 (1.04) 
Asthmatic athlete defined as having a 10% fall in FEV, fol"ng bronchoprarocation. 
"Significantly different (p<0.05) from pre-test value. 
Table 2 True and false positive and negative 
diagnoses based on FEF50 cut off value of 26% 
True positive 39 
True negative 55 
Total true 94 
Falz negative 21 
false *five I 
Total tthe 22 
Total with EIA 60 
Total without EIA 56 
Told 116 
True positive-AFEV1 of 10% and a fall in FEF50 of 26%. 
Truenegahvs -AFEV1 of 10% and did not have a foil in 
FEFso of X26%. 
False positive -AFEVi of < 10% and a fall in FEF50 of 
'26%. 
False ne©ative-MEV1 of a10% and a fall in FEFSo of 
<26%. 
Table 3 True and false positive and negative 
diagnoses based on FEF0 cut off value of 14% 
True positive 51 
True negative 43 
Told true 94 
False negative 9 
False itive 13 
Told fdse 22 
Told with EIA 60 
Total without EIA 56 
Total 116 
True positive. AFEV I of 10% and a fall in FEF50 of 14%. True nefive-AFEV1 of ; -10% and did not have a fall in 
FEFý or..., 4%. 
False positive -AFEV, of <10%and a fall in FEF&) of 
>14%. 
False negative -AFEV, of a10%and a fall in FEFso of 
< 14%. 
Medical Ltd, Rochester, UK) which met ATS guidelines. The 
lowest values of FEV, and FEF50 following either exercise or 
EVH were recorded and the change was calculated (A). A 
AFEVI of , -10% and AFEF50 of %-26% were considered 
cut off criteria for EIA diagnosis" 
RESULTS 
There was a strong positive correlation between AFEV1 and 
AFEF, 0 following bronchoprovocation (r = 0.94, p=0.000). 
Sixty athletes (52%) had a AFEVI fall of , 10% leading to the 
diagnosis of BIA (fig 1). Using the FEFsa criteria alone led to 
21 (35%) asthmatic athletes receiving a false negative 
diagnosis; thus, 39 athletes met both FEVI and FEF50 criteria. 
The lowest fall in AFEF, O in an athlete with a , 10% fall in 
FEV 1 was 14.3%. Reducing the FEF50 criterion to a =14% fall 
included 13 athletes whose AFEVI was not ; 10% (mean 
AFBVI =5.7, range -8.9 to -1.5). Only one athlete had a 
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, 26% fall in FEF, 0 in the absence of a %10% in FEVI 
(AFEV i=8.9%). 
Of the 83 athletes with a previous diagnosis of EIA, 33 
failed to develop EIA (AFEVI <10%) following bronchopro- 
vocation challenge. Of the 33 athletes who had been referred 
for testing but had no previous diagnosis of EIA, 10 athletes 
presented with EIA following bronchoprovocation. 
The values for FEF50 and forced vital capacity (FVC) before 
and after bronchoprovocation challenge are shown in table 1. 
FEF50 (p = 0.000) and FVC (p = 0.000) were significantly 
lower after bronchoprovocation in the asthmatic athletes. 
There was no significant change in FEF50 or FVC before and 
after bronchoprovocation challenge in athletes who did not 
have a fall in FEV1 of 310%. 
The specificity, sensitivity, predictive value of positive test 
and efficiency of FEFso cut off criteria of 26% and 14% are 
shown in tables 2,3 and 4, respectively. 
DISCUSSION 
This study shows that the addition of FEF, 0 reduces the 
sensitivity of EIA diagnosis following exercise or EVH 
challenge. Of the 60 athletes who were diagnosed with EIA 
using IOC-MC criteria of a 310% fall in FEV1,21 (35%) 
would have received a false negative diagnosis using a 
combination of FEV1 and FEFso falls. Furthermore, only one 
athlete exceeded the criterion for FEPsa but not for FEVI. Our 
study therefore suggests that FEF, 0 does not improve the 
diagnosis of EIA in elite athletes using the IOC-MC criteria. 
In previous studies, measurements of PEFZ5. - 
have been 
used to supplement FEV1 in the diagnosis of EIA in 
children" " and athletes"' The studies conducted on 
children have supported the addition of FEF25-75 measure- 
ments to improve the diagnosis of EIA. It has been suggested 
that FEF25_75 is a more sensitive measure of obstruction in 
the small airways than FEV,. " Thus, EIA may be a disease 
that consistently affects the expiratory flow through the 
small airways. Fonseca-Guedes et aP' noted that only 60% of 
children with "intermittent" EIA met the criteria for both 
FEVI and PEP25-75 compared with 94.4% of children with 
"severe persistent" EIA. They suggested that FEF25_75 is more 
likely to fall significantly than FEV i in children with mild 
EIA. Our data do not agree with this finding and suggest that 
FEV1 is more likely to fall significantly in athletes with mild 
asthma. Indeed, only one athlete had a significant fall in 
FEF, 0 (ý1,26%) in the absence of a significant fall in FEVI, 
while 21 athletes had a significant fall in FEVI (, 10%) in the 
absence of a significant fall in FEFso. Only 39 athletes met 
both criteria for PBPso and FEV1, which would have resulted 
in 21 (35%) athletes (who met FEV1 criteria) receiving a false 
negative diagnosis for EIA The reduced sensitivity found 
following the inclusion of the FEP, 0 measurement suggests 
that, in elite athletes with mild BIA, expiratory airflow is just 
as likely to be restricted in the larger airways as in the smaller 
airways. It is therefore appropriate to assess expiratory flow 
using an index of function for both the larger and smaller 
airways of the lung-that is, FEV1. 
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A number of studies have examined the diagnosis of EIA in 
athletes but they have not specifically used mid-expiratory 
flow rates as a criterion for making the diagnosis. Rundell et 
aF suggested that a fall in PEFZ5-7S of 14% is significant in the 
diagnosis of EIA in winter athletes. This lower limit was 
calculated by taking the mean post exercise change from 
baseline spirometry and subtracting 2 standard deviations. 
Lowering the FEFso cut off value in our data to %14% 
resulted in an increase in the sensitivity but a decrease in the 
specificity from 98% to 77%. Using a 14% cut off value, 13 
athletes would have been diagnosed with EIA who did not 
meet the IOC-MC criterion of a 10% fall in FEVI from 
baseline values. 
A further problem associated with the use of PEF50 as a 
criterion measurement is that its reliability is dependent 
upon the constancy of FVC. Our results show that the mean 
fall in FEPsa following bronchoconstriction was accompanied 
by a mean fall in FVC in athletes with EIA. The fall in FBF50 
seen in some of athletes following a bronchoprovocation test 
may therefore be partially attributable to a reduction in FVC. 
The reduction in FVC in asthmatic athletes may be due to the 
prolongation and discomfort associated with exhaling to 
residual volume during bronchoconstriction. Despite stan- 
dard controls, this may cause the athlete to stop exhaling 
before reaching residual volume. This shortcoming further 
undermines the potential value of PEFso for diagnosing EIA. 
In conclusion, the addition of FEF50 to FEV, reduces the 
sensitivity of a diagnosis of EIA in elite athletes. Our data 
suggest that a more global measure of maximal expiratory 
airflow (FEV1) provides the most sensitive and specific 
diagnosis of EIA, especially when the severity of the disease 
is thought to be mild. This would suggest that EIA is a disease 
that is associated with expiratory flow limitation in the larger 
and smaller airways of elite athletes. However, methodolo- 
gical issues associated with assessment of PEF50 (reliance 
upon FVC) mean that this interpretation should be viewed 
cautiously. The authors suggest that future studies should 
investigate the efficacy of the IOC-MC criterion of a 10% fall 
in FEV 1 to define a more statistically justified cut off point for 
the diagnosis of EIA in elite athletes. 
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